The role of community pharmacy in diabetes prevention by Katangwe, Thando
   1 
    
 
 
The role of community pharmacy in 
diabetes prevention 




Ms. Thando Katangwe, MRPharmS, PGDip, MSc 
 
Submitted for the degree of Doctor of Philosophy  
University of East Anglia  







This copy of the thesis is supplied on condition that anyone who consults it is understood 
to recognise that its copyright rests with the author and that use of any information 
there from must be in accordance with current UK Copyright Law. In addition, any 
quotation or extract must include attribution. 
 
 
   2 





I am the vine; you are the branches. He 
who abides in Me and I in him, he bears 
much fruit; for apart from Me you can do 
nothing.  
 






   3 
    
Abstract 
 
The role of community pharmacy in diabetes prevention 
By Thando Katangwe 
 
Background 
Diabetes Prevention Programmes (DPPs), comprising intensive lifestyle 
interventions, may delay or even prevent the onset of type 2 diabetes in Non-
diabetic hyperglycaemia (NDH). Unfortunately, engagement with DPPs is variable 
with accessibility being a reported barrier; this may be addressed by community 
pharmacy involvement given its accessibility. The aim of this thesis was to explore 
the potential role of community pharmacy in diabetes prevention in England.  
 
Methods  
This thesis includes four studies; the first, a mixed methods study exploring 
engagement with the national DPP and eliciting views from people with NDH on the 
role of community pharmacy in diabetes prevention. The second, a qualitative 
study exploring views of healthcare providers and commissioners on the potential 
role of community pharmacy in diabetes prevention. The third, a questionnaire-
based validation study. The fourth, a nominal group technique study designed to 
identify interventions most likely to facilitate successful implementation of 
community pharmacy-based diabetes prevention services (DPS). The studies were 
underpinned by the Behaviour Change Wheel framework which framed data 
collection, analysis and intervention development.  
 
Results  
The mixed methods study highlighted barriers to engagement in the national DPP 
including inconvenient location and session times and identified community 
pharmacy as a potential setting for delivering alternative DPS. The qualitative study 
and the subsequent validation questionnaire identified facilitators for the provision 
of community pharmacy-based DPS including the provision of integrated services in 
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primary care. The final study identified key interventions for ensuring engagement 
with (e.g. service promotion) and delivery of (e.g. training) community pharmacy-
based DPS.  
 
Conclusions 
The thesis provides an overview of evidence underpinning the role of community 
pharmacy in the provision of accessible DPS and presents a model for 
implementation. The proposed model, which advocates integration of primary care 
services, aligns with the community pharmacy contractual framework and the 
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1.1 Prevalence, cost and aetiology of type 2 diabetes 
 
Diabetes mellitus has been highlighted as one of the main non-communicable 
diseases responsible for the major health and development challenges of the 21st 
century (1). Globally, the prevalence of diabetes has nearly doubled from 4.7% in 
1980 to 8.5% in 2014 (2, 3). In England, approximately 3.5 million people aged 16 
years and over are estimated to be living with type 2 diabetes (diagnosed and 
undiagnosed), a prevalence rate of 7.7% (4). This is expected to rise to 4.4 million, 
which is 8.7% of the adult population, by 2035 (4). The management of type 2 
diabetes and its complications poses a financial burden on the National Health 
Service (NHS) in England, currently costing £8.8 billion a year, almost 10% of the 
total budget (5).  
  
Diabetes mellitus is a chronic endocrine disorder, characterised by hyperglycaemia 
resulting from inadequate secretion of insulin by the pancreas with or without 
insulin resistance (6). Diabetes mellitus is classified according to aetiology with type 
1 and type 2 being the most common. Type 1, which usually develops in children 
and adolescents, constitutes 10% of people diagnosed with the condition (7). It 
occurs due to the autoimmune destruction of insulin producing pancreatic β-cells 
often triggered by exogenous factors such as food and viral infections in genetically 
pre-disposed individuals (6). Individuals diagnosed with type 1 diabetes require 
daily administration of insulin to regulate blood glucose (7).  
 
Type 2 diabetes usually develops above the age of 40 (although it is increasingly 
diagnosed in younger people and even children). This thesis is focused on type 2 
diabetes, which comprises almost 90% of all diabetes cases (6). Type 2 diabetes 
occurs due to a progressive development of insulin resistance and dysfunction of 
pancreatic β-cells leading to insulin deficiency and impaired glucose regulation 
(IGR) (6). The main symptoms of diabetes, polyuria (increased urine production) 
and polydipsia (increased thirst), occur due to osmotic diuresis secondary to 
hyperglycaemia (6). Hyperglycaemia may also cause blurred vision due to changes 
in lens fraction, and a higher infection rate (especially candida and urinary tract 
   22 
    
infections) due to increased urinary glucose levels (6). The symptoms of type 2 
diabetes, although similar to type 1 diabetes, are associated with a much slower 
and less marked onset due to the progressive nature of its development (6).  
 
Sustained hyperglycaemia in diabetes mellitus can lead to the development of 
macrovascular and microvascular complications from atherosclerosis of the vessels 
(6). Macrovascular complications , including cardiovascular disease (CVD) (coronary 
heart disease and stroke) and peripheral vascular disease, are the major cause of 
death and disability in people with diabetes mellitus (8). The risk of developing such 
complications is twice as likely in people with diabetes mellitus compared with 
those without (9). Additionally, the risk of hospital admission for heart failure, 
myocardial infarction and stroke is respectively 73%, 55% and 34% higher among 
people with diabetes mellitus than those without (10).  
 
Microvascular complications include nephropathy (kidney disease), retinopathy, 
and neuropathy (nerve damage) and result from damage to small blood vessels (6). 
It is estimated that 3 in 4 people with diabetes mellitus develop kidney disease 
during their lifetime with nearly 1 in 5 people possibly requiring treatment (11). 
Retinopathy, resulting from long term accumulated damage in the small blood 
vessels of the retina, can lead to blindness. Diabetic retinopathy accounts for 
approximately 14% of the main causes of blindness certifications in England and 
Wales and is the leading cause of preventable sight loss amongst people of working 
age in the UK (11, 12). The progressive loss of nerve fibres in people with diabetes 
mellitus, resulting from nerve dysfunction, can give rise to neuropathies which can 
affect up to 50% of patients (11). Chronic painful peripheral neuropathy, the most 
common type of neuropathy, is estimated to affect up to 26% of people with 
diabetes mellitus (13). This is a sensory neuropathy which reduces the sensation in 
the feet and lower limbs, contributing to increased rates of ulceration, infection 
and amputation (6, 13). In England there are higher rates of amputations in people 
with diabetes mellitus than those without, with over 7,000 people undergoing leg, 
foot or toe amputations each year (14). In 2010-11, the NHS in England spent an 
estimated £650 million on diabetic foot ulcers and amputations (15). Autonomic 
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neuropathy in diabetes mellitus may also give rise to other conditions such as 
diabetic impotence, bladder dysfunction and diabetic diarrhoea (6).  
 
The risk of developing type 2 diabetes depends on multiple non-modifiable and 
modifiable risk factors. Non-modifiable risk factors include age, family history (first 
degree relative with type 2 diabetes) and ethnicity (6, 16). Type 2 diabetes has a 
strong genetic predisposition, with a 5-10% risk of development in children whose 
parents have the condition compared to 1-2% for type 1 diabetes (6). High risk 
populations include African, Hispanic or South Asian descent with Asia accounting 
for at least 60% of the world’s population of people living with diabetes mellitus 
(17, 18). There is also a clear association between type 2 diabetes and modifiable 
factors such as being overweight or obese (19). Obesity accounts for approximately 
80-85% of the overall risk of developing type 2 diabetes and together with physical 
inactivity, is estimated to cause a large proportion of the global diabetes burden 
(20, 21). It is suggested that an increase of 1kg/m2 of Body Mass Index (BMI) and 
1cm increase in waist circumference increases the risk of developing new-onset 
type 2 diabetes by 8.4% and 3.2% respectively (22). In England, almost 50% of the 
projected increase in prevalence of diabetes mellitus is attributed to the increasing 
prevalence of obesity which has risen amongst adults from 14.9% to 25.6% 
between 1993 and 2014 (23). By 2050 it is predicted that obesity will affect 60% of 
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1.2 Detection of type 2 diabetes 
  
Diabetes mellitus  is usually diagnosed using blood tests that measure plasma 
glucose levels or glycosylated haemoglobin levels (HbA1c)(16, 25).  Plasma glucose 
can be measured using the fasting plasma glucose test (FPG) or the oral glucose 
tolerance test (OGTT).  The FPG test requires individuals to fast for at least 8 hours 
prior to blood samples being taken. The OGTT also requires individuals to fast for at 
least 8 hours and then ingest a 75g oral glucose load prior to blood samples being 
taken (2, 6).   
 
Glycated haemoglobin measures the amount of glucose carried by haemoglobin, a 
protein within the red blood cells which joins with glucose (26). Measuring HbA1c, 
although more costly than blood glucose measurement, has an advantage of 
reflecting the average blood glucose concentration over a period of two or three 
months, rather than the momentary blood glucose concentration (26, 27). HbA1c is 
estimated on a single non-fasting blood test but may vary with ethnicity, leading to 
either overestimation or underestimation of the result and could be inaccurate in 
the presence of haemoglobinopathies (28). Additionally, there are other conditions 
whereby the HbA1c test cannot be used for diagnosis including suspected type 1 
diabetes, children or young adults, gestational diabetes and people who are acutely 
ill (29, 30). In these conditions, glucose values fluctuate quickly and therefore HbA1c 
measurements may not accurately reflect glycaemic exposure (29). However, to 
date, HbA1c is the most convenient test used to measure blood glucose, requiring 
no fasting and providing measurements that reflect glycemic control over a 3-
month period. 
 
The internationally agreed criteria for diagnosis of diabetes mellitus is summarised 
in Table 1.1 (31, 32). In order to allow global comparison, the presentation of HbA1c 
levels in this thesis adopts the International Federation of Clinical Chemistry (IFCC) 
standardisation of HbA1c results which are expressed in mmol/mol (33).
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Table 1.1 Internationally agreed diagnostic criteria for diabetic mellitus 
 
                                           Diagnosis 
 
Diagnostic test Units Normoglycemia Diabetes  
 
FPG  mmol/L <5.5 ≥7.0 
OGTT mmol/L <7.8 ≥11.1 




1.3 Non-diabetic hyperglycaemia  
 
Owing to the progressive loss of β-cell function associated with type 2 diabetes, 
where insulin production decreases over a sustained period of time, IGR may be 
detected before overt diabetes develops (6, 32). IGR is a term which refers to blood 
glucose levels above normal range but not high enough for diagnosis of type 2 
diabetes (2, 32). It is therefore an umbrella term used to describe the presence of 
impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) as defined 
by the World Health Organization (WHO) (25, 32). 
  
IGT is a term adopted by the WHO in 1980 from the US national diabetes data 
group to denote a state of increased risk of progressing to diabetes (25). It is mainly 
associated with insulin resistance in the muscles and impaired insulin secretion 
(34). IFG, another term adopted by the WHO in 1999 from the American Diabetes 
Association (ADA) expert committee (25), describes the zone between the upper 
limit of normal fasting glucose and the lower limit of the diabetic fasting glucose 
(25). IFG is associated with impaired insulin secretion and impaired suppression of 
hepatic glucose output, hence its development is usually associated with an 
increased glucose secretion into the bloodstream from the liver overnight (35). 
Individuals diagnosed with isolated IFG have a fasting blood glucose that is higher 
than the normal range, but levels do not rise abnormally following an OGTT (35). It 
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is possible to have a diagnosis of both IGT and IFG. Both (IGT and IFG) are not 
clinical entities in themselves but are a risk factor for future diabetes mellitus 
and/or adverse outcomes (25, 32). 
 
In recent years, other terms such as ‘pre-diabetes’ and ‘non-diabetic 
hyperglycaemia (NDH)’ (32) have been adopted as umbrella terms to describe IGR. 
The term ‘pre-diabetes’ was originally introduced by the ADA and is most 
commonly used in the USA (36). Although the term has not been widely accepted 
by other expert groups including the WHO, it has been adopted in health care 
systems and is widely referred to in research (37). WHO and the International 
Diabetes Federation, recommend using the term ‘intermediate hyperglycaemia’ in 
order to avoid stigma and potential anxiety about developing future complications 
associated with diabetes and to reflect evidence that a significant amount of people 
do not actually progress to type 2 diabetes. In the UK, the National Institute for 
health and Care Excellence (NICE) advocates the use of the term ‘non-diabetic 
hyperglycemia’ but recognises the use of terms such as pre-diabetes when referring 
to individuals with IGR. NICE is an executive non-departmental public body of the 
Department of Health in the UK which provides guidance, advice and information 
services for health, public health and social care professionals. Therefore, for 
consistency in UK terminology, this thesis primarily uses the term non-diabetic 
hyperglycemia (NDH) when referring to IGR.  However, the term ‘pre-diabetes’, has 
also been adopted in the primary research undertaken for this study in order to 
reflect the language that may be used by healthcare professionals and patients.   
 
Due to the progressive deterioration of β-cell function, undetected NDH could lead 
to the development of type 2 diabetes. There are currently 5 million people in 
England with NDH (38). It is estimated that the annual risk of progression to type 2 
diabetes is >5 times in isolated IGT, 7 times in isolated IFG and >12 times in both 
IGT and IFG compared to normoglycaemic individuals (39). Evidence suggests that if 
NDH is detected before overt diabetes develops and intensive lifestyle 
interventions are implemented, the onset of type 2 diabetes may be delayed or 
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even prevented (40, 41). This thesis will primarily focus on the management of NDH 
in England.  
 
 
1.4 Detecting non-diabetic hyperglecemia  
 
WHO defines screening as ‘a process of identifying individuals who are at 
sufficiently high risk of a specific disorder to warrant further investigation or direct 
action’ (42). To guide the selection of conditions that would be suitable for 
screening, the WHO commissioned a report on the criteria which warrants 








The rising prevalence of type 2 diabetes worldwide, the substantial proportion of 
people who are undiagnosed, the long latent asymptomatic period in which the 
condition can be detected and the increasing prevalence of complications in newly 
diagnosed cases are some of the strong arguments for screening (42, 44, 45). 
However, in the past due to the lack of evidence evaluating the effectiveness of 
screening programmes in decreasing mortality and morbidity and the unknown 
 The condition sought should be an important health problem 
 There should be an accepted treatment for patients with recognized disease 
 Facilities for diagnosis and treatment should be available 
 There should be a recognisable latent or early symptomatic stage 
 There should be a suitable test or examination 
 The test should be acceptable to the population 
 The natural history of the condition, including development from latent to declared 
disease, should be adequately understood 
 There should be an agreed policy on whom to treat as patients 
 The cost of case-finding (including diagnosis and treatment of patients diagnosed) should 
be economically balanced in relation to possible expenditure on medical care as a whole 
 Case-finding should be a continuing process and not a “once and for all” project 
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psychological and economic consequences of screening, it has been concluded that 
type 2 diabetes fulfils many but not all of the WHO criteria for population mass 
screening (46, 47). 
 
In more recent years, evidence suggesting a greater risk of disease progression to 
develop type 2 diabetes in people with NDH has contributed to the growing interest 
in developing screening methods (40, 48-51). Additionally, concerns over the 
psychological impact and the cost-effectiveness of screening have been addressed 
by trials such as the ADDITION study, a pragmatic cluster randomised, parallel-
group trail conducted in three European countries (Denmark, the Netherlands and 
the UK) (52). The study, which investigated the effect of early multifactorial 
treatment of type 2 diabetes after diagnosis by screening, also set out to test the 
feasibility of a primary care-based two-step screening approach for type 2 diabetes 
(53). Step 1 of the screening phase involved the use of questionnaires by 
participating general practices to randomly assess the risk of developing type 2 
diabetes in registered patients aged 40-69 (54). In step 2, those identified as high 
risk were referred for a confirmatory blood test.  
 
Although the early intensive management of patients with type 2 diabetes was 
associated with a non-significant reduction in the incidence of cardiovascular 
events and was not cost-effective compared to standard care, the study generated 
important findings for the identification and management of individuals identified 
with NDH (52, 54). The trial demonstrated that screening for type 2 diabetes is 
feasible in general practice and has limited short and long-term adverse 
psychological impact on study participants (52). Additionally, the study also found 
that screening for type 2 diabetes identified more people with NDH and high 
cardiovascular risk than those with overt diabetes (55). In Denmark for each person 
identified with diabetes, two were identified as having NDH (IFG and IGT) and six 
with high CVD risk (55). Approximately one in three people identified with NDH 
during the study developed type 2 diabetes within three and a half years (56, 57). 
These findings therefore highlighted a missed therapeutic opportunity, in the 
individuals who were identified as at risk, as they were not offered advice or 
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treatment as part of the intervention programme (58). A major recommendation 
from the trial suggested the development of systems to enable detection of both 
type 2 diabetes and high-risk individuals, including opportunistic screening and the 
development of preventative interventions (58).  
 
1.4.1 National guidelines for detection of non-diabetic hyperglycaemia 
 
National guidelines for the management of NDH have therefore been developed 
considering this evidence. Both NICE and European evidence-based guidelines for 
the prevention of type 2 diabetes recommend a two-stepped approach for the 
identification of individuals with NDH (32, 59). The first step involves the use of 
non-invasive screening tests to identify individuals at high risk whilst the second 
step involves a subsequent confirmatory blood test to identify those who may be 
suitable for intensive lifestyle interventions (32).  
 
In England, the first step of the risk identification process is recommended for 
implementation in general practice settings and by other healthcare professionals 
including pharmacists, opticians and occupational health nurses (32). Whilst general 
practices employ the use of validated computer-based risk assessment tools to first 
identify individuals with NDH, community pharmacies use validated self-assessment 
questionnaires  or signpost individuals to online validated self-assessment tools 
(32). Confirmatory blood tests (step 2) are currently recommended for 
implementation in general practice settings only (32). Other  primary care settings, 
including community pharmacy, involved in step 1 of the screening assessments are 
advised to refer individuals identified as high risk to general practices for 
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1.4.2 Non-invasive tests (step 1) 
 
In recent years, in order to reduce the number of individuals requiring invasive 
tests, a stepwise approach involving scores based on non-invasive information, has 
been recommended to initially identify individuals or population subgroups which 
may benefit from blood tests (60). Multivariate risk scores have been 
recommended in current practice guidance as a non-invasive way of identifying 
individuals with NDH (32, 61). Risk scores may be based on information available 
from routine clinical data (age, gender, body mass index and family history of 
diabetes) or collected by questionnaires completed manually or online (60). Risk 
scores based on routine health service data  are also improved by adding commonly 
measured biochemical data e.g. FPG (60).  
 
Due to the varying purposes of diabetes risk scores, including targeting prevention 
interventions to those at greatest risk, their validity has great implications (60). A 
systematic review examining evidence for the performance of diabetes risk scores 
in adults, recommended the use of risk prediction models that are validated within 
the population in which they are intended to be used, especially if ethnicities and 
countries differ from the derivation cohorts (60).  
 
In the UK, NICE has recommended the use of validated risk scores such as the 
Cambridge risk score, the Leicester Practice Risk score and the QDiabetes score 
which use routine clinical data (32, 38). NICE also recommends the use of self-
assessment questionnaires such as the Leicester Diabetes Risk Assessment Score 
and the FINDRISC which are available online or on paper (32, 38). This thesis 
focused on validated risk scores which have been recommended for use in the UK, 
the components of which are summarized in Table 1.3.  
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Table 1.3 Predictive variables for diabetes risk assessment tools 
 
 









     
Gender - 
    




Family history of diabetes  
     
History of prevalent/latent diabetes  
 
- - - - 
BMI 
     
Waist circumference  
  
- - - 
Physical activity  
 
- - - - 
Daily consumption of fruit and veg 
 
- - - - 
Townsend deprivation score - - - - 
 
Smoking status - - - 
  
Cardiovascular disease - - -  
 
Prescribed steroids  - - - 
  
High blood pressure or prescribed 
hypertensive medicine      
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1.4.2.1 The Finnish Diabetes Risk Score (FINDRISC) 
The Finnish Diabetes Risk Score is a self-assessment questionnaire which was 
developed and validated using two large, population-based cohorts in Finland (62). 
The questionnaire uses weighted scores from eight categories to detect the risk of 
developing type 2 diabetes within 10 years (62). The score ranks the risk as low (< 
7), slightly elevated (7-11), moderate (12-14), high (15-20) and very high (>20). 
Having been validated in 8 independent cohorts, the FINDRISC is the most validated 
screening tool to date (60). It has also been found useful in identifying high risk 
groups that are most likely to benefit from intensive lifestyle interventions to 
prevent type 2 diabetes (63).  
 
1.4.2.2 The Leicester Risk Assessment Score 
The Leicester Risk Assessment Score is a validated assessment tool developed by 
Leicester University and University Hospitals of Leicester NHS Trust in England (64). 
The score was developed from FINDRISC to identify people who may have NDH and 
type 2 diabetes. The score is in the form of a questionnaire that can be completed 
without intervention by healthcare professionals (38). The questionnaire consists of 
seven questions whose score highlights a person’s risk of developing type 2 
diabetes in the next 10 years. It uses a points system to identity if a person is at low 
(0-6), increased (7-15), moderate (16-24), or high risk (>25) of developing type 2 
diabetes. The Leicester Risk Assessment Score has been validated for use in a multi-
ethnic population in the UK (64).  
 
1.4.2.3 The Leicester Practice Risk Score 
The Leicester Practice Risk Score was developed for use within primary care 
databases using the same data as that of the Leicester Risk Assessment Score (38). 
The main difference between the two scores is that the practice risk score does not 
include waist circumference as a component as this is not routinely available on 
primary care databases. The risk score has been recommended by NICE for use in 
general practice and other primary care settings to identify undiagnosed type 2 
diabetes and those with NDH for suitable interventions (32). The Leicester Practice 
   33 
    
Score, available as a software, calculates the risk score for all those aged between 
18 and 75 years old excluding people with known diabetes, the terminally ill and 
those coded with gestational diabetes (65). The software may also be used for the 
analysis of OGTT/HbA1c/glucose data in order to identify the number of people that 
have been screened and those who may have been missed, allowing practices to 
invite those at greatest risk for screening (65). 
 
1.4.2.4 The Cambridge Diabetes Risk Score 
The Cambridge risk score was originally developed to identify individuals with 
undiagnosed type 2 diabetes using data routinely collected in general practices 
(66). The score has been validated in a large cohort of people in the UK recruited 
from general practices in Wessex and Ely (60, 66). The score has also been validated 
for use in identifying those with NDH using a population-based prospective cohort 
(67). However, the study cohort used to develop the risk score were predominantly 
white, hence ethnicity is not included as a component variable in the model. 
Additionally, the cohort is unlikely to be a representative sample for all UK.   
 
1.4.2.5 The QDiabetes score 
The QDiabetes score is the first validated risk score to account for both social 
deprivation and ethnicity when estimating the 10-year risk of developing diabetes 
(68). The cohort study used to validate the score employed routinely collected data 
from 355 general practices in England and Wales to develop the score and 176 
practices to validate the score (68). The predictive components rank the scores as 
low (0-10), moderate (10-20) or high (>20) risk of developing diabetes. The 
QDiabetes has since been updated to include new risk factors such as medical 
conditions (e.g. gestational diabetes and polycystic ovary syndrome), medication 
(e.g. atypical antipsychotics and statins) and blood glucose readings (FPG and 
HbA1c) (69).  
 
The risk scores selected by NICE for use in the UK have been identified above. 
However, the decision to use them largely depends on the setting where screening 
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is undertaken, the availability of clinical information and the population being 
screened. In clinical settings, where patient data such as blood glucose readings and 
medical histories are readily available, tools such as the QDiabetes score, the 
Leicester Practice Risk Score and the Cambridge Diabetes Risk Score could be used. 
However, it is important to ensure that tools used are appropriately validated for 
the population being screened (60). For example, the Cambridge Diabetes Risk 
Score, which has been developed for use in clinical settings and validated in a 
predominantly white population (34, 62, 70-72), has weaker discriminatory 
performance with regards to ethnicity (17, 18). 
 
In non-clinical settings, more pragmatic tools which are accessible as online or 
paper-based tools (e.g. FINDRISC and the Leicester Risk Assessment Score) can be 
used. 
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1.4.3 Follow-up blood tests (step 2) 
 
In 1979, the OGTT was the first test to be used to diagnose NDH (as IGT) (25).  In 
1999, due to the laborious nature of conducting the OGTT, WHO recommendations 
for the diagnosis of NDH expanded to include the FPG test (25).  
 
In 2010, in keeping with the development of reference methods to standardise 
assays, the HbA1c became the third test to be used to diagnose diabetes (HbA1c) 
(mmol/mol or %)(27). The expansion of tests for identifying elevated glucose levels 
has led to the development of guidelines from NICE and the ADA that recommend 
the use of both FPG and HbA1c for identifying people with NDH. The WHO 
recommends HbA1c measurements only for the diagnosis of diabetes, provided the 
tests are quality assured, standardised to international criteria and there are no 
conditions that may prevent accurate measurements (27). However, although WHO 
acknowledge HbA1c levels below 48 mmol/mol to indicate the presence of NDH, 
they have not committed to a specific lower cut-off point (73). Their position, which 
mirrors that of the International Expert Committee, is primarily based on the 
consideration that although the continuum risk of developing diabetes may be 
captured by the HbA1c assay, the actual point where the risk begins or becomes 
clinically important is currently unknown. The International Expert Committee has, 
however, suggested people with HbA1c level of 42-47 mmol/mol to be at a 
particularly high risk of developing diabetes and recommended them to be 
considered for preventative interventions. Current NICE, ADA and WHO 
recommendations for the detection of NDH are detailed in Table 1.4. In the UK, the 
standard diagnostic tests for NDH are HbA1c and FPG, except where the test is 
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Table 1.4 Criteria for classifying non-diabetic hyperglycemia 
 
Guideline diagnostic criteria 
 






6.1-6.9  5.6-6.9  
OGTT 
(mmol/L) 










Globally, there is no agreed consensus on the range of FPG and HbA1c levels that 
should be classed as NDH. Wide diagnostic ranges have the potential to increase 
the prevalence of NDH and consequently increase healthcare costs. Research 
suggests that a global implementation of ADAs definition of NDH (which is wider 
than that proposed by NICE and the International Expert Committee) could lead to 
approximately 50% of the Chinese adult population (over half a billion people) 
being diagnosed with NDH (76). The decision to implement lower cut-off points for 
NDH, should therefore consider the availability sufficient resources to cope with the 
increasing number of identified cases including sufficient evidence-based 
interventions (42, 77). WHO has advised consideration to be made whether local 
healthcare resources are sufficient to cope with the extra workload (2). It is 
therefore important that guideline recommended ranges for NDH do not create an 
unsustainable burden on healthcare systems and cause unnecessary anxiety about 
the complications of diabetes in those identified with NDH.  
 
1.4.3.1 Accuracy of blood tests used to identify non-diabetic hyperglycemia 
The OGTT, the first test to be used for diagnosis of NDH, has been considered (by 
some researchers and clinicians) to be the ‘gold standard’ test for identifying NDH 
(78). To date OGTT, has the most research evidence for predicting the incidence of 
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developing diabetes and coronary heart disease (76). Additionally, key randomised 
controlled trials that form the evidence base for interventions for people with NDH 
have been conducted in people with IGT (79-82). 
 
In recent years, the expansion of tests for identifying NDH to include both FPG and 
HbA1c has raised concerns with regards to the diagnostic accuracy of the tests. A 
meta-analysis conducted by Barry et al. challenged the diagnostic accuracy of using 
both the HbA1c and FPG tests to identify NDH (78). The review, which aimed to 
assess the diagnostic accuracy of screening tests for NDH, found the HbA1c test to 
be neither sensitive (mean sensitivity of 0.49 (95% CI 0.40-0.58)) nor specific (mean 
specificity of 0.79 (95% CI 0.73-0.84)) and found the FPG test to be specific (mean 
specificity of 0.94 (95% CI 0.92-0.96)) but not sensitive (mean sensitivity of 0.25 
(95% CI 0.19-0.32)). The findings therefore suggested that using these tests to 
identify NDH could result in identifying (and treating) a population with an incorrect 
diagnosis of NDH while falsely reassuring another cohort of people with NDH that 
could benefit from intervention.  
 
In considering this evidence, it is important to highlight that the meta-analysis 
measured the sensitivity and specificity of the HbA1c and FPG tests using OGTT as 
the ‘gold standard’ (78). However, evidence shows that the OGTT test is poorly 
reproducible, with people identified with IGT in a first test having a 30% chance of a 
normal result on repeat testing (83).  Additionally, although key randomised trials 
examining the effectiveness of interventions in people with NDH used the OGTT, 
the majority of the studies were undertaken at a time when newer assays such as 
HbA1c has not been developed (79-81). Therefore, rather than consider the OGTT as 
the ‘gold standard’ or the most accurate test, it should rather be regarded as the 
test with the most available evidence to date. Arguably, there is a need to generate 
similar evidence for newer tests including the HbA1c test.  
 
Research evidence suggests that using both the HbA1c and the FPG tests has 
potential to create heterogenous categories of NDH. For example, a study 
conducted using the ADA cut-off points in Chinese adults identified a prevalence of 
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8.3% of IGT, and 27.3% of IFG and 35% of those meeting the HbA1c range for NDH 
(84).  
 
With these findings, however, it is important to consider that current tests for 
diagnosing NDH identify three different types of glucose intolerances. The OGTT 
reflects the degree of insulin resistance in individuals, the IFG test measures 
glucose levels caused by excess liver glucose production and the HbA1c test 
measures glycated haemoglobin. Therefore, rather than concluding tests to be 
‘inaccurate’, consideration should be paid to the necessity of the categorisation of 
impaired glucose states. The IEC, for example, have suggested that perhaps 
dichotomous classifications, such as IFG and IGT, should be eliminated due their 
failure to capture the continuum risk in the sub-diabetic range (75). They have 
proposed the phasing out of these categorical clinical states as HbA1c 
measurements replace glucose measurements.  
 
In England, NICE recommends using both the HbA1c and the FPG for identifying 
suitable people for the intervention, provided the same test is used throughout the 
intervention (85). NICE cut-off points mirror IEC recommendations for identifying 
people suitable for intervention (32). Current screening interventions, that use both 
HbA1c and FPG to identify NDH, have the potential to generate some much-needed 
evidence with regards to associations between their use in detecting NDH and, the 
incidence of diabetes and the development of CVD complications. 
 
 
1.5 Management of type 2 diabetes   
 
The short-term management of type 2 diabetes aims to control blood glucose levels 
in order to alleviate symptoms of hyperglycaemia (6). The long-term management 
involves the minimisation of cardiovascular risk in order to delay and even prevent 
the development of complications and premature death.  
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In the management of type 2 diabetes, where obesity is a major risk factor, diet and 
physical activity interventions lie at the centre of improving disease outcomes (2, 
20, 86). Exercise has been shown to significantly improve glycaemic control and 
reduce visceral adipose tissue, even without weight loss (87, 88). In those who are 
overweight or obese, a modest weight loss of 5-10% through increased physical 
exercise and calorie restriction has been associated with improvements in diabetes 
and cardiovascular risk factors (16, 89). Whilst diet and lifestyle changes are the 
mainstay treatment in the management of type 2 diabetes, the progressive loss of 
glycaemic control means that people with type 2 diabetes eventually require 
pharmacological treatment (16). Initial pharmacological interventions involve the 
combination of oral hypoglycaemic agents such as metformin and sulphonylureas 
and as the condition progresses patients may require insulin therapy (16).  
 
The complexity of type 2 diabetes encompassing the multiple risk factors, 
complications, lifestyle choices, treatments and monitoring, makes structured self-
management education the cornerstone in management (6). In the UK, NICE has 
recommended offering structured education with annual reinforcement and review 
to adults with type 2 diabetes and/or their family members or carers at and around 
the time of diagnosis (16, 90, 91)  
 
 
1.6 Review of evidence for the management of non-diabetic 
hyperglycaemia   
 
To develop an initial understanding of the current practice for the management of 
non-diabetic hyperglycemia (NDH) and the underpinning evidence, a non-
exhaustive review of the literature was conducted. The literature review also aimed 
to identify gaps in the current management of NDH which could be addressed by 
community pharmacy. The focus of the search was therefore to identify both 
primary (e.g. randomised controlled trials) and secondary (systematic reviews and 
meta-analyses) evidence as well as identify relevant documents such as national 
guidelines and protocols for the management of NDH.   
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The search commenced with Google scholar and further expanded to databases 
such as MEDLINE and EMBASE. Relevant websites such as the National Institute for 
Health and Care Excellence, Public Health England, NHS England and Diabetes UK 
were also hand searched for key documents. Search terms consisting of key words 
and free text were used to conduct the searches without setting limits to study 
design, study outcome, comparator or peer reviewed journals. The terms used 
included key words reflecting impaired glucose regulation (e.g. nondiabetic 
hyperglycemia, pre-diabetes, impaired glucose tolerance and impaired fasting 
glucose), pharmacological and non-pharmacological interventions (e.g.  metformin, 
orlistat, medication, diabetes prevention programme, diabetes prevention service, 
diabetes prevention study, lifestyle intervention, diet and lifestyle, exercise and 
physical activity). 
  
The following sections highlight guideline recommendations for the management of 
NDH and examines key research evidence underpinning them. This thesis, reflecting 
current guideline recommendations, focuses on non-pharmacological interventions, 
particularly Diabetes Prevention Programmes (DPP). This is because overall 
research evidence has suggested non-pharmacological interventions to be more 
effective at reducing the risk of progression to type 2 diabetes than 
pharmacological interventions (78).  
 
1.6.1 National guidelines for the management of non-diabetic hyperglycaemia 
 
In England, following identification of people with NDH, NICE guidelines 
recommend the provision of intensive lifestyle interventions to prevent or delay the 
onset of type 2 diabetes (32). The lifestyle interventions are mainly targeted at 
modifiable risk factors such as obesity and physical inactivity and aim to achieve a 
prescribed reduction of initial body weight (usually 5-10%) (32). Similarly, the ADA 
recommend intensive behavioral counselling programmes targeting a weight loss of 
7% and increased physical activity to at least 150 minutes per week (92).  
 
   41 
    
Both NICE and the ADA regard lifestyle education as the cornerstone for the 
prevention of type 2 diabetes (16, 93). NICE recommends education to be offered 
as brief advice (one-off, 5-15-minute consultation) to individuals with a low to 
intermediate risk and as a major part of an intensive lifestyle-change programme in 
those with NDH (32). When delivered as part of an intensive lifestyle-change 
programme, education comprises of ongoing tailored advice on exercise and diet 
with the aim to lose weight (32). NICE also recommends established behaviour 
change techniques including information provision, goal setting, action planning 
and coping plans to be used when delivering intensive lifestyle-change programmes 
(32). This recommendation is in line with evidence which highlights effective 
behavioural change strategies such as counselling (group or individual) and goal 
setting as essential components in effective lifestyle-change programmes (94, 95). 
As well as dietary and exercise education, intensive lifestyle change programmes 
may also offer exercise sessions delivered in groups or one to one. 
 
In the management of people with NDH, pharmacological treatment such as 
metformin and orlistat to manage hyperglycemia and aid weight reduction 
respectively are recommended as second-line options in those whom intensive 
lifestyle-change programmes have been unsuccessful (32, 59, 92). Pharmacological 
options are only recommended as first line in individuals who are unable to 
participate in intensive lifestyle-change programmes.  
 
The development of national guidance for the management of NDH has been 
underpinned by extensive primary and secondary research examining the 
effectiveness of both pharmacological and non-pharmacological approaches. The 
following sections aim to discuss the evidence behind both pharmacological and 
non-pharmacological approaches including implementation into real life settings.  
 
1.6.2 Pharmacological interventions 
 
Evidence from systematic reviews has highlighted the benefits of using 
pharmacological interventions to reduce the risk of progression to type 2 diabetes 
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in individuals with NDH (48). Pharmacological treatments which have shown to be 
effective include metformin, glitazones, acarbose and orlistat (81, 96-98). The 
effects of pharmacological interventions, particularly metformin, have been 
examined in major randomised controlled trials such as the US DPP and the Indian 
DPP, where metformin achieved a relative risk reduction in the onset of type 2 
diabetes of 31% and 26.4% respectively compared to standard lifestyle advice (81, 
82). Metformin has also shown lower or similar effects to intensive lifestyle 
interventions in reducing the incidence of type 2 diabetes and no added benefit 
when in combination (49, 81, 82).  
 
The choice to implement either an intensive lifestyle intervention or medication for 
the management of NDH should therefore consider individual characteristics and 
potential risks and benefits such as effectiveness and adverse events (48, 99). 
Whilst lifestyle interventions may be beneficial in motivated individuals, non-
motivated individuals may benefit from pharmacological interventions (99). 
However, minor adverse events such as gastro-intestinal disturbances are of great 
importance if interventions are to be taken long-term (99). Additionally, 
appropriate dosage adjustments should be considered to minimise hypoglycaemic 
side-effects (82). 
 
1.6.3 Non-pharmacological interventions 
 
Systematic review evidence exploring the efficacy of non-pharmacological 
approaches such as lifestyle modification interventions, has highlighted diet and 
exercise as an effective combination for delaying or preventing the incidence of 
type 2 diabetes in people with NDH (41, 94, 100). A systematic review and meta-
analysis conducted by Gilles et al. for example, demonstrated a 49% relative risk 
reduction in developing type 2 diabetes in trial intervention arms compared to 
control arms (49). This review has informed NICE guidelines on preventing type 2 
diabetes and provided useful information on the impact of the interventions longer 
term.  
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Primary evidence underpinning the delivery intensive lifestyle-change interventions 
designed for the prevention of type 2 diabetes constitutes four major studies; the 
Finnish Diabetes Prevention Study, the Chinese Da Qing Study, the US DPP and the 
Indian DPP (79-82). The four studies, which assessed the effectiveness of diet and 
exercise modification, established intensive lifestyle modification interventions as 
an efficacious approach for delaying or preventing the incidence of diabetes in 
individuals with NDH (79-82). The trials also assessed the long-term effects of 
lifestyle-change programmes on the incidence of diabetes and explored how factors 
such as ethnicity may alter their effectiveness. A summary of research evidence for 
DPPs is provided below and the characteristics of interventions explored in the 
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Table 1.5 Intervention characteristics of major diabetes prevention studies 
 The Chinese Da Qing study The Finish Diabetes Prevention 
Study   
The US Diabetes prevention 
programme  
The Indian Diabetes 
Prevention programme  
Year 
 
1986-1992 1993 to 1998  1999 -2002 2002-2005 
Country  
 
China Finland USA India 
Study size 
 
577 522 3,234 531 
Study aim To assess the long-term effects 
of intensive lifestyle 
interventions on diabetes risk, 
diabetes-related complications 
and mortality   
To determine the effects of a lifestyle 
change program in preventing or 
delaying the onset of type 2 diabetes 
in IGT 
To compare the efficacy and safety of 
intensive lifestyle interventions or 
standard lifestyle recommendations 
plus metformin or placebo in 
preventing or delaying the 
development of diabetes  
To examine the influence of 
high insulin resistance in 
native Asian Indians on the 
effectiveness of diabetes 
prevention programmes    
Population 
description 
Men and women from the city 
of Da Qing.   
 
High risk-groups  
(first degree relatives of patients 
with T2D) 
 
68% women and 
45% ethnic and social minority groups 
(African-American, Hispanic, American 
Indian, Asian American and Pacific 
Islander) 
Middle-class population 
working in service 
organizations identified via 
workplace announcements 




Age >25 with a positive 
screening test for IGT 
 
Age (40-64);   
overweight (BMI >25)   and IGT 
Age >25; BMI>24kg/m2; FPG-5.3 to 
6.9mmol/l and OGTT-7.8 to 
11.0mmol/l 
 
Age: 35-55 years  
IGT 
 
Screening  OGTT  
 
OGTT  Risk score questionnaire plus an OGTT  OGTT 
Interventions Diet: advice to increase 
vegetable intake and reduce 
Diet and exercise: Individualized 
dietary and exercise counselling to 
promote weight reduction (5% or 
Intensive lifestyle intervention: Dietary 
advice to promote at least 7% weight 
reduction of initial body weight and a 
Lifestyle modification: 
Dietary and physical activity: 
counselling  
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sugar and alcohol intake and to 
promote weight reduction   
or  
Exercise: Goal was to increase 
leisure time physical activity  
or 
Diet plus exercise: As detailed 
above 
more) including supervised exercise 
sessions  
level of physical activity of at least 
150min/week. Supervised exercise 
sessions twice weekly.  
or 
Metformin 850mg twice daily plus 




Metformin 250mg twice 
daily 
or  
Lifestyle modification plus 
Metformin:  as above 
 
Control  General diet and physical 
activity advice  






Individual: initial counselling 
session by physicians  
 
Group: weekly for 1 month, 
monthly for 3 months and the 
once every 3 months 
Individual: 7 face-to-face counselling 
(30 min to 1 hr) sessions in the first 




Individual: 16 initial sessions in the 
first 24 weeks and at least monthly 
thereafter 
 
Group: quarterly with each course 
lasting 4 weeks. 
Individual: at baseline and 
every 6 months. Phone 
contact after 2 weeks and 
then monthly thereafter.  
 
Group: 6 × 2 h education 
sessions of varying content 
Intervention 
duration  
6 years  3.2 years 2.8 years  2.5 years  
Primary 
outcome 
Diabetes incidence, CVD 
incidence, mortality and 
complications 
 Diabetes incidence  
 
Diabetes incidence  
 
Diabetes incidence  
 
Setting  Community health clinics  Five study centres in Helsinki, 
Kuopio, Turku, Tampere and Oulu 
27 clinical centres Community based 
intervention 
Personnel   Physicians, nurses and 
technicians 
Nutritionists Registered dieticians  A physician, a dietician and a 
social worker. 
Training A 2-day training session each 
year on diet and exercise 
intervention instructions and 
examination procedures 
Not described Qualification in nutrition, exercise or 
behaviour modification. 
Not described 
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1.6.3.1 The Chinese Da Qing study 
The Chinese Da Qing study examined the effect of a six-year diet and exercise 
intervention by randomising 577 Chinese adults with IGT to either a control group 
or to one of three intervention groups (diet, exercise or diet plus exercise) (80). The 
study showed that diet alone was associated with a 31% reduction in the risk of 
developing type 2 diabetes, while exercise and combined diet plus exercise 
demonstrated a 46% and 42% reduction respectively. The 20-year follow-up study 
examining the long-term effects of the interventions showed that group-based 
lifestyle interventions over 6 years can prevent or delay diabetes for up to 14 years 
after an active intervention (101). The six-year active intervention (diet or exercise 
or diet plus exercise) which resulted in a 51% lower incidence of diabetes in 
intervention participants compared to control, demonstrated a 43% lower 
incidence of diabetes 14 years after the active intervention period and a delay in 
the onset of diabetes of approximately 3.6 years. 
 
This study generated important findings with respect to the long-term effects of 
DPP. However, the six-year active intervention, does not mirror pragmatic 
interventions where often intervention duration could be limited by availability of 
resources.  
 
1.6.3.2 The Finnish Diabetes Prevention Study 
The Finnish Diabetes Prevention Study examined the effect of lifestyle interventions 
in preventing type 2 diabetes (79, 102). The study randomised 522 overweight 
participants with IGT to either an intensive lifestyle intervention (diet and exercise) 
or usual care for 3.2 years and followed them up for approximately 4 years. The aim 
of the intervention was to promote the reduction of dietary saturated fat and 
weight loss and to increase dietary fibre and physical activity. The lifestyle 
intervention, delivered using individualised dietary counselling and circuit 
resistance training sessions, demonstrated a 58% relative risk reduction during the 
active intervention period and a 36% relative risk reduction during the follow-up 
period compared to control. Each component of the intervention (weight loss, 
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physical activity, the reduction of total and saturated fat intake and the increase in 
dietary fibre) was shown to contribute to the risk reduction. Although the Finnish 
Diabetes Prevention programme generated some important findings, the 
generalisability of the data into real-world settings may be low. Important data 
which may influence the uptake of the programmes such as attrition rates were not 
reported in the published findings (79). Additionally, the methods of recruitment 
used in the Finnish Diabetes Prevention Study which included local advertisements, 
have not been shown to result in high programme participation (103). 
 
1.6.3.3 The US Diabetes Prevention Programme  
The US DPP, one of the largest randomised controlled clinical trials to date, was 
conducted in 3,234 adults with IFG and IGT (81). The study assessed the reduction 
in the incidence of type 2 diabetes following a lifestyle modification programme or 
metformin plus standard lifestyle advice over 2.8 years. The study showed that a 
lifestyle intervention with the goals of at least 7% weight loss and at least 150 
minutes of physical activity per week, reduced the incidence of diabetes by 58% 
compared to control. The study also showed lifestyle intervention to be more 
effective than metformin, which reduced the incidence of type 2 diabetes by 31% 
compared to control. Findings from the follow-up study showed that during the 10-
year study period the incidence of diabetes was reduced by 34% in the lifestyle 
intervention group and 18% in the metformin group compared with the control 
group (104).  
 
The effectiveness of the DPP in a multi-ethnic population was also explored as part 
of the study. The study enrolled 68% women and 45% participants from ethnic and 
racial minority groups (African-American, Hispanic, American Indian, Asian 
American, and Pacific Islander). The study demonstrated that diabetes prevention 
interventions can reduce the incidence of diabetes with similar effects in men and 
women and in all racial and ethnic groups. However, resource limitations in real-
world settings are a likely limit to the generalisability of the findings in the US DPP 
which offered a 16-week core curriculum, monthly group and/or individual 
sessions, long-term maintenance sessions and incentives. This has been highlighted 
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by variations in outcomes including weight loss in a number of studies focused on 
translating modified versions of the US DPP into real-world settings (105). 
Therefore, implementation of such an intervention should consider the effects of 
delivering modified versions of the US DPP on clinical outcomes, attrition and 
reach.  
 
1.6.3.4 The Indian Diabetes Prevention Programme 
The Indian DPP, a 3-year prospective community-based study, primarily aimed to 
examine the influence of diabetes prevention interventions on the progression to 
diabetes in Asian Indians with IGT (82). The study randomised individuals to a 
control group or three intervention groups (lifestyle modification or metformin or 
lifestyle modification plus metformin) and demonstrated relative risk reductions of 
28.5%, 26.4% and 28.2% in the intervention groups respectively. The study 
demonstrated no net benefit in combining lifestyle modification and metformin. 
The rate of progression in Asian Indians, who often display relatively low BMI and 
high insulin resistance, was compared against previously studied populations 
(multi-ethnic Americans, Finnish and Chinese). Findings showed that although 
lifestyle modification significantly reduces the incidence of diabetes in Asian 
Indians, the progression of IGT to diabetes is higher in this ethnic origin. The 
progression rate of IGT, assessed in the control groups, was significantly higher in 
Asian Indians (18.3% per year) than the Finnish (6% per year), the Chinese (11.3% 
per year) and the Americans (11%) population.  
 
Although the study generated important findings in Asian Indians, there was a lack 
of recommendations from the study to assist the modification of current clinical 
practice in order to address the increased progression of NDH in this ethnic group. 
Additionally, the control intervention was not described, making it difficult to 
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1.7 The implementation of diabetes prevention programmes in real-
world settings: evidence from translational studies 
 
Systematic reviews and meta-analyses of translational studies have also reported 
the effectiveness of lifestyle intervention programmes in real world settings. A 
review conducted by Dunkley et al. demonstrated that translational DPPs have the 
potential to produce significant weight reduction in intervention arms by a mean 
2.3 kg at 12 months follow-up. 
 
However, despite the effectiveness demonstrated by intensive lifestyle 
programmes, intervention uptake and long-term adherence to behaviour changes 
remain a challenge in implementing DPPs into real-life settings (94). Evidence 
demonstrates that in order to engage target NDH populations, there is a need for 
intervention designs to focus on balancing both effectiveness (mostly determined 
by content) and participant experience (103). A thorough examination of current 
recruitment models, to develop strategies for achieving high programme reach, 
engagement and retention in lifestyle programmes whilst promoting long-term 
behaviour changes is therefore crucial (103). The following section discusses key 
intervention characteristics of translated DPPs with respect to their effectiveness, 
reach and potential impact. 
 
1.7.1 Intensity, duration and mode of delivery   
 
Adherence to guideline recommendations on intervention content, intensity and 
delivery has been associated with greater effectiveness of real-world interventions, 
particularly in achieving weight loss (103, 106). Additionally, evidence has shown 
DPPs with a high degree of contact to have greater potential for achieving positive 
outcomes (103).  
 
To examine the implementation of DPPs into routine healthcare settings, studies 
have explored a number of modifications to original trial interventions such as 
intensity (number of sessions), programme duration and mode of delivery (103, 
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107). Most pragmatic studies have modified intervention intensity to offer fewer 
counselling sessions (105). Systematic review evidence shows that although such 
programmes’ effectiveness in weight reduction may be low or moderate, diabetes 
risk reduction can be high provided they have a long duration (103). This is a 
promising finding especially where large populations can be reached but resources 
are limited (103). Another modification which has been explored and successfully 
adopted by national guidelines to limit resource requirements is the delivery of 
group-based education or telephone counselling as opposed to individual 
counselling (32, 103, 105, 107, 108). This modification is in line with evidence 
exploring the efficacy of type 2 diabetes education which has suggested that there 
is no difference in glycaemic control between group-based and individual education 




The majority of pragmatic lifestyle intervention studies have used similar personnel 
to those in major randomised controlled trials (105). Such personnel primarily 
consisted of medical and allied health personnel, including physicians, dieticians, 
nutritionists, certified diabetes educators, nurses and nurse practitioners, health 
coaches and exercise physiologists (105). However, systematic review evidence has 
found that lay educators, with minimal training requirements, can achieve similar 
weight loss as medical and allied health personnel (109). Evidence proposes that 
training for lay educators should include minimum core competencies such as basic 
knowledge, organisational skills and empathy (109). The use of lay personnel in the 
delivery of DPPs may significantly reduce required resources and increase scalability 
of interventions thus reducing financial barriers to implementation (107, 110).  
 
The use of lay personnel in the provision of DPPs has been investigated in the UK’s 
Norfolk diabetes prevention study which used lay people diagnosed with type 2 
diabetes as lifestyle mentors (111). The study, whose primary aim was to assess the 
effectiveness of a 40-month intensive diet and exercise intervention in reducing the 
progression to type 2 diabetes in people with NDH, also aimed to describe the 
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practicalities associated with recruiting, training and retaining individuals with 
existing type 2 diabetes to be diabetes prevention mentors (112). The study 
recruited and randomised 1,028 people with NDH to one of three arms (a control 
group or an intervention group with mentors or an intervention group without 
mentors). Although there are currently no published results for the effectiveness of 
the 40-month intervention, results for the secondary aim of the study have recently 
been published. The findings showed that lay members of the public with existing 
type 2 diabetes can be recruited, trained and retained as lay volunteer mentors to 
help support diabetes prevention in NDH. In the study, mentors were recruited 
through GP databases and assigned up to 7 participants. Their primary role was to 
work with health care personnel providing the intervention to support people with 
NDH through telephone calls scheduled once a month for the first 3 months and 
then once every two months until the programme ended. The mentors received 
group training delivered in the form of seminars over a 7-week period. The aim of 
the training was to provide up-to-date information on physical activity, diet, NDH 
and lifestyle related areas and the second was to develop key skills for the role. 
Additionally, the mentors received one-to-one practice work consisting of role play 
of telephone calls organised by the research team. The study successfully recruited 
and trained 104 mentors and had a withdrawal rate of 45% (n=47) at the end of the 
3-year study period.  
 
This research concluded that cost associated with diabetes prevention can be 
reduced, without compromising efficacy, by using non healthcare-professionals. 
However, without the primary clinical outcomes of the study being reported it is 
difficult to make informed judgements from the findings. Additionally, the extent to 
which healthcare personnel still played a role in delivering the intervention was not 
clearly described in the study, hence there is limited evidence to suggest the extent 
to which the implementation of such a delivery model would reduce healthcare 
resource requirements. The training package would need to be feasibility tested to 
investigate both the effectiveness and the cost-effectiveness of using mentors. The 
study described an intensive recruiting process which included four stages 
(screening, telephone interview, questionnaire and face to face interviews) which 
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could pose challenges in implementing in real-life settings. With almost half of the 
mentors withdrawing over the 3-year period of the study, this also raises questions 
about whether such a delivery model could be sustainable. More importantly, this 
delivery model would need to be evaluated to examine the impact of its 
implementation in different contexts in the UK, particularly in multi-ethic 
populations which are known to be at greater risk of developing type 2 diabetes 
(113). Therefore, although this study generated important findings with regards to 
the use of non-healthcare professional in diabetes prevention interventions, further 
research is needed before implementation of diabetes prevention models that 
include lay people with type 2 diabetes as mentors.  
 
1.7.3 Settings and context 
 
Based on the recognition that determinants of efficacy in trials might be 
fundamentally different from the vital characteristics necessary for 
implementation, evidence has also examined the impact of intervention 
characteristics such as the setting (103, 105, 114). Studies focused on the 
transferability of DPPs to real-world settings have explored four distinct settings 
including hospital outpatient, primary care, community and work/church (103, 105, 
108-110).  Whittemore et al. conducted a systematic review to assess the 
implementation of DPPs in different settings by evaluating factors such as efficacy, 
reach to the targeted population and adoption by providers (105). Hospital settings 
demonstrated ideal characteristics for the adoption and implementation of DPPs 
(105). This was attributed to the availability of facilities and resources which enable 
DPPs to be delivered with little adaptation from the original protocols.  Additionally, 
since the hospital staff providing the programmes are often highly qualified, this 
setting showed the highest effectiveness in terms of weight loss. However, in terms 
of reach, the hospital outpatient setting displayed the least population diversity and 
had a high attrition rate. The review recommended the hospital setting as ideal for 
the delivery of DPPs for highly motivated and committed individuals.  
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Unlike hospital settings, primary care settings demonstrated a greater potential to 
reach adults of diverse ethnicity and had lower attrition rates. Primary care also 
showed the potential to implement and deliver efficacious DPPs. The review 
highlighted factors such as established relationships between participants and 
providers as well as the potential to manage co-morbidities that frequently occur in 
adults with NDH as beneficial attributes of the setting. However, the limited 
availability of key personnel that tend to deliver DPPs such as health educators, 
nurses and dieticians in primary care settings and the lack of space to facilitate the 
implementation of group-based care are amongst the challenges highlighted.  
 
Church and work-based settings showed the greatest potential to reach adults with 
a diverse race and ethnicity. However, not only did programmes delivered in these 
settings face implementation challenges, but they also showed great variations in 
efficacy with some not achieving targeted weight reductions.  
 
1.7.4 Potential impact of implementing diabetes prevention programmes in real 
world settings  
 
In developed countries, attempts to halt the increasing prevalence of type 2 
diabetes have led to the implementation of national interventions that identify 
people with NDH and treat them with intensive lifestyle interventions (115, 116). 
However, this approach has not been widely embraced due to concerns about the 
impact of providing nationwide DPPs.  
 
Generally, there are two main approaches that could be adopted to prevent 
diabetes, including screen and treat interventions and the population-wide 
interventions (1, 117, 118). Central to both interventions is the promotion of 
healthy diet and exercise in order to reduce the rise in obesity (1). Population-wide 
interventions promote the prevention of obesity, healthy eating and physical 
activity by focusing primarily on policy reforms on food, transport, education, 
health and economics (1). Screen and treat approaches target subpopulations 
identified with NDH and offer them interventions aimed to prevent or delay the 
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development of type 2 diabetes (1, 78). This approach is favoured by national 
guidelines as it also promotes the early detection of individuals with undiagnosed 
type 2 diabetes (107). However, a prevalent perception amongst those in favour of 
the population-wide approach is that screen and treat addresses individual risk 
factors without considering wider social influences such as deprivation, local 
environments, food advertising and the affordability of healthy foods. 
 
Whilst countries such as the USA and Australia have opted for screening and 
treating, other countries such as Finland have chosen a multi-level model by 
adopting both population-wide and the screen and treat interventions (32, 117). 
Countries such as Finland have thus demonstrated that one approach does not 
preclude the other. In England, despite some research evidence suggesting 
otherwise (78), Public Health England has also implemented a three-tiered 
(primary, secondary and tertiary) approach to diabetes prevention. The first tier, 
primary prevention, is a population approach which focuses on prevention of 
obesity by improving diet, increasing physical activity levels and obesity prevention 
through campaigns and introducing sugar tax policies (119). The second tier, 
secondary prevention, implements a screen and treat approach targeted at people 
with NDH (115). The tertiary approach focusses on improving adult diabetes 
services to reduce complications (7). This thesis focuses on the secondary 
prevention of type 2 diabetes which is the implementation of a nationwide 
programme known as the NHS DPP.  
 
 
1.8 The NHS diabetes prevention programme 
 
The NHS DPP is an evidence based, nationwide programme developed jointly by 
Public Health England, NHS England and Diabetes UK (40). The development of the 
programme was primarily based on findings of a commissioned systematic review 
which included 36 pragmatic lifestyle interventions for the prevention of type 2 
diabetes in routine practice. The interventions ranged from diet only, physical 
activity or a combination of both. The findings of the review suggested that DPPs 
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can reduce the incidence of type 2 diabetes by 26% compared to usual care. The 
review also reported DPPs to be associated with an average weight loss of 1.57kg 
more than usual care. The NHS DPP is a 9-month intervention which identifies 
people with NDH (>18 years) primarily through retrospective screening of general 
practice databases and refers them onto a behavioural change intervention to 
reduce the risk of developing type 2 diabetes (120). Individuals with NDH can also 
be identified using validated self-assessment questionnaires or screening 
programmes such as NHS Health Checks by community pharmacists, occupational 
health nurses and community leaders. People identified through the latter route 
are then referred to their general practice for confirmatory blood tests (32). Both 
the HbA1c and the FPG blood tests can be used for referral into the intervention and 
are recommended to be performed using venous blood. The NHS DPP aims to 
achieve three main goals including weight loss, improved diet and increased 
physical activity (121). The key measures of success for the programme are weight 
reduction, risk reduction (measured through blood glucose parameters at 12 
months and beyond (HbA1c or FPG)), reduction in the incidence of type 2 diabetes 
and retention of people on the programme. The characteristics of the intervention 
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Table 1.6 Summary of lifestyle change intervention characteristics recommended by NICE 
 
* Settings such as workplaces, leisure, community and faith centres and outpatient departments and clinics 
**in the NHS, private, voluntary and community organisation
 Setting  Providers  Delivery Duration Frequency  Contact 
time 
Content Behavior change 
techniques 
NICE (32) Primary 






















Follow up: at 




(minimum 8 times 
over duration of 
the intervention)  
 






physical activity (150 
min/week). Weight 
loss to healthy BMI 
 
Diet modification - 
Increase consumption 
of dietary fibre and 
reduction in total 




interviewing to explore 
and reinforce 
participants’ reason for 
change 
Goal setting; action 


















9 months Minimum of 13 
sessions lasting 




to make positive 
lifestyle changes in 





Education (type 2 
diabetes and its risk 
factors, weight loss 
and dietary 
information), 
Support to increase 







The provider utilizes 
behavior change 
theory and techniques. 
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The programme is commissioned and funded by NHS England and is delivered 
nationally by framework providers who are selected through a national commercial 
procurement process conducted every four years (120, 123). The programme can 
be delivered by both primary care providers (e.g. community pharmacy and general 
practices) and non-healthcare providers (e.g. voluntary or private sector 
organisations) (124). The national procurement consists of a framework agreement 
that sets the cost of delivering DPP against national specification. NHS England 
work with Clinical Commissioning Groups (CCGs) to organise tender processes to 
procure the services to deliver locally specific DPPs.   
 
NHS DPP providers receive staged payments based on the number of participants 
who complete defined milestones of the course. Thus, a key objective of the 
payment mechanism is incentivisation of providers to retain participants on the 
programme and to encourage completion. The milestones which determine the 
completion of a stage and relative payment include programme registration, 
attendance to initial face to face meeting and attendance to 25%, 50%, 75% and 
100% of the planned course time. The implementation process began with a first 
wave of 27 areas in England in 2016 and achieved nationwide coverage in 2018. The 
programme was first delivered by private public health services providers including 
Reed Momenta, ICS Health and Wellbeing, Health Exchange CIC and Ingeus UK 
Limited (115). 
 
1.8.1 Potential impact of implementing the NHS diabetes prevention programme 
 
Systematic review evidence has shown lifestyle interventions to be a cost-effective 
strategy for the prevention of type 2 diabetes in individuals with NDH (49, 100, 125, 
126). Furthermore, research evidence suggests screen and treat approaches to be 
cost-effective (127). However, there is a current lack of evidence demonstrating the 
impact of implementing nationwide screen and treat approaches such as the NHS 
DPP, particularly on long-term outcomes such as mortality, morbidity and cost on 
healthcare systems.  
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In 2016, an impact analysis performed to estimate the implications of implementing 
the NHS DPP on NHS resources and health outcomes formed the evidence base for 
implementing the programme (128).  Suggesting lifestyle-change programmes to be 
cost-effective, the analysis estimated that the NHS DPP would achieve a net saving 
of £35 million over 20 years and cumulative direct health benefits of 18,000 Quality 
Adjusted Life Years relative to doing nothing. The analysis also estimated that over 
5 years (2016-2021) the programme would prevent or delay approximately 4,500 
diabetes diagnoses for every 100,000 people enrolled.  
 
The impact analysis was based on assumptions of uptake and participant retention 
which are the central drivers of success of the NHS DPP. However, due to lack of 
available data, uncertainty in the likely uptake and retention rates in the NHS DPP 
remains a key risk in implementing the intervention nationally and a limitation in 
modelling its likely impact. Research evidence also suggests that the impact of DPPs 
could be undermined by poor engagement amongst people with NDH (78).  
Evidence from a meta-analysis has highlighted high withdrawal and attrition rates 
in DPP clinical trials, with only 27% of the identified population with NDH 
completing the intervention (78). Primary reasons for attrition identified by the 
meta-analysis were declining or withdrawal from the intervention and not being 
eligible for participation. Similar findings were also identified in a study evaluating 
an existing community-based DPP in England (129, 130). The study demonstrated 
low uptake (23% of the targeted population) following initial invitation letters 
mailed from 17 general practices which further decreased to 10% just before 
randomisation.  
 
Qualitative research evidence investigating participation in DPPs or similar 
programmes has identified common barriers for uptake. Laws et al. who explored 
factors influencing participation in a practice based vascular disease prevention 
programme highlighted accessibility barriers such as transportation and 
geographical location (131). In addition, they highlighted challenges in organising 
group-based sessions suitable for most of the participants and identified the need 
for flexibility, including delivering nighttime, weekend or individual sessions and 
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offering telephone-based follow-up (131). Kullgren et al. who examined 
engagement of people identified with NDH through work-based screening 
identified primary reasons for not engaging as work and social commitments and 
accessibility of exercise facilities (132). Similar social barriers were also highlighted 
by a qualitative study conducted by Penn et al. which aimed to understand the 
experience of participants who maintained behaviour change following lifestyle 
interventions (133).  
 
Both programme uptake and retention are therefore key determinants of the 
projected impact of the NHS DPP. A progress report on the NHS DPP has indicated 
that of those referred onto the programme, 49% attend the initial assessment 
meeting (128). Additionally, reports indicate that between 36% and 55% of people 
referred into the NHS DPP decline the intervention and between 26% and 50%, do 
not progress onto the group-based sessions (124).  Qualitative research evidence 
highlights important barriers and facilitators that would need to be addressed by 
the current NHS DPP to ensure intervention uptake and retention. However, there is 
currently no published evidence investigating the barriers to uptake in the NHS DPP. 
Neither is there research investigating impact of delivering the programmes in 
alternative settings to increase uptake.   
 
 
1.9 Exploring community pharmacy as a potential setting for 
delivering Diabetes Prevention Programmes 
 
Systematic review evidence, exploring the implementation of DPPs in real world 
settings, has highlighted primary healthcare and community settings to have the 
greatest reach to people with NDH (103, 105).  Furthermore, evidence suggests 
established participant/provider relationships and opportunities for the 
management of co-morbidities to play an important role in engaging with targeted 
populations in primary care settings (105).  Globally, primary healthcare settings 
such as community pharmacy have been identified as suitable for delivering health 
promotional and disease prevention services (134). Community pharmacy’s offering 
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convenient locations, extended opening hours (135) and the availability of a private 
consultation room, present an opportunity to support behaviour change 
interventions such as the NHS DPP by directly addressing some of the barriers to 
DPP uptake (135, 136). Additionally, potential facilitators to engagement with DPPs 
such as face to face interaction with professionals (3, 20) and continuity of 
providers (11, 21) are highly applicable to community pharmacy. 
 
1.9.1 The community pharmacy setting 
 
Over recent years, the traditional dispensing role of community pharmacists has 
developed towards the delivery of public health services such as diabetes 
screening, smoking cessation and weight reduction programmes (135-138). This is 
primarily due to the accessibility of community pharmacies (139). In England, there 
are over 11,688 community pharmacies which are estimated to provide health-
related services to approximately 1.2 million visitors every day (139, 140). As the 
most visited NHS care setting in England, approximately 90% of the population has 
access to a community pharmacy within a 20-minute walk (141).  
 
Accessibility of community pharmacies increases to over 99% in highly deprived 
populations including lower socioeconomic groups and ethnic minority groups 
(141). In these populations, obesity, the greatest modifiable risk factor of type 2 
diabetes, has been shown to have the highest prevalence (19, 142).  Evidence 
shows that general practices, the current primary route of identification of NDH, 
have a low uptake of diabetes screening services in highly deprived populations (32, 
142). Therefore, with evidence demonstrating a higher accessibility in deprived 
areas than general practices, the community pharmacy is a potentially valuable 
setting for tackling existing health inequalities (114, 140, 143).  
 
1.9.2 Community pharmacy personnel  
 
Evidence suggests that DPPs can be successfully delivered by both healthcare and 
non-healthcare personnel (109). As the third largest healthcare profession in 
   61 
    
England, the pharmacy workforce consisting of registered pharmacists, registered 
pharmacy technicians, non-registered dispensing and healthcare assistants, has 
potential capacity to deliver DPPs (144). Additionally, the proposed introduction of 
dispensing hubs and the widening of technicians’ wider role on the national 
agenda, further serves in increasing potential capacity for the involvement of 
community pharmacy in delivering public health interventions.  
 
The increased representativeness of the community pharmacy personnel to local 
communities also has potential to address current health inequalities. Research 
investigating uptake of DPPs in different ethnic backgrounds such as South Asians 
(145), Hispanic (146), Black Africans (147) and Bangladeshi (148) has highlighted 
language (145, 146, 148), social roles (145, 148) and poor cultural and religious 
understanding of healthcare professionals (135, 148, 149) as barriers to uptake. 
NICE recommends the use of local staff in delivering DPPs to overcome contextual 
factors such as language and other personal factors such as ethnicity, faith, culture 
or any disability. Community pharmacy personnel, who often tend to reflect local 
populations with respect to ethnicity, culture and language, could therefore play an 
important role in engaging hard to reach groups and thus maximize the impact of 
the NHS DPP (149).  
 
1.9.3 Evidence for community pharmacy-based diabetes prevention programmes  
 
Systematic review evidence suggests community pharmacy to be a potential setting 
for delivering public health interventions (150). However, despite such 
recommendations, there is a lack of evidence exploring the delivery of DPPs in the 
community pharmacy setting. Most studies investigating the role of community 
pharmacy in diabetes prevention have focused on diabetes screening rather than 
screen and treat interventions such as DPPs. For example, a study conducted by 
Ayoride et al. suggested diabetes screening interventions which include an element 
of education to be feasible and acceptable for delivery in community pharmacy 
(151). However, the study indicated that referrals made following screening in this 
setting to have a poor attendance rate. Similar findings were also highlighted by a 
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meta-analysis by Willis et al. which aimed to evaluate existing literature on 
community pharmacy-based screening interventions for type 2 diabetes and CVD 
(152). Whilst indicating such interventions to be feasible in the community 
pharmacy setting, the review highlighted that in those identified as being at high 
risk and referred to other services, a significant proportion do not attend follow-up 
appointment with their general practitioners (GPs). This evidence suggests that 
whilst uptake to screening may not be a problem in this setting, there is a need for 
research to focus on developing interventions that encourage attendance to early 
intervention.  
 
The implementation of the DPP in community pharmacy has been investigated by 
Dhippayom et al. (153). The study was conducted in pharmacies in Thailand and 
used a validated risk assessment tool and a follow-up FPG Point of Care Test (POCT) 
to identify people with NDH.  For those identified as high risk, the intervention 
included a lifestyle education intervention based on guideline recommendations. 
The education intervention was delivered by pharmacists through leaflets and face 
to face consultations and consisted of information about lifestyle modification 
regarding diet, exercise and weight reduction.  
 
The study identified potential diabetes and NDH in 12.7% and 28.4% (respectively) 
of all participants that were screened. The study also indicated poor attendance 
rates to referred services in those who had potential diabetes and suggested 
inconvenience as the primary reason for non-attendance. However, although the 
study suggested successful delivery of an education intervention in those identified 
with NDH, the one-off intervention does not mirror the ongoing lifestyle 
interventions provided in the NHS DPPs. There is, therefore, a need to explore the 
delivery of ongoing lifestyle interventions in the community pharmacy setting.  
 
1.9.4 Guidelines for the management of non-diabetic hyperglycemia in 
community pharmacy 
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Public Health England has recognised the potential significant and sustainable 
impact that community pharmacy could make in reducing the risk of disease 
including diabetes (144). A potential key role of community pharmacy in delivering 
effective and impactful preventative interventions, supporting healthy living and 
reducing health inequalities has also been highlighted (154). NICE recommends the 
delivery of intensive lifestyle programs by primary health care teams which includes 
community pharmacies (32). The guidelines recommend community pharmacy 
teams to offer individual behavioral support for people with NDH in weight 
management by offering lifestyle interventions or referral to other behavioral 
support services where lifestyle interventions are not available in the pharmacy. 
However, despite NICE recommendations for the role of community pharmacy, 
routine primary care appointments or retrospective screening of general practice 
databases remains the primary route for identifying people with NDH (40, 120, 
155).  
 
In England, the only current involvement of community pharmacy in diabetes 
prevention is the delivery of screening programmes, such as the NHS Health Check 
(135, 137). The NHS Health Check is a nationwide risk assessment, awareness and 
management programme, offered free of charge to eligible adults aged between 40 
to 74 years (156). Whilst the programme primarily aims to establish the risk of 
developing CVD, it also incorporates a diabetes filter whereby individuals at high 
CVD risk are offered diabetes FPG POCT (157). All individuals accessing the 
programme receive one-off tailored lifestyle advice from trained community 
pharmacy personnel and if identified as high risk, are referred to their GP for 
further testing.  
 
The programme is primarily delivered in general practice and community pharmacy 
settings but can also be offered in other accessible settings such as workplaces and 
other community settings. Evidence evaluating the NHS Health Check has shown 
that community pharmacies successfully reach the targeted population, with higher 
referral rates to lifestyle services than those referred through other means (137, 
158). However, although the programme can identify people with NDH, it is 
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currently not modified to enable direct referrals to the NHS DPP. Firstly, the 
programme does not offer venous blood tests (FPG and HbA1c) which are required 
for referral onto the NHS DPP and secondly, it is only eligible to people age 40-74 
with no existing cardiovascular risk, hence potentially excludes many people with 
NDH. The limitations to the use of the NHS Health Check as a referral pathway has 
therefore eliminated referrals from a potentially accessible setting (32, 135).  
 
Therefore, despite the growing recognition that public health interventions 
delivered in community pharmacy should be integrated in a local primary care and 
public health network (144, 159), current pharmacy services do not offer pathways 
to current services interventions. Furthermore, at present there are no routine 
lifestyle interventions being delivered in the community pharmacy setting for 
people with NDH. In other countries such as the USA, where a large-scale 
implementation of a national DPP began in 2010, recommendations for further 
expansion have resulted in the development of clear guidance outlining the delivery 
of DPPs in accessible settings such as community pharmacy (160). In England, 
however, there are no clear guidelines for how community pharmacists could 





Evidence demonstrates a potential to delay or prevent the development of type 2 
diabetes in people with NDH through DPPs (100). The current preferred method for 
identifying NDH is a two-step screening approach involving the use of validated risk 
assessment tools followed by confirmatory blood tests (32). National guidance 
recommends the delivery of intensive lifestyle interventions in those identified with 
NDH to delay or prevent the incidence of type 2 diabetes (32, 100). The impact and 
scalability of lifestyle interventions is largely determined by the reach of the 
programmes (105).   
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In England, the NHS DPP has been implemented to delay and prevent the incidence 
of diabetes in NDH. However, uncertainties in potential uptake and retention in the 
targeted population could negatively affect the projected impact of the 
programme. Qualitative research has highlighted accessibility as an important 
barrier to uptake in DPPs. With the primary care setting demonstrating the greatest 
diversity, NICE recommends the delivery of intensive lifestyle interventions in 
settings such as the community pharmacy (32). However, although evidence 
investigating the implementation of DPPs in community pharmacy settings has 
demonstrated screening interventions to be feasible, there is a need to investigate 
the delivery of follow-up lifestyle interventions or referral routes in this setting 
(152, 153, 161, 162). As such the research question for this thesis is: What is the 
role of community pharmacy in providing DPPs in England? 
 
1.10.1 Research aims 
 
This thesis aims to characterise the current and potential role of community 
pharmacy in the prevention of type 2 diabetes and to explore community pharmacy 
as an option for the delivery of diabetes prevention services (DPS) in England.  
[In this thesis, the term DPS will be adopted to refer to potential diabetes prevention 
interventions that could be delivered in the community pharmacy setting. This term, 
rather than DPP, has been adopted since the role of community pharmacy in 
diabetes prevention in England is currently unclear]. 
 
1.10.2 Research objectives 
 
1. To identify the potential role of community pharmacy in delivering diabetes 
prevention services for people with non-diabetic hyperglycemia. 
2. To describe acceptable intervention characteristics for people identified 
with NDH. 
3. To identify the barriers and facilitators to implementing community 
pharmacy-based diabetes prevention services in primary care.
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Chapter 2: The application of theory in 
exploring the role of community pharmacy 





























The delivery of public health interventions such as DPPs usually require behaviour 
change at many levels (e.g. individual, organisational and societal) (163, 164). 
Behaviours may be those of healthcare personnel e.g. pharmacy technicians, or of 
the general population e.g. people with NDH, or of organisations such as CCGs. The 
development and implementation of effective interventions therefore require a 
clear contextual understanding of the problem being addressed, the behaviours 
driving the unwanted outcome and the processes that may usher in the desired 
outcome (165-168). For example, successful engagement with diabetes prevention 
interventions would require an understanding of the determinants of engagement 
and non-engagement in people with NDH. This information would in turn assist in 
identifying appropriate behaviour change interventions that would drive 
engagement. Similarly, the delivery of DPS by community pharmacy teams would 
require a thorough understanding of processes that would facilitate intervention 
delivery in this setting in order to implement behaviour change interventions that 
would enable the provision of these services.  
 
Evidence suggests behaviour change interventions based on theory to be more 
effective than those that are not (169, 170). Theory not only guides the systematic 
understanding of targeted behaviours i.e. the problem being addressed, but also 
assists the development and implementation of effective interventions to influence 
and change behaviours (166-168, 171). Theory can be developed from existing 
literature and stakeholder perspectives (e.g. potential patients who may use the 
intervention and practitioners who may deliver the intervention) (172).  Relevant 
existing psychological and social theories can also be used to develop theory led 
questions that need to be answered when conducting primary research such as 
interviews and focus groups with key stakeholders (78, 173). This research 
employed the use of existing literature, stakeholder perspectives and an existing 
psychological theory to thoroughly investigate the potential role of community 




This chapter describes how theory has been applied to enhance the description of 
the role of community pharmacy in diabetes prevention, following the initial 
literature search (chapter 1). This process is outlined in two stages including: 
1. Selecting a relevant theoretical framework 
2. Application of the selected theory to current research 
 
 
2.2. Selecting a relevant theoretical framework  
 
Theory presents a systematic way of understanding behaviours. A theory can be 
defined as ‘a set of interrelated concepts, definitions, and propositions that explain 
or predict events or situations by illustrating relationships between variables (174). 
By nature, theories are abstract without a pre-specified topic and only become 
useful when applied to practical topics and problems. Theories are made of 
constructs (key concepts of a given theory) and variables (the operational form of 
the constructs usually defining the measurement of a construct in a particular 
situation) (175). A number of theories may also be merged to assist the 
understanding a particular problem in a specified setting or context. These are 
known as frameworks (175).  
 
Generally, there are two broad types of behavioural theory, explanatory theory and 
change theory (165). Explanatory theories largely seek to understand behaviour, 
often describing why a problem exists and identifying factors that contribute to a 
problem e.g. lack of knowledge or resources. Examples of explanatory theories 
include the Health Belief Model and the Theory of Planned Behaviour (176). Change 
theories guide the selection of behaviour change intervention(s) by identifying 
concepts that can be translated into intervention strategies and providing 
clarifications of why interventions are likely to be effective (165). Examples of such 
theories include the Diffusion of Innovations theory (177). Whilst these types of 
theories (explanatory and change) may have different emphases, they are often 




Over the years, there has been a growing interest in the use of theories in health 
services research to understand behaviours and inform intervention design and 
implementation (179, 180). However, evidence shows significant variations in the 
application of theory in implementation research (181). These variations, which 
primarily occur due to the challenges with selecting appropriate theories and their 
practical application are discussed below:  
 
 Numerous existing theoretical models with little consensus  
There are a large number of existing theoretical models (182), with most 
focusing on particular constructs (167). A 2015 scoping review by Davis et al. 
identified 82 behaviour change theories in the social sciences alone (183). Over 
the years several reviews have highlighted a lack of consensus between theories 
with similar constructs particularly with regards to the terminology used (184-
187). Additionally, because most theories do not cover the full range of possible 
constructs, even with the combination of one or two theories there is a risk of 
excluding potentially important variables (188). For example, the Theory of 
Planned Behaviour and Health Belief Model, the two most commonly used 
theories in public health, between them do not address the important 
influences such as habit, self-control and emotional processing (189).  
 
To overcome these problems, psychologists have proposed integrative 
frameworks of theory that combine concepts and constructs from several 
existing theories and are subjected to rigorous testing across behaviors and 
situations and refined as necessary (190, 191). Frameworks, which incorporate a 
wide range of theories, allow researchers to capture and evaluate more 
behaviour determinants than they would with one theory alone. The Behavior 
Change Wheel and the Theoretical Domains Frameworks are examples of such 
integrated frameworks (188, 192). These frameworks will be discussed in more 
detail later in this chapter. 
 
 Lack of analysis to guide the choice of theories 
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Research suggests that the potential effectiveness of evidence-based 
interventions increase with the number of theories used (170). However, due to 
the abundance of behaviour theories, researchers and intervention developers 
often face challenges with selecting the most appropriate theories. Additionally, 
whilst most existing theories used in health services intervention development 
are from a social science or psychological background, intervention developers 
often consist of researchers and healthcare personnel with no background in 
psychology or social science (193). This has, over the years, led to very little use 
of theory in intervention development, consequently leading to failed 
interventions (188). The few studies that have used theories, have shown no 
clear rationale for theory use and selection of constructs (168, 181). The lack of 
specification on how to select and apply appropriate theory poses challenges 
for intervention designers who are often non-psychologists (193).  
 
What follows is a discussion of some of the most common theories used in the 
design and implementation of public health interventions. These common 
theories are: The Health Belief Model, The Theory of Planned Behaviour, The 
Stages of Change (Transtheoretical Model) and the Diffusion of Innovation 
theory. Newer frameworks that have been developed and adapted to resolve 
the challenges outlined above such as the Theoretical Domains Framework 
(171) and the Behaviour Change Wheel (188, 192) will also be discussed.  
 
2.2.1 The Health Belief Model  
 
The Health Belief Model (HBM), one of the first theories of health behaviour, was 
developed in the early 1950s by social scientists at the U.S. Public Health Service to 
help understand why people did or did not use preventative services offered by 
public health departments (165, 175). The HBM, derived from psychological and 
behavioural theory, suggests that components of health-related behaviour are a 
combination of 1) the desire to avoid illness and 2) the belief that a specific health 
action will prevent or cure illness. The model addresses an individual’s perceptions 
of the threat/risk posed by a health problem (susceptibility, severity), the benefits 
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of avoiding the threat and factors influencing the decision to act (barriers, cues to 
action, and self-efficacy). There are six core constructs of the HBM: 
 
1. Perceived susceptibility: Individual’s subjective perception of the risk of 
acquiring an illness or disease.  
2. Perceived severity: Individual’s beliefs towards the seriousness of 
contracting an illness and disease as well as its consequences.  
3. Perceived benefits: A person’s perception of the effectiveness of advised 
actions to reduce risk or seriousness of impact.    
4. Perceived barriers: A person’s feeling on the obstacles to performing a 
recommended health action. 
5. Cues to action: This is the stimulus needed to trigger the decision-making 
process to accept a recommended health action. 
6. Self-efficacy: The level of a person’s confidence in his or her ability to 
successfully perform a behaviour. This construct was added to the model 
recently in the mid-1980s and is a construct in many behavioural theories as 
it directly related to whether a person preforms a desired behaviour.  
 
The HBM, which is explanatory and targeted at the individual level, has mostly been 
applied for health concerns that are prevention related and asymptomatic, such as 
early cancer detection and hypertension screening (194). Therefore, this model 
could be used in the present research to explain why some people at high risk of 
T2D engage and others do not engage with DPPs. However, there are several 
limitations to its use that could hinder its application in the present study. Firstly, 
the HBM does not take into account other individual determinants that could 
influence a person’s acceptance of a behaviour such as attitudes or beliefs which 
have been shown to be important in determining the intent to perform a behaviour 
(195). This is an important factor for this research since in health concerns that are 
prevention related, an individual’s beliefs could be as important or more important 
than overt symptoms. Secondly, because the HBM is also more explanatory, it does 
not suggest a strategy for change (165). Therefore, whilst the individual constructs 
may be useful for this research, the model would need to be integrated with other 
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models that account for environmental contexts and suggest strategies for change. 
Thirdly, because the HBM does not account for other behaviours that are 
performed for non-health related reasons (e.g. exercising for aesthetic reasons), it 
does not consider other influences such as social acceptability, environmental or 
economic factors that may prohibit or promote the recommended action. This 
therefore limits its use in the present study that is primarily exploring the potential 
role of community pharmacy in delivering diabetes prevention services in primary 
care.  
 
2.2.2 Theory of Planned Behaviour 
 
The Theory of Planned Behaviour (TPB), developed in the 1980s by Icek Ajzen, 
suggests that behavioural intention determines behaviour performance (196, 197). 
Intention is therefore the key component of the model and is defined “as the 
cognitive representation of the person’s readiness to perform a certain behaviour” 
(198). The theory suggests that intention captures motivational factors that 
influence a behaviour and thus is an indication of the extent to which one is willing 
to try and the amount of effort one is prepared to exert to perform the behaviour. 
 
The TPB initially started as the theory of reasoned action to predict an individual’s 
intention to engage in a behaviour at a specific time and place journal of clinical 
epidemiology (199). The theory was developed to explain all behaviours over which 
people have the ability to exert self-control i.e. voluntary behaviour and was largely 
related to attitudes towards the behaviour. However, further research revealed 
that behaviour appeared not to be entirely voluntary and under one’s control 
resulting in the addition of perceived behavioural control. With this addition the 
theory was changed to the Theory of Planned Behaviour (See Figure 2.1). The 
theory therefore has three main constructs that determine an intention towards 
performing a behaviour:  
 
 Attitude towards the behaviour: the degree to which a person has a 
favourable or unfavourable evaluation of the behaviour of interest.  
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 Subjective norms: the belief about whether most people (peers or people of 
importance to the person) approve or disapprove of the behaviour. This also 
includes a consideration of social norms i.e. accepted behaviour that an 
individual is expected to conform to in a particular group, community or 
culture. 
 Perceived behavioural control: an individual’s perception/beliefs of the 

















The TPB has been used to predict deliberate behaviour and explain a wide range of 
health behaviours and intentions including health service utilisation (200, 201). 
Although the TPB has shown greater applicability in public health than the HBM, its 
inability to consider environmental and economic influences has also limited its use 
(195). Its assumption that individuals have acquired the opportunities and 
resources to be successful in performing the desired behaviour regardless of the 
intention would therefore also limit its application in this research (195). 
Additionally, because the model also does not take into account other variables 







behavioural control   
Behaviour  
Figure 2.1 Theory of planned behaviour 
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and past experience, its use to explore engagement with diabetes prevention 
programmes would also be limited (195, 198). Like the HBM, the TPB is mostly 
explanatory and does not offer interventions to address behaviour. Therefore, 
although the constructs of this model are useful, it still needs to be integrated with 
components from other theories to make it a more functional model for this 
research. 
 
2.2.3 Stages of Change (Trans-Theoretical) model 
  
The Trans-Theoretical model (TTM) was developed by Prochaska and DiClemente 
and emerged out of studies comparing experiences of smokers who quit on their 
own with those of smokers receiving professional support (178). The model is 
based on three assumptions 1) behaviour change is a process that unfolds over 
time and involves a series of different stages 2) there are common stages and 
processes of change across a variety of health behaviours 3) tailoring an 
intervention to the individual’s current stage of change is more effective than not 
evaluating readiness at all.  Stages of change therefore forms the main construct of 
the model and proposes that people are at different stages of readiness to adopt 
behaviour change (see Figure 2.2).  While the time a person can stay in each stage 
is variable, the tasks required to move to the next stage are not. Certain principles 
and processes of change work best at each stage to reduce resistance, facilitate 
progress, and prevent relapse. Those principles make up the three other constructs 
of the TTM i.e. decisional balance, self-efficacy, and processes of change. 
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Decisional balance: This construct has two elements, the pros and the cons. As 
individuals progress through the Stages of Change, decisional balance shifts in 
critical ways e.g. when an individual is in the pre-contemplation stage, the pros in 
favour of behaviour change are outweighed by the relative cons for change and in 
favour of maintaining the existing behaviour. 
 
Self-efficacy: This construct reflects the degree of confidence individuals have in 
maintaining their desired behaviour change in situations that often trigger relapse. 
It is measured by the degree to which individuals feel tempted to return to their 
problem behaviour in high-risk situations e.g. in the pre-contemplation and 
contemplation stages, temptation to engage in the problem behaviour is far greater 
than self-efficacy to abstain. 
 
Process of change: While the stages of change are useful in explaining when 
changes in cognition, emotion, and behaviour take place, the processes of change 
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help to explain how those changes occur. This construct consists of ten covert and 
overt processes that need to be implemented to successfully progress through the 
stages of change and attain the desired behaviour change. These processes result in 
strategies that help people make and maintain change. The stages of change and 
the potential strategies suggested by the process of change construct are presented 
in Table 2.1. 
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Table 2.1 Stages of Change model 
 





No intention of taking action 
within the next six months 
Consciousness raising - increasing awareness about the healthy 
behaviour. 
Increase awareness of need for 
change; personalise 




Intends to take action in the next 
six months 
Dramatic relief – emotional arousal about the health behaviour, whether 
positive or negative arousal. 
Self-re-evaluation - self reappraisal to realise the healthy behaviour is part 
of who they want to be. 
Environmental re-evaluation - social reappraisal to realise how their 
unhealthy behaviour affects others. 
Motivate; encourage making 
specific plans  
Preparation Intends to take action within next 
30 days and has taken some 
behavioural steps in this direction 
Self-liberation - commitment to change behaviour based on the belief 
that achievement of the healthy behaviour is possible. 
Assist with developing and 
implementing concrete action 




Has changed behaviour for less 
than six months 
Social liberation - environmental opportunities that exist to show society 
is supportive of the healthy behaviour. 
Helping relationships - finding supportive relationships that encourage 
the desired change. 
Counter-conditioning - substituting healthy behaviours and thoughts for 
unhealthy behaviours and thoughts. 
Reinforcement management - rewarding the positive behaviour and 
reducing the rewards that come from negative behaviour. 
Assist with feedback, problem 
solving, social support and 
reinforcement  
Maintenance Has changed behaviour for more 
than six months  
 
Stimulus control - re-engineering the environment to have reminders and 
cues that support and encourage the healthy behaviour and remove 
those that encourage the unhealthy behaviour. 
Assist with coping, reminders, 




The stages of change model has been applied in both individual behaviours such as 
the development of smoking cessation interventions (202) and organisational 
change such as informing practitioners’ discussions with individual patients about 
engaging with screening tests (203). The key benefit of this model is that it provides 
suggested strategies for public health interventions to address people at various 
stages of the decision-making process. This can result in tailored interventions. In 
addressing our research problems, however, although this model could be used to 
assess the readiness of people at high risk of T2D to engage with diabetes 
prevention services, its lack of consideration for the social context in which change 
occurs may limit its application when considering the delivery of diabetes 
prevention services by community pharmacy teams. Overall, the theory is more 
targeted at individuals thus may not be very useful when considering organisational 
change in the community pharmacy or primary care.  
 
2.2.4 Diffusion of Innovation Theory 
  
Diffusion of Innovation Theory (DOI) is a social science theory, developed by E.M. 
Rogers in 1962, to explain how an idea, product or behaviour gains momentum and 
diffuses (or spreads) through a specific population or social system over time (204). 
The theory has two concepts:  
1. The outcome of the diffusion is that people adopt the new idea, behaviour 
or product with the key to adoption being a perception that it is new and 
innovative.  
2. Due to people having different characteristics, adoption of the innovation 
does not happen simultaneously, rather that some people are more likely to 
embrace the innovation earlier than others (177).  
The theory therefore stresses the importance of understanding the characteristics 
of the target population that will help or hinder adoption of the innovation when 
promoting it to the population. The theory therefore has five established adopter 
categories (see Figure 2.3), including suggested strategies to use to make the 















1. Innovators: These people are venturesome, risk takers and take interest in 
new ideas.  Because these people are likely to be ones that want to be the 
first to use try the innovation, very little needs to be done to appeal to 
them. 
2. Early adopters: These are leaders whose awareness of the need for change 
makes them very comfortable adopting new ideas. Strategies that appeal to 
this population include how-to manuals and information sheets on 
implementation.  
3. Early Majority: These are people who adopt new ideas before the average 
person but need some convincing to adopt a new idea. Strategies to appeal 
to this population include success stories and evidence of the innovation’s 
effectiveness.  
4. Late majority: These are sceptical of change and will only adopt an 
innovation after it has been tried by the majority. Strategies that appeal to 
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this population include information on how many other people have tried 
the innovation and have adopted it successfully. 
5. Laggards: This constitutes the hardest group to bring on board due to their 
sceptical and conservative nature. Strategies that appeal to this population 
include statistics, fear appeals and pressure from people in other adopter 
groups.  
 
The theory also has five main factors that influence adoption of an innovation and 
each of these factors is at play to a different extent in the five adopter categories: 
 
1. Relative advantage: the degree to which an innovation is seen as better 
than the idea, programme or product it replaces  
2. Compatibility: how consistent the innovation is with the values, experiences 
and needs of the potential adopters 
3. Complexity: how difficult the innovation is to understand and/or use  
4. Triability: the extent to which the innovation can be tested or experimented 
with before a commitment to adopt is made 
5. Observability: the extent to which the innovation provides tangible results 
 
The theory has been applied in various fields including communication and public 
health. Its application in public health including diabetes prevention emphasises 
that the most successful adoption of public health programmes result from 
understanding the target population and the factors influencing their rate of 
adoption (205). However, certain limitations to its use in public health that have 
been highlighted by research include concerns that the theory, including the 
adopter categories, do not have origins in public health and therefore were not 
developed explicitly to apply to adoption of new behaviours or health innovations 
(195). Additionally, because the theory works better with adoption of behaviours, 
its use in cessation or prevention of behaviours would likely be limited (195). Like 
most other theories the DOI also does not take into account individuals’ resources 
or social support to adopt the new behaviour.  
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2.2.5 Integrated frameworks (The Theoretical Domains Framework and the 
Behaviour Change Wheel) 
 
Newer theoretical models and frameworks have sought to overcome challenges in 
theory selection and application outlined earlier in this chapter. The development 
of the frameworks considered recommendations from leading psychological 
theorists suggesting the simplification of existing behaviour change theories and 
models in order to achieve consensus on behavioural constructs. Their 
development also particularly focused on increasing the ease of use of theory in the 
implementation of evidence-based practice which is often carried out by healthcare 
professionals and researchers with no psychology background. The Theoretical 
Domains Framework (193) and the Behaviour Change Wheel (188, 192) are two 
such frameworks that have been recently developed for this purpose. 
 
2.2.5.1 The Theoretical Domains Framework (TDF) 
The Theoretical Domains Framework (TDF), developed in 2005, is an integrative 
framework of theories of behaviour change which was developed through a 
consensus approach by a team of psychological theorists in collaboration with 
health services researchers and health psychologists (193, 206). The TDF was 
developed to address two main problems faced in the implementation of evidence-
based practice:  
 
1. The large number of possible theories and theoretical constructs developed 
within the social and behaviour sciences which often led to critical theories 
being missed. 
2. The lack of a clear rationale for selecting theories and the suboptimal 
application of theory in implementation research.  
 
Based on a recognition that research in the implementation of evidence-based 
practice is often applied by non-psychologists, the development of the TDF aimed 
to simplify and integrate the profusion of behaviour change theories and make 
theory more accessible to and usable by other disciplines. The TDF is therefore an 
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integration of 33 theories and 128 key constructs related to behaviour change 
which were identified in literature and synthesised into a single framework to 
assess implementation and other behavioural problems to inform intervention 
design (193, 206). The development process employed a six-stage consensus 
approach:  
 
1. Identification of theories and theoretical constructs (a theoretical construct 
was defined as a concept specially devised to be part of a theory)  
2. Simplification of constructs into overarching theoretical domains (a domain 
was defined as a group of related theoretical constructs) 
3. Evaluation of the importance of the theoretical domains 
4. Interdisciplinary evaluation and synthesis of the domains and constructs 
5. Validation of the domains list by health psychologists 
6. Piloting interview questions relevant to the constructs and domains with 
health services researchers   
 
The resulting framework consisted of 12 domains, each with exemplar questions for 
use in interviews or focus groups to assist comprehensive theoretical assessments 
of implementation problems (193). Since the development of the framework, its 
use and development has been documented to advance the science and 
implementation research. In 2012, the TDF was revised and validated (191). This 
revision examined the frameworks’ content validity and sought to confirm optimal 
domain structure (number of domains), content (component constructs in each 
domain) and labels (most appropriate names that best reflected the content of the 
validated domain structure). This exercise supported the refinement of the 
framework which resulted in 84 theoretical constructs sorted into 14 domains 
(191). Since its development, the TDF has been applied by research teams across 
several healthcare systems and in various countries including the UK to explain 
implementation problems and inform interventions aimed at behaviour change 
(191, 207, 208). The framework has mostly been applied to facilitate the 
understanding of healthcare professional behaviours (209). For example, the TDF 
has been used to understand prescribing behaviours amongst trainee doctors in 
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order to identify effective interventions to reduce errors (210). The TDF has also 
been used in a study investigating healthcare provider behaviour in performing 
assessments for rehabilitation following a stroke (211). In the above study, 
qualitative findings from focus groups with health professionals were mapped to 
the domains of the TDF and identified key behavioural influences such as ‘beliefs 
about consequences’ identified that could be targeted for implementation of 
appropriate interventions (211).  
 
The TDF has several advantages to its use including the consideration of both 
individual (e.g. beliefs and motivations) and social/environmental factors. Thus, 
making it a useful tool for identifying barriers and facilitators that could be 
addressed to positively improve implementation outcomes. The framework is also a 
useful evaluation tool for assessing the effectiveness of interventions aimed at 
behaviour change (212). However, whilst the TDF is a useful framework for 
identifying and describing factors that influence a behaviour, it does not explain the 
relationship between cause and effect about a behaviour in a given context. The 
domain ‘Nature of the Behaviours’, which was removed following refinement of the 
framework to strengthen coherence, leaves the framework with no domain 
primarily dedicated to understanding the nature of behaviour. This domain, 
originally designed to identify ‘what needs to be changed’ in order for the 
behaviour to be performed, was useful in the provision of guidance on the extent of 
variation in the desired behaviour. Therefore, the elimination of this domain in the 
TDF, excluded constructs related to habit and experiences/past behaviours that 
could be key understanding targeted behaviours.  
 
The rationale for removing the domain was that analysing the nature of behaviour 
is a different task to analysing influences on behaviour. Additionally, evidence 
suggested that previous studies that had adopted the TDF framework seldom used 
the ‘Nature of the Behaviours’ domain, meaning that behaviour analysis was not 
made as a basis of intervention design (213). Therefore, in order to perform a 
behaviour analysis prior to designing interventions, it has been recommended that 
the TDF be used alongside the Behaviour Change Wheel (BCW) (188, 192), a 
84 
 
complementary theoretical framework which characterises the target behaviour in 
terms of Capability, Opportunity and Motivation. It is suggested using the BCW 
allows intervention developers to start with a behavioural analysis to facilitate the 
selection of important domains to focus on when designing interventions. An 
example of this application was in a study examining antibiotic prescribing in long-
term care facilities, where data from interviews with healthcare professionals were 
analysed using the COM-B model which is at the hub of the BCW to facilitate the 
understanding of factors influencing prescribing patterns prior to TDF mapping 
(214). 
 
Another challenge with using the TDF is its accessibility to, and usability by, other 
disciplines. Although the framework was designed for simplicity of use by 
healthcare professionals and researchers with no psychology background, evidence 
shows that even amongst experienced health professionals who received some 
training on the TDF, challenges regarding the comprehension and independence of 
the domains still remain (215). Qualitative findings from a study exploring the 
experiences of using the TDF, showed that although the framework had been 
applied by healthcare professionals across different settings and disciplines 
including pharmacy, considerable variations in reported understanding of the 
frameworks domains and a perceived overlap between the domains exists (215). 
The reported difficulties in domain and construct interpretation were viewed by the 
participants to be due to unfamiliarity with psychology constructs and complexity 
of the TDF language thus leaving participants with a perceived need for 
underpinning knowledge in psychology (215).  
 
In this thesis, a great importance has been placed on understanding the nature of 
behaviours as a basis for designing interventions. This is because the study is largely 
exploratory, and thus needing contextual understanding of the problem and 
behaviours being investigated.  Therefore, although the TDF could provide a list of 
factors that could potentially influence behaviour, it was not used in this research 
as it does not fully explore the nature of behaviour (212, 216). 
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2.2.5.2 The Behaviour Change Wheel 
The Behaviour Change Wheel (BCW) is a more recent integrative framework 
developed in 2011 to increase accessibility of theories to researchers or 
intervention designers without a psychology background (188, 192). The 
development of the framework began with a systematic literature search of 
databases and consultation with behaviour change experts to identify behaviour 
change frameworks. The development then proceeded to evaluate the identified 
frameworks according to three criteria: comprehensiveness, coherence and a clear 
link to an overarching model of behaviour. Below are brief descriptions of the 
criteria:  
 
a) Comprehensiveness: An assessment of the number of intervention options 
covered by the identified frameworks. For researchers or intervention 
designers to identify the types of interventions likely to be effective, 
theoretical frameworks should cover the full range of available options. 
Ideally, the framework should also possess a logical system of selecting the 
most appropriate intervention from the available options. 
 
b) Coherence: An examination of whether categories or concepts in a 
framework were all similar in type and specificity. Ideally theoretical 
frameworks should not include categories that are very broad and others 
that are very specific. 
 
c) A clear link to an overarching model of behaviour: An assessment of 
whether frameworks provided a process for linking the model of behaviour 
to categories and specific behaviour change mechanisms. Research shows 
that insufficient attention is often given to analysing the nature of behaviour 
as the starting point of behaviour change interventions (217). The selection 
of effective interventions is primarily dependent on a thorough diagnosis of 
the behaviour in question to determine behaviour influences that are likely 
to be fruitful targets. Additionally, it is also important to establish how the 
behaviour analysis appropriately links to the possible interventions.
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Two examples of frameworks that were included in the evaluation were 
MINDSPACE (218) and the Cochrane Effective Practice and Organisation of Care 
Review Group (EPOC)'s 2010 taxonomy (219). An evaluation of MINDSPACE, a 
framework consisting of nine categories/influences on behaviour highlighted a lack 
of comprehensiveness where the framework did not encompass all intervention 
types (188). The evaluation also highlighted the categories of the framework 
(influences on behaviour) to be a mixture of types of delivery, prompts and 
characteristics of target populations. Hence this framework, although widely used 
was highlighted to lack comprehensiveness and coherence.  
 
The second example, EPOC, is a framework comprising 4 categories of interventions 
(Professional, Financial, Organisational and Regulatory), with each covering many 
intervention types to change health professional behaviour (219). An analysis of 
interventions within each category however demonstrated that because the 
categories were broad, they consisted of a mixture of different types of 
interventions at different conceptual levels (188). For example, the ‘professional 
category’ includes both individual (distributing educational materials) and 
organisational interventions (local consensus processes) and the 'financial category' 
includes individual and organisational incentives and environmental restructuring 
(changing the available products). Hence this framework also lacked coherence.  
 
Overall, the evaluation of existing frameworks identified from the literature search 
highlighted a lack of comprehensiveness and coherence. Additionally, the 
frameworks also lacked a clear link between the model of behaviour to the 
overarching framework thus failing to provide guidance on selecting the most 
appropriate interventions. The development of the behaviour change wheel (BCW) 
was therefore intended to address this gap by providing a framework that achieved 
coherence whilst providing a system for intervention developers to apply theory 
and evidence to designing and evaluating behaviour change interventions (188).  
 
The BCW is a synthesis of 19 frameworks of behaviour change found in the 
literature and is composed of a behaviour system/model at the hub, encircled by 
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nine intervention functions and then by seven policy categories (Figure 2.4) (188, 
192). The framework proposes that in order to choose interventions likely to be 
most effective, one should start with a model of behaviour to assess the 
circumstances in which different interventions are likely to be effective as a basis 
for intervention design. For example, when designing interventions to promote 
healthy eating, the model of behaviour could be used to assess and identify 
influences on healthy eating such as availability of healthy foods in order to 
propose intervention that are likely to be effective. Therefore, at the core of the 
BCW is a theoretical model of behaviour known as the COM-B which is used to 
conduct an analysis of the behaviour in question. The COM-B model is based on the 
hypothesis that the interaction between ones’ capability (C), opportunity (O) and 
motivation (M) can provide explanations of why a behaviour (B) is or isn’t being 



























The central principle of the model is that for any behaviour to occur there must be 
‘capability’ to do it, there must be ‘opportunity’ for the behaviour to occur and 
there must be enough strong ‘motivation’ to perform it. These components are 
then divided to two types. Capability could be either physical (e.g. physical skills 
and strength) or psychological (e.g. knowledge). Opportunity can be physical (e.g. 
resources) or social (e.g. cultural norms). Motivation can be reflective (e.g. beliefs 
about what is good or bad) or automatic (e.g. processes involving wants or needs). 
The components also interact as illustrated in Figure 2.5. For example, increasing 
ones’ capability and opportunity can increase motivation e.g. having a gym 
membership (opportunity) and knowing how to use a treadmill (capability) may 
increase motivation to use the gym. But motivation alone is not enough to use the 






Psychological or physical ability to enact the 
behaviour  
Reflective and automatic mechanisms that 
activate or inhibit behaviour   
Physical and social environment that enables 
the behaviour    
Figure 2.5 The COM-B theoretical model for behaviour change 
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The theoretical analysis at the hub of the wheel therefore identifies sources of 
behaviour which could serve as fruitful targets for intervention. This analysis then 
guides the choice of intervention functions (or strategies) most likely to achieve 
behavioural change. The outer layer of the hub consists of nine broad intervention 
functions to choose from when targeting the identified behaviour targets 
(behaviour determinants or influences). Intervention functions are broad categories 
of means by which an intervention can change behaviour. These intervention 
functions, although largely broad can be used to select appropriate interventions as 
they are specifically linked to a taxonomy of 93 behaviour change techniques  (188, 
192, 220). The final outer shell of the wheel consists of policies that can be used to 
drive the selected intervention functions.  
 
The BCW has been tested for reliability in two domains of behaviour change, 
tobacco control and obesity, where it was used reliably to characterise 
interventions within the Department of Health’s 2010 tobacco control strategy 
(221) and NICE guidance on reducing obesity (222). These areas and documents 
were selected due to their importance in public health, their wide coverage of 
behaviour change approaches and the availability of evidence highlighting a lack of 
adherence to evidence-based guidelines by health professional behaviour (223-
225). 
 
This research adopted the use of the BCW to explore the role of community 
pharmacy in diabetes prevention. This framework was considered reliable for 
application in this research which is also addressing a public health concern. The 
BCW was selected due to its incorporation of both a system from which types of 
interventions likely to be effective can be identified (as it canvasses a 
comprehensive range of intervention options available) and a rational system for 
matching them to the behavioural target, the target population and the context in 
which the intervention will be delivered. The BCW was selected, rather than the 
TDF, due to its incorporation of a model to facilitate a formal behaviour analysis 
prior to intervention design (188, 192). Understanding engagement among people 
with T2D and barriers and facilitators for delivering interventions in a community 
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pharmacy setting was considered as central to describing the role of community 
pharmacy in diabetes prevention. Additionally, because the TDF was originally 
designed for healthcare professionals, it was felt that most of the constructs within 
its domains may not be wholly relevant when exploring engagement in people at 
high risk of developing T2D. Finally, considering the usability challenges of the TDF 
highlighted by research including the differences in comprehension and the 
perceived lack of independence of the domains, the framework was considered to 
have potential to pose challenges in exploring the multiple behaviours in this 
research (215).  
 
 
2.3 The application of the Behaviour Change Wheel to current 
research  
 
The following sections describe the application of the BCW to the present research 
which is exploring the role of the community pharmacy in diabetes prevention. This 
application followed the guidance provided by Michie et al. in the book entitled 
‘The Behaviour Change Wheel – a guide to designing interventions’ (192). In this 
guidance Michie describes three stages: 1) understanding the behaviour; 2) 
identifying behaviour options; and 3) identifying implementation options, which 











Table 2.2 Eight steps to designing behaviour change interventions using the Behaviour Change Wheel 
 
Stage  BCW steps  
 
Key questions being addressed 
1. Understanding the behaviour   1.Defining the problem in behaviour terms What is the problem you are trying to solve?  
2.Selecting the target behaviour What behaviour are you trying to change and in what 
way?  3.Specifying the target behaviour 
4.Identifying what needs to change  What will it take to bring about the desired behaviour 
change? 
 
2. Identifying intervention options  
 
5. Intervention functions What interventions are likely to bring about the desired 
change?   6. Policy categories 
 
3. Identifying implementation options 7.Behaviour change techniques  What should be the specific intervention content and 
how should this be implemented? 










2.3.1 Understanding the behaviour  
 
Guidance for developing interventions recommends input from a variety of sources 
including existing literature and stakeholders to develop a strong theory of the 
problem being addressed (226, 227). In this research, gaps in the evidence base for 
the current management of non-diabetic hyperglycaemia with DPPs were identified 
through literature searches (Chapter 1). Additionally, the literature search explored 
the current role of community pharmacy in delivering public health interventions, 
specifically diabetes prevention services in England. In summary, this evidence 
suggested DPPs to be effective interventions for delaying and preventing the 
development of T2D amongst people at high risk (40). However, systematic review 
evidence did highlight high attrition and low uptake rates amongst the targeted 
population as key factors which could undermine the impact of the programmes 
(78, 192). Qualitative evidence highlighted work and social commitments, 
transportation and challenges in organising group-based sessions as key barriers for 
engagement. Evidence regarding the current role of community pharmacy in 
England highlighted the setting as potentially accessible for delivering diabetes 
prevention services but indicated that currently no services were being provided in 
this setting for people at high risk of T2D. 
 
From this perspective the BCW was applied in this research to clearly define the 
broad problem identified from the existing literature which is poor engagement 
with DPPs amongst people with NDH. The BCW was also used to assess the 
community pharmacy setting as the potential solution for poor engagement with 
the current national DPP. This process involved four main steps: 1) defining the 
problem in behaviour terms; 2) selecting the target behaviour; 3) specifying the 
target behaviour; and 4) identifying what needs to change. 
 
Step 1: Defining the problem in behavioural terms 
This step aims to clarify the behavioural problem being targeted. It involves 
defining a behaviour in terms of the target group or population involved in the 
behaviour and concerning the behaviour itself, the location and relevant 
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behaviours. For the present study, three main behaviours identified from existing 
literature were defined in behavioural terms with respect to the type of the 
problem being targeted, the population involved and the location of the behaviour. 








































Table 2.3 Defining the problem in behavioural terms 
 
What behaviour? 1. Poor engagement with diabetes 
prevention services  
2. Potential engagement with 
community pharmacy DPS 
3. Delivery of DPS 
Where does the 
behaviour occur? 
 
Primary care or community settings 
e.g. general practices or community 
halls  
  
Community pharmacy Community pharmacy 

















Step 2: Selecting the target behaviour 
Behaviours are part of a system and do not occur in isolation. Since behaviours can 
occur within the context of other behaviours of the same or other individuals, it is 
important to consider other behaviours that the targeted behaviour might be 
dependent on.  In this research, potential engagement with community pharmacy-
based DPS, could largely be dependent on the engagement in the current NHS DPP 
as well as the availability of these services in the community pharmacy setting. 
Similarly, the delivery of community pharmacy based DPS could depend on the 
potential demand for the services, the need for the service in primary care and the 
likelihood of the service being commissioned. Therefore, all relevant behaviours 
were included in the COM-B analysis.  
 
Steps 3 and 4: Specify the target behaviour and identifying what needs to change  
Specification of selected behaviours in their context improves the quality of the 
behaviour analysis (192). The precision of the behaviour can be achieved by 
describing the behaviours in terms of ‘who needs to perform the behaviour’, ‘what 
does the person need to do differently to achieve the desired behaviour’,  ‘when 
will they do it’, ‘where will they do it’, ‘how often will the do it’ and ‘with whom will 
they do it’. Furthermore, identifying changes that need to occur in the targeted 
population or environment in order to achieve the desired change in behaviour is a 
crucial step that avoids wrong assumptions and determines intervention success. 
The present research applied the COM-B theoretical model, the hub of the BCW, to 
develop a more detailed description of the target behaviours and to conduct an 
analysis of what needs to change. The COM-B model was therefore used as a 
starting point for understanding the behaviours in the context in which they occur.  
 
2.3.2. Application of the COM-B  
 
Guidance for the application of the BCW recommends exploring the components of 
the COM-B model with multiple relevant stakeholders to develop a more accurate 
picture and strengthen the understanding of the behaviour (192, 226, 227). 
Obtaining a consistent picture of a behaviour and factors influencing it from more 
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than one source and using more than one method is thought to increase confidence 
in the analysis. Suggested sources of behaviour include the frontline healthcare 
providers and patients who perform the target and suggested data collecting 
methods include interviews, focus groups, direct observations and questionnaires.  
 
Due to a lack of evidence in exploring engagement with DPPs in primary care 
settings in England, research was conducted involving mixed methods to obtain 
contextual evidence of key barriers and facilitators to engagement with the NHS 
DPP. Additionally, the studies also explored likely engagement with potential 
services in the community pharmacy setting amongst people at high risk of T2D. 
This was explored with key stakeholders including people at high risk of T2D, 
community pharmacy personnel, GPs and nurses. Similarly, in order to enhance the 
evidence base for the role of community pharmacy, both qualitative and 
quantitative methods were used to identify barriers and facilitators for delivering 
such interventions in this setting. This was explored with key stakeholders including 
community pharmacists, pharmacy technicians, dispensers, healthcare assistants, 
general practitioners, primary care diabetes nurses and commissioners. 
 
This research employed the COM-B theoretical model to further enhance the 
understanding of behaviours relating to engagement and delivery of diabetes 
prevention intervention in a community setting in order to  identify what needs to 
change (188, 192). As such, all primary research undertaken to explore 
stakeholders’ perspectives employed the use of the COM-B theoretical model. The 
overall aim of conducting the studies was to identify the key components of the 
COM-B model that could serve as fruitful targets for intervention design.  
Therefore, the next four chapters of this thesis are dedicated to specifying the 
target behaviour and identifying what needs to change. A summary of the studies 
exploring the three key behaviours have been outlined in Table 2.4.  
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Table 2.4 Studies undertaken to understand the target behaviours 
 
BCW steps Thesis 
Chapter 





Engagement with potential 
community pharmacy DPS 
Delivery of community 
pharmacy based DPS 
Steps 3 and 4 
specifying the target 
behaviour and 
identifying what 
needs to change  
3 Questionnaire study A 






3 Qualitative study  






4 Qualitative study 




5 Questionnaire study B 




6 Nominal Group Technique study  
Practitioners and commissioners  








2.3.3 Identifying behaviour options  
 
Steps 5 and 6: Intervention functions and policy categories 
A COM-B analysis performed at the start of developing an intervention is key for 
reaching a behavioural diagnosis of what needs to change for the desired behaviour 
to occur. The next step is therefore to link this diagnosis to intervention functions 
and policy categories.  
 
Intervention functions are broad categories of means by which an intervention can 
change behaviour. The term intervention function refers to the function that 
effective interventions are likely to serve rather than the intervention itself.  This 
term, rather than intervention, is used because it is possible for an intervention 
strategy or behaviour change technique to serve more than one function. For 
example, a poster communicating the harmfulness of smoking may also include a 
picture of a person with damaged lungs. Therefore, although the poster may be 
designed to improve knowledge, it may also serve to evoke emotion that goes 
beyond the improvement of knowledge to persuasion. In the BCW framework 
intervention functions are further linked to policy categories that could support 
their delivery.  
 
In the present research the COM-B analysis performed in Chapters 3-5 and finalised 
in Chapter 6 identify the change required for the desired behaviours to be achieved 
i.e. what to target in an intervention. Therefore, in this step, each COM-B 
component identified as relevant in bringing about desired change in the target 
behaviours was linked to intervention functions and policy categories which were 
likely to be effective in bringing about that change. This exercise has been 
documented in Chapter 6. The selection of the intervention functions and policy 
categories was guided by the APEASE criteria, which are criteria designed to assist 
in making strategic judgements as to what might be the most appropriate 
intervention and policies for the context (192). All behaviour change interventions 
operate within a social context, effectiveness alone is not an adequate 
consideration when designing an intervention. Therefore, the APEASE criteria 
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assisted the consideration of how other factors may affect the design of the 
interventions including affordability, practicability, effectiveness and cost-
effectiveness, acceptability, side-effects/ safety and equity.  
 
2.3.4 Identifying implementation options  
 
Step 7 and 8: Behaviour change techniques and mode of delivery 
Following the selection of intervention functions and policy categories, the next 
step in designing interventions involved selecting Behaviour Change Techniques 
(BCTs) which best serve intervention functions and the appropriate mode of 
delivery for the implementation of the intervention.   
 
A BCT is therefore the active component of an intervention required to change 
behaviour. The characteristics of a BCT are that it is observable, replicable and an 
irreducible component of an intervention designed to change behaviour. An 
example of a BCT is goal setting, where an individual agrees to do a daily walking 
goal (e.g. walk for at least 30 minutes every day). The BCT taxonomy, a 
standardised language for describing the active ingredients of interventions has 
been identified in relation to particular types of behaviour such as physical activity, 
healthy eating, smoking, excessive alcohol use, professional practice and 
medication use (228-234). From these behaviour-specific taxonomies, BCTs have 
then been synthesised and refined in an internationally supported piece of work to 
produce BCT taxonomy (220). The taxonomy has 93 BCTs which have been 
organised into 16 groups including goals and planning, feedback and monitoring 
and social support.  
 
In this research, following the recommendations of Michie et al., the selection of 
the BCTs started with identifying the most frequently used BCTs that are relevant to 
the intervention functions selected and considering their appropriateness in terms 
of how well they met the APEASE criteria in the context of the behaviour. As well as 
identifying appropriate BCTs, decisions were made about the mode of delivery of 
the interventions. Mode of delivery describes features of delivery such as face to 
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face, group-based or telephone-based interventions (235). However, because there 
is often less detail about the mode of delivery (e.g. face to face vs telephone) 
guidance for the application of the BCW recommends that mode of delivery is 
considered explicitly at this stage (192). Therefore, in this research the mode of 
delivery was considered in light of data collected from all studies (Chapter 3-6) and 
selected with consideration to the APEASE criteria.  
 
 
2.4 The application of the Medical Research Council guidance to the 
current research  
 
Public health is defined as ‘the science and art of preventing disease, prolonging life 
and promoting health through the organised efforts and informed choices of 
society, organisations, public and private communities and individuals’ (236).To 
achieve this public health practitioners must first define the public health problem, 
assess the fundamental causes and determine the population most at risk. 
Secondly, practitioners must develop and implement evidence-based interventions 
or public health programs. 
 
The Medical Research Council (MRC) have provided guidance on how to develop 
complex interventions such as DPS. The guidance comprises of a framework (Figure 
2.6) (227) which proposes an iterative process of developing interventions 
consisting of four stages; 1) development, 2) feasibility testing/piloting, 3) 
implementation and 4) evaluation. In the present research that is exploring the 
community pharmacy setting as an option for delivering DPS, the focus will be on 


























1. Testing procedures  
2. Estimating recruitment /retention  
3. Determining sample size 
 
Development  
1. Identifying the evidence base  
2. Identifying/developing theory 
3. Modelling process & outcomes  
Evaluation  
1. Assessing effectiveness  
2. Understanding change process  
3. Assessing cost-effectiveness 
 
Implementation  
1. Dissemination  
2. Surveillance and monitoring 




2.4.1 Identifying the evidence base 
 
The guidance recommends undertaking or using a high-quality systematic review 
and reviewing the literature to identify the need for developing a new (or modified) 
intervention and the likely impact of behavioural change. This stage can also be 
supplemented by new research as demonstrated by Sinnott et al, who addressed 
gaps identified from their review of literature by conducting qualitative interviews 
with stakeholders (237).  
 
In considering the application MRC framework in present research, a literature 
review (Chapter 1) has been conducted to identify the evidence base for the 
effectiveness of DPPs, gaps in the current interventions for NDH as well as the 
current and potential role of community pharmacy in diabetes prevention. 
Additionally, mixed-methods research will be conducted to supplement the 
literature search with more contextualised evidence regarding engagement with 
current national DPPs and the current use of community pharmacy services in a UK 
based population (Chapter 3, 4 & 5). 
 
2.4.2 Developing theory 
 
In the second stage, the MRC recommends the use of theory, suggesting that 
interventions that use theory are more likely to be effective than interventions that 
are purely pragmatic (226, 227). In cases where the rationale for intervention 
development is unclear, the MRC recommend developing a programme theory of 
how an intervention is likely to produce its effects. A programme theory assists the 
development of a theoretical understanding of the likely process of change by 
drawing on existing or new evidence (e.g. interviews and focus groups with 
stakeholders i.e. those targeted by the interventions and those delivering the 
intervention) and applying them to existing social and psychological theoretical 
models. The MRC recommends the use of social or psychological theorical models 
to identify the determinants of the target behaviour, to select appropriate 
behaviour change techniques and measures of change. 
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In the present study, the BCW, a theoretical framework for behaviour change and 
primary research (Chapter 3-6), was used to develop an understanding of the role 
of community pharmacy in diabetes prevention in England. The BCW was used to 
develop a thorough understanding of nature of behaviour of stakeholders including 
people with NDH (service users) and community pharmacy teams (service 
providers) in order to define the problem that is being addressed in behavioural 
terms (188). More importantly, an assessment of these behaviours has been 
considered in the context in which they would potentially occur i.e. the community 
pharmacy setting. Following the definition of the problem, the BCW has been used 
to identify the most effective interventions that could be implemented to address 
the problem (Chapter 6). 
 
2.4.3 Modelling process and outcomes 
 
In the third stage the MRC recommends a modelling process whereby 
implementation is considered at an early stage prior to a full-scale evaluation. This 
stage considers questions surrounding the targeted population (patients, the 
public, etc.), the population involved in the delivery of the interventions (national 
or local policy-makers, opinion leaders/formers, practitioners) and the setting. It 
also considers the barriers and facilitators for the delivery of the interventions. 
In the present research, the modelling process and outcomes was considered 
throughout the research process by conducting primary research with key 
stakeholders and presenting the programme theory for development of community 
pharmacy-based DPS in a logic model at the end of the thesis (Chapter 7). 
 
 
2.5 Conclusion  
 
This research employed the Behaviour Change Wheel framework to develop an 
understanding of the influences behind engagement (or the lack of it) in diabetes 
prevention services. The framework was also used to explore the role of community 
pharmacy in delivering diabetes prevention services and gathered information to 
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assist the design of an effective intervention to enhance delivery in this setting. The 
research drew on existing evidence from literature (Chapter 1), supplemented by 
primary research with key stakeholders (Chapters 3-6), to develop a clear rationale 
for the intervention development and to identify effective intervention strategies 
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3.1 Introduction  
 
In England, five million people are estimated to have NDH (32, 38). Evidence 
suggests that if individuals with NDH are identified and intensive lifestyle 
interventions are implemented early, the onset of type 2 diabetes may be delayed 
or even prevented (40, 41, 79, 81, 82, 101, 106, 109, 117). In England, the NHS DPP 
has been implemented in light of this evidence (40). The programme was first 
launched in 2016 despite evidence suggesting that its impact could be undermined 
by several factors including uptake (78). Qualitative research evidence investigating 
uptake in DPPs has highlighted accessibility, work and social commitments and 
practical challenges with organising group-based sessions to be amongst the 
common barriers for uptake (131, 132, 238).  
 
UK guidelines recommend the delivery of DPPs by primary health care teams, 
including community pharmacy, as these settings have been associated with the 
greatest reach to the target population (32, 103, 105). However, although some 
community pharmacies deliver opportunistic screening and mainly refer to general 
practice services (135, 137), there are currently no routine lifestyle interventions 
being delivered in this setting for people with NDH and neither are there clear 
guidelines of how community pharmacy teams could deliver lifestyle interventions 
for this population. Therefore, with the current implementation of the NHS DPP 
underway, it is important to establish whether community pharmacy has a role in 
supporting implementation of the national programme. Additionally, there is a 
need to better understand the likely barriers and facilitators to engagement with 
the current programme in people with NDH in order to establish the context in 
which community pharmacy may play a role. Although previous research has 
identified likely barriers and facilitators to participating, DPP interventions 
delivered in the studies were dissimilar to the current NHS DPP and included factors 
likely to enhance participation. For example, Laws et al. describe an intervention 
with a significant involvement of healthcare personnel such as general 
practitioners, nurses and dieticians, a factor which was identified to influence study 




included factors that potentially encouraged participation including social 
(partners) and external support networks (telephone calls from health coaches) 
(129, 130, 132, 238). Therefore, with the current NHS DPP delivered by mainly non-
healthcare personnel and not including support networks and personalised 
support, it is important to establish contextual barriers and facilitators to 
participation in the programme. 
 
The COM-B approach offers a theoretical model for identifying key factors 
influencing desired behaviour (i.e. engaging in DPPs) (188, 192). In this study, the 
COM-B was applied to understand two target behaviours: (1) people with NDH 
engaging in the NHS DPP and (2) people with NDH engaging with potential 
community pharmacy-based diabetes prevention services (DPS). Analysing these 
behaviours using the COM-B would help identify behavioural determinants and 
assist in developing future interventions that could enhance engagement of people 
with NDH in community pharmacy-based DPS through the application of the BCW.  
 
3.1.1 Aims  
 
To explore factors influencing engagement with the current NHS DPP and elicit 
views from people with NDH on the role of the community pharmacy in diabetes 
prevention using the COM-B to frame the data collection, analysis and future 
direction of interventions aimed at patients and healthcare professionals.  
 
3.1.2 Objectives  
 
1 To characterise participation in the current NHS DPP. 
2 To describe the barriers and facilitators to engagement with the NHS DPP. 
3 To describe the views and perceptions of people with NDH on the role of 






3.2 Methods  
 
3.2.1 Study design and ethics approval   
 
This research adopted a pragmatic epistemology and used mixed methods 
consisting of a questionnaire, a focus group and interviews to address the study 
objectives (239). Ethical approval was obtained from the Health Research Authority 
(IRAS project ID: 227930) before commencing the research. The study protocol can 
be found in Appendix 3.1, together with the ethics approvals (Appendix 3.2), ethics 
amendment approvals (Appendix 3.3) and research and development office 
approvals (Appendix 3.4). The study took place in Norfolk between November 2017 
and May 2018. 
 
3.2.2 Rationale for study design  
 
This study adopted the exploratory sequential mixed method design whereby 
quantitative and qualitative data were collected sequentially in two phases (240). 
The questionnaire data were collected and analysed in the first phase. The 
questionnaire method was adopted following a literature search of factors 
influencing participation in DPPs which provided sufficient insight to enable the 
exploration of engagement in the current NHS DPP (131-133). The questionnaire 
provided the most efficient way, in terms of time and cost, to obtain data from a 
large sample of participants (241). In the second phase, qualitative (interviews and 
focus group) data were collected and analysed to get a deeper understanding of 
questionnaire responses with regards to influences on engagement with the NHS 
DPPs and the role of the community pharmacy in preventing type 2 diabetes (242). 
Using both interviews and focus groups also provided a degree of data 
triangulation.  
 
Focus groups were the preferred data collection method as they are especially 
useful for confirming insights from a wide variety of participants (242). In this study, 




DPP and community pharmacy services, it was important for data generation to 
include an exchange of viewpoints and experiences in order to give participants the 
opportunity to reflect and consider their own standpoint in light of what they hear 
from others. Thus, in this study, the use of focus group discussions, which is 
thought to facilitate the refinement of individual responses, was viewed to be 
appropriate (242). Furthermore, the interaction of the researcher was felt to have 
less of an influence than in one-to-one interviews, allowing data and insights to be 
generated from a social context (242). 
 
In order to provide a more accessible option to the studied population and 
encourage participation, an option of either face to face or telephone interviews 
was given as an alternative to attending a focus group (242). Semi-structured 
interviews were adopted rather than open-ended interviews to facilitate the 
gathering of focused subjective data (242). 
 
3.2.3 Study terminology  
 
The term ‘engagers’ as used in this study referred to participation sessions of the 
NHS DPP whether partial, current or complete whereas ‘non-engagers’ referred to 
participation in none of the sessions. This study therefore adopted five categories 
referred to as ‘engagement status’ to describe participant engagement with the 
NHS DPP and these included: dropped out (‘partial engager’), attending (‘current 
engager’), completed (‘complete engager’), declined (‘non-engager’) and waiting 
for assessment (‘non-engager’).  These groups were adopted from the current 










3.2.4 Participant identification  
 
3.2.4.1 Routine NHS DPP inclusion criteria 
General practices: All general practices operating within the 27 areas selected for 
the initial implementation of the NHS DPP in England (Including Norfolk) were 
eligible to provide screening and referral services to the NHS DPP. Participating 
general practices were primarily required to identify eligible individuals for referral 
to the NHS DPP by performing retrospective screening of their databases. 
 
People with non-diabetic hyperglycaemia: People with NDH are primarily 
identified for referral to the NHS DPP during routine primary care appointments or 
through retrospective screening of general practice databases. Eligible patients for 
referral were individuals who were 18 years or over and had an HbA1c blood tests 
within the NDH range (42-47mmol/mol) in the last 12 months (32). Following 
identification, individuals were sent letters communicating their risk and inviting 
them to participate in the NHS DPP (243). At this point patients could voluntarily 
enrol onto the programme by contacting the providers via a telephone number 
highlighted in the referral letter. General practices kept track of individuals 
identified through screening based on feedback they received from NHS DPP 
providers. 
 
3.2.4.2 Study recruitment  
General practices: General practices were the participant identification site for the 
research. All general practices in Norfolk who were participating in NDH screening 
and referral to the NHS DPP were eligible for the study. Participating general 
practices were identified via the North Norfolk CCG, an NHS organisation 
responsible for the planning and commissioning of healthcare services for the local 
area. 
 
At the time the study commenced the NHS DPP was undergoing implementation 
across Norfolk. Therefore, to ensure the recruiting of participants who had 




in the NHS DPP for at least six months were invited to participate in the study. 
Participating general practices were reimbursed a one-off payment of £75 for 
identifying participants and posting questionnaires. 
 
People with non-diabetic hyperglycaemia   
Identification of eligible participants was performed by general practice staff by 
retrospective screening of databases. All patients who met the following 
inclusion/exclusion criteria were invited to participate:  
 
Inclusion criteria 
 Registered with a GP practice in Norfolk 
 Referred to the NHS DPP in the previous 12 months  
 
Exclusion criteria 
 Non-English speaking 
 History of type 2 diabetes 
 Unable to give consent  
 
Following identification of potential participants by general practices, envelopes 
containing a covering letter (Appendix 3.5) and a questionnaire (Appendix 3.6) 
provided by the research team were mailed to eligible participants. As part of the 
questionnaire, participants were given an option to express an interest in interview 
or focus group participation. Identification of participants was anonymous with the 
researchers not seeing any patient identifiable data until completed questionnaires 
were returned to the research team.  
 
Once completed questionnaires were returned to the research team, participants 
who expressed willingness to be contacted for further research were identified. 
Selected participants received a covering letter (Appendix 3.7) and an information 
sheet (Appendix 3.8) which provided more information about the interviews/focus 




before making the final decision to participate in the research. Potential 
participants were then contacted by the research team to confirm participation and 
arrange a suitable time for the interview/focus groups. Following this, participants 
who opted for telephone interviews also receive a consent form (Appendix 3.9).  
 
3.2.5 Sampling and sample size  
 
3.2.5.1 Questionnaire 
At the time of conducting the study, the NHS DPP was undergoing implementation 
in Norfolk, which was one of the first wave of 27 areas across the UK. North Norfolk 
and Norwich, consisting of 60 general practices in total, were the initial areas to 
start the screening and referral processes.  Based on participation data provided by 
North Norfolk CCG we planned to approach all 9 practices that had completed the 
identification and referral processes within these areas. These practices had a 
recorded total of 1,570 patients who had received a letter inviting them to 
participate in the NHS DPP and had initiated first contact with the providers. Based 
on the assumption that, all 9 practices would participate in the study, we planned 
to post questionnaires to all 1,570 patients. Based on previous work which used a 
similar method of recruiting, a 10-20% response rate was expected, giving 150 to 
300 questionnaire responses. Questionnaires were sent to all eligible participants 
regardless of their NHS DPP engagement status.   
 
3.2.5.2 Interviews and focus group 
Participants expressing willingness to be contacted for the qualitative element were 
identified from returned questionnaires. To gain the perspectives of both engagers 
and non-engagers in the NHS DPP, a purposive sampling method based on 
questionnaire responses was used to select participants (242). Selection of 
participants was primarily based on NHS DPP engagement status. Diversity was 
further sought by selecting participants according to employment status and 
community pharmacy use. The aim was to achieve maximum variation with regards 
to engagement with the NHS DPP and to obtain a diverse experience with 




most participants were older, female and retired, balance was sought by specifically 
also targeting younger, male or employed participants. 
 
The selection of participants was an iterative, ongoing process whereby selection 
criteria for subsequent interviews were constantly being modified to ensure 
intended diversity of participants was achieved. The selection of participants and 
data collection was therefore performed in parallel between December 2017 and 
April 2018. The number of interviews and focus groups conducted was based on 
participants’ availability and data saturation (242). In this study data saturation was 
determined by the degree to which new data was expressed in previous data and 
thus had an emphasis on data collection rather than data analysis. Data saturation 
was therefore determined when there was no additional data expressed in new 
data (244).  Participants were offered a £10 voucher as a thank you for participation 
and had their travel expenses reimbursed where applicable. 
 
3.2.5.3 Under-representation of non-engagers following questionnaire responses 
The focus of this study was primarily to address factors influencing engagement in 
DPPs. The study therefore sought to have a good representation of people who had 
not engaged with the current NHS DPP. In order to ensure that the views and 
perceptions of non-engagers were adequately considered a preliminary analysis on 
the questionnaire data was carried out to establish whether or not this population 
is adequately represented.  
 
Where those who had declined to participate in the NHS DPP consisted of less than 
20% of the questionnaire responses, efforts to increase the representation by 
specifically targeting this population were made by recruiting one or two new 
practices through which invitation letters (Appendix 3.10) were sent to all 
participants who had been invited to the NHS DPP. The invitation letter was only 
targeted at people who had declined participation in the NHS DPP despite being 
referred to it by their general practice. The envelope also contained an expression 




with non-engagers were sought to be undertaken when this underrepresentation 
was identified.  
 
3.2.6 Data collection 
 
3.2.6.1 Questionnaire 
The questionnaire (Appendix 3.6) consisted of four sections which collected the 
following information: 1) demographics including NHS DPP participation, 2) 
feedback on the NHS DPP including accessibility, 3) community pharmacy use 
including general views on community pharmacy based DPS, and 4) expression to 
participate in further research. The first three sections consisted primarily of Likert 
scale questions and also included open ended questions in order to cover topics 
that had not been addressed by the closed questions. Respondents who had 
engaged with the NHS DPP were asked to provide comments on various aspects of 
the programme and those who had not engaged were asked to comment on 
influences behind their decision.  
 
Questions exploring general views on potential engagement with community 
pharmacy based DPP were formulated by the research team (188, 192), to explore 
participants’ views on the use of the setting for delivering DPS as well as willingness 
for participation. Questions exploring NHS DPP accessibility were based on previous 
qualitative research which had identified common barriers and facilitators to 
participation (131-133). The questionnaire, although primarily designed to validate 
accessibility barriers and facilitators identified from previous qualitative research 
within the context of the NHS DPP, also sought to explore other factors influencing 
engagement with the NHS DPP. 
 
3.2.6.2 Interviews and focus groups 
Interviews were conducted by the main researcher (TK) and lasted up to one hour. 
The focus group was conducted by two members of the research team (TK and 
MT/HA/SS) at the University of East Anglia (UEA) and lasted approximately 90 




structured topic guide based on the COM-B model (192) was used to facilitate the 
discussions (Appendix 3.12). Topics explored included experiences with NDH 
diagnosis, influences behind engagement or non-engagement, experiences with the 
NHS DPP or alternatives, experiences with community pharmacy services and views 
on community pharmacy delivering DPS. Written or verbal consent for focus group 
and interviews was obtained respectively (Appendix 3.9).  
 
3.2.7 Data analysis  
 
3.2.7.1 Questionnaire  
Statistical Package for Social Sciences (SPSS) statistics (version 23; IBM Corp) was 
used for questionnaire data analysis. Medians (interquartile ranges (IQs)) were used 
to describe the data. Data was explored to identify the distribution of respondents’ 
feedback on the NHS DPP, community pharmacy use and views on community 
pharmacy based DPS.  To conduct inferential statistics on influences of NHS DPP 
accessibility on participation (location and session times), programme outcomes 
(weight and physical activity) and feedback on the programme (satisfaction and 
need of the programme) participants were separated into groups based on their 
engagement (i.e. engagers and non-engagers) (Kruskal-Wallis test and Mann 
Whitney U). Additionally, descriptive analysis (n (%) and Medians (IQs)) was 
performed to analyse data on community pharmacy use. Participants were again 
separated into groups based on their use of community pharmacy and general 
practice to conduct inferential statistics on their views on the involvement of 
community pharmacy in delivering DPS (Mann Whitney U).  
 
3.2.7.2 Interviews and focus groups  
Thematic analysis  
Interview and focus group recordings were transcribed verbatim by a member of 
the research team (TK) or a paid transcription contractor, loaded in NVivo 11, and 
then checked for accuracy by listening back to the original recording. All written 
comments made on the open-ended sections of the questionnaires were 




data in NVivo for analysis. To provide an iterative process Braun and Clarke’s six 
phases of thematic analysis was utilised (245). This approach was adopted because 
it can be used to analyse data from different types of communication media, 
providing a flexible approach to analyse data from both audio recorded interviews 
and focus groups (246). The activities involved in each step of the analysis are 
highlighted below: 
 
Step 1: Familiarisation 
The transcribed data were checked by re-listening to original recordings. The data 
were then read and re-read to gain an overview of the content and identify topics 
and subjects that were of interest and that were linked to the research questions. 
  
Step 2: Inductive coding 
The transcribed data were re-read and inductively coded. To aid the inductive 
analysis and provide a deeper understanding of the data, codes were discussed 
with another member of the research team (MT) and any disagreements resolved 
by consensus, referring to the transcripts and original recordings. 
 
Step 3: Development of themes 
Relationships between the codes were sought to develop subthemes and 
subsequent themes by two members of the research team (TK and MT). Any 
disagreements about the themes/subthemes were resolved by discussion, referring 
to the transcripts and original recordings. 
 
Step 4: Reviewing themes  
Transcripts were re-read to ensure that correspondence between the developed 
themes and the data. At this point iterative judgements were made in order to give 
a richer description of the themes. 
  
Step 5: Defining themes 
Each theme was given a name which captured the essence of the contents and a 




a richer description of the themes and to identify representative extracts to use in 
the written analysis. Extracts were selected to obtain a good representation of 
participant characteristics in terms of engagement and study involvement 
(questionnaire and qualitative elements).  
 
Step 6: Reporting  
A clear and concise narrative of the themes was written using extracts identified in 
step 5 as illustrative evidence of the themes. This ensured authenticity of the 
findings. Codes and themes generated from each phase contributed to the 
description to the role of community pharmacy in diabetes prevention.  
 
COM-B analysis  
To obtain a deeper understanding, codes of the themes associated with two target 
behaviours i.e. (1) people with NDH engaging in DPP and (2) people with NDH 
engaging with community pharmacy based DPS, were categorised as barriers and 
facilitators to facilitate further mapping onto the components of the COM-B model. 
Mapping was conducted according to the heuristic subdivisions of each of the 
components of the COM-B model where Capability can be either ‘physical’ (e.g. 
physical skills) or ‘psychological’ (e.g. knowledge) ability to perform the behaviour; 
Opportunity can be ‘physical’ (e.g. Resources) or ‘social’ (e.g. interpersonal 
influences); Motivation may be ‘reflective’ (e.g. beliefs about what it good or bad) 
or ‘automatic’ (e.g. processes involving wants and needs).  
 
Mapping processes were conducted with reference to the target behaviours and 
aided by discussion amongst the research team (247). The process involved 
mapping coded interviewee narratives to relevant COM-B categories. However, 
where there was overlap between COM-B categories, discussions were held 
amongst the research team and interviewee narratives mapped to the COM-B 
category relevant to the “primary determinant”. The ‘primary determinant’ was 





Mapping was conducted by the main researcher (TK) and then discussed with 
another member of the research team (MT). The final mapping was then re-
analysed independently by another member of the research team with expertise in 
psychology and using the COM-B (HF). Any disagreements were resolved by 




3.3. Results  
 
3.3.1 Questionnaire: NHS DPP 
 
Nine hundred and sixty-two questionnaires were posted via five general practices 
which agreed to participate resulting in 181 (18.8%) responses. Participants’ 
demographics and NHS DPP engagement status are summarised in Table 3.1. The 
majority of the respondents were white 176 (97.8%) and almost half reported to 
have either completed the programme or were still attending sessions. A quarter of 
respondents reported to be waiting for an initial assessment following contact with 






Table 3.1 Questionnaire participant characteristics 
 
Characteristics N Measure Classification 
 
Responses   
Replied 
 
962 n (%)  181 (18.8) 
Female  
 
180 n (%)  103 (57.2) 
Age (years) 180 Mean (sd) 
 




181 n (%) Employed 41 (22.7) 
 Student 9 (5) 







167 % (95% CI) Waiting  25.7 (19.1, 32.2) 
 Attending  24.6 (18.1, 31.1) 
 Dropped-out 9.6 (5.1, 14.1) 
 Completed 25.1 (18.5, 31.7) 






Feedback on the NHS DPP is summarised in Table 3.2. There were significant 
differences between the groups in terms of convenience of programme location 
and session times with a general trend being towards agreeing or strongly agreeing 
for those who were attending, had completed or had dropped out of the 
programme compared to those who had declined or were waiting for an initial 
assessment (Kruskal-Wallis test: p < 0.001 ((X2 = 38.69, df = 4) and p < 0.001 (X2 = 









Table 3.2 Feedback on the NHS DPP 
*Likert scale: strongly disagree (1), disagree (2), neither agree nor disagree (3), agree (4), strongly agree (5) 
** Kruskal-Wallis Test 
*** Mann Whitney U












The location of the programme was 
convenient for me  
 
3 (3,4.75) 4 (4,5) 5 (4,5) 4 (4,5) 3 (2,3) <0.001 ** 
 
The times that the sessions were offered were 
convenient for me  
 
3 (2, 5) 4 (4,5) 5 (4,5) 3.5 (2,4) 
 
3 (2,3.5) <0.001 ** 
 
I found attending the sessions as a group 
helpful 
 
- 4 (4,5) 5 (4,5) 4 (3,4) 
 
- 0.019 ** 
The programme has helped me or is helping 




4 (4,5) 4 (4,5) 4 (2,4) - 0.075 ** 
 
The programme has helped me or is helping 




4 (3,5) 4 (3,4.75) 4 (2,4) - 0.045 ** 
 
Please indicate your level of satisfaction with 




4 (4,5) 5 (4,5) 3 (2,4) - 0.001 ** 





There was also a variation between ‘non-engagers’ (waiting for an initial 
assessment and declined) with regards to feeling the need to attend the 
programme. Those who had declined agreed to feeling that they did not need the 
programme (Mann Whitney U, p=0.014) whilst those who were waiting had no 
strong views about whether they needed the help of the programme.  
 
Overall feedback on the NHS DPP from ‘engagers’ (attending, completed and 
dropped out) was positive. There was little variation in feedback about programme 
outcomes, with most respondents reporting the programme to have successfully 
helped them in achieving weight loss and increasing physical activity. However, 
overall satisfaction with the programme and views concerning the helpfulness of 
group sessions varied amongst the three groups with responses being less positive 
amongst people who had dropped out of the programme.   
 
3.3.2 Questionnaire: community pharmacy  
 
Most participants reported taking prescribed medication (88.6% (156)). In total, 
59.5% reported collecting their medication from community pharmacy rather than 
dispensing GPs (practices that dispense medicines they prescribe to patients living 
remotely from a community pharmacy). Ninety three percent of participants on 
prescribed medication collected their medication in person. A larger proportion of 
respondents (82.8%) who collected medication from the community pharmacy 
reported visiting the pharmacy more frequently, i.e. either once a month or most 
days, than those who collected medication from dispensing doctors (54.1%). Most 
of the respondents who collected their medication from a local community 
pharmacy reported a shorter travel distance (90.4%; 1-2 miles) compared to those 
collecting their medication from dispensing general practices (44.3%; +3 miles).  
 
Table 3.3 summarises the reported use of community pharmacy services by 
respondents.  Most respondents reported using community pharmacy for either 




quarter of respondents reported to have either never heard of or used any of the 

















Table 3.3 Community pharmacy services use 
 
Which community pharmacy 
service have you used before? 
Service description Intervention  
% (n = 157) 
Over the counter advice 
 
Clinical advice on non-prescription medicines for a range of minor illnesses, such as coughs, 
colds, fungal infections, and aches and pains. This advice also includes diet and lifestyle 
recommendations and signposting to more appropriate services including general practice 
for more serious conditions.  
29.7 (47) 
Blood Pressure check A blood pressure screening service. 25.3 (40)  
NHS Health check  
 
A screening service designed to predict the 10-year risk of developing heart disease and offer 
lifestyle advice and intervention where necessary. The check is for adults in England aged 40-
74 and consists of a combination of BMI measurements, blood pressure, blood glucose and 
cholesterol screening, diet and physical activity information. 
19.0 (30)  
Cholesterol check A cholesterol screening service.  17.7 (28) 
Health leaflets 
 
Free health-related leaflets on various conditions including diabetes and hypertension as 
well as advice on healthy living advice. 
16.5 (26) 
Diabetes check  A diabetes screening service (random or fasting plasma glucose test). 14.6 (23) 
Smoking cessation 
 
A one to one service delivered by trained pharmacy advisers that provides a range of proven 
smoking cessation methods. The programme provides information and advice on stopping 
smoking, as well as professional support, during the first few months following cessation.  
4.4 (7) 
Weight loss programme  
 
A service delivered by trained pharmacists to support patients to lose weight through the 





Other services including seasonal influenza vaccination services and medicine related 
services (e.g. medicines use reviews).  
4.4 (7) 







Table 3.4 illustrates responses relating to the role of community pharmacy in 
diabetes prevention. People who collected medication from community pharmacy 
were more inclined to think that community pharmacy was capable of delivering 
DPS (p=0.023). Most respondents agreed that they would consider using 
community pharmacy for DPS and would be motivated to utilise community 
pharmacy-based DPS. There was no significant difference in participants’ 
motivation (p=0.076) and consideration (p=0.124) to use community pharmacy for 
DPS between people who collected their prescriptions in community pharmacy and 


























Table 3.4 Views on potential engagement with and delivery of community pharmacy diabetes prevention services
Questionnaire statement  All participants 
 












                                                          Median (IQ) 
I think community pharmacy is capable of 
providing a diabetes prevention service  
 
4 (3,4) 4 (3,4) 3 (3,4) 0.023 
I would consider community pharmacy (as 
an option) for a diabetes prevention 
service  
 
4 (3,4) 4 (3,4) 4 (3,4) 0.124 
I would be motivated to attend a pre-
diabetes screening or prevention service 
provided by the community pharmacy 
team 




3.3.3 Interviews and focus groups 
 
One hundred and four respondents (57.5%) expressed an interest in the qualitative 
element of the study. With most participants opting for interviews, one focus group 
consisting of six participants and 10 telephone interviews were conducted. Table 
3.5 presents the demographics of the 16 participants purposively sampled to 
participate in the qualitative element. Included in the table is also a participant 
identification key for the illustrative quotes. 
 
There were slightly more females than males and more were retired than 
employed. There was an even distribution across those who had engaged with the 
NHS DPP (completed or attending (n= 6)) and those who had declined or dropped 
out (n=7). The sample also included participants who were waiting for initial 
assessment (n=3). As a preliminary analysis of questionnaire responses indicated a 
response rate from those who had declined of less than 20% of the respondents, an 
additional general practice was recruited to identify five additional interviewees 
who had not engaged with the NHS DPP. However, there was no response from 


















Table 3.5 Characteristics of interview and focus group participants 
 
Characteristic  N Measure  Classification Responses 
Age (years) 16 Mean (sd)  68.4 (5.6) 
Female  16 n (%)  9 (56.3) 
Employment 
status  
16 n (%)   
   Employed  4 (25) 
   Retired 12 (75) 
Engagement 
status   
16 n (%)   
   Attending 3 (18.8) 
   Completed  3 (18.8) 
   Waiting  3 (18.8) 
   Dropped out 2 (12.5) 
   Declined   5 (31.3) 
Community 
pharmacy use  
16 n (%)   
   About once a month  4 (25) 
   Once every two to 
three months  
1 (6.3) 
   Two or three times 
a year 
8 (50) 
   Never 3 (18.8) 
Key for illustrative quotes:  
FG = focus group participant, I= interview participant, Q= participants’ response to open-
ended questionnaire sections. All participant identifiers include a questionnaire 











One hundred and forty-four participants (80%) responded to the open-ended 
sections of the questionnaire and these responses were included in the analysis. 
The thematic analysis produced four main themes 1) Perceptions of non-diabetic 
hyperglycaemia 2) Factors influencing engagement in the NHS DPP 3) Feedback on 
the NHS DPP and 4) The role of community pharmacy in non-diabetic 
hyperglycaemia. Two themes (‘Factors influencing engagement in the NHS DPP’ and 
‘The role of community pharmacy in non-diabetic hyperglycaemia’) were identified 
as closely linked to the target behaviours (‘people with non-diabetic 
hyperglycaemia engaging in DPP’ and ‘people with pre-diabetes engaging with 
community pharmacy based DPS’) respectively. Tables 6 and 7 present the mapping 
of the codes associated with these two themes to the components of the COM-B 
model.  
 
3.3.3.1 Theme 1: Perceptions of non-diabetic hyperglycaemia 
Participants expressed a lack of awareness of NDH prior to diagnosis. Reactions 
following diagnoses were mainly that of shock particularly due to positive self-
perception about diet, lifestyle and lack of family history. Those who were not 
shocked were clearly able to relate the diagnosis to risk factors such as age, weight, 
family history, co-morbidities and poor dietary choices. Whilst a few participants 
were not concerned with the diagnosis and had made the conclusion that the risk 
of developing diabetes was not serious, others highlighted the need for earlier 
interventions, prior to a formal diagnosis of pre-diabetes, to address poor lifestyle 
behaviours before they became an issue.  
 
‘I know I’m a wee bit overweight but not extortionately and we have a very healthy 
diet in so much as we eat plenty of fruit and vegetables… nobody else in my family is 
diabetic so it did take me by surprise that I could be going that way’ [I-017, 
attending] 
 
‘I think you drift into bad habits and if someone says to you your blood sugars are 




process rather than go and say 42 [meaning HbA1c reading] now this is what you 
need to do’ [FG-025, waiting] 
 
3.3.3.2 Theme 2: Factors influencing engagement with the NHS DPP 
There were several factors that influenced participation in the NHS DPP following 
diagnosis of NDH. Table 3.6 summarises barriers and facilitators to engagement 
mapped to the COM-B, along with illustrative quotes. The table also consists of 
summary phrases for each identified barrier and facilitator together with the 
descriptions of Capability, Opportunity and Motivation. The target behaviour linked 











Table 3.6 A COM-B analysis of factors influencing engagement with the NHS DPP 
 
COM-B components with 
definitions 
Mapped codes Illustrative quotes 
Barriers  Facilitators 
Physical capability - 
physical skill, strength or 
stamina to perform the 
behaviour  
Co-morbidities  “My level of exercise has been hampered by other health problems” [Q-98, 
completed] 
Psychological capability - 
knowledge or 
psychological skills, 
strength or stamina to 
engage in the necessary 
mental processes 
   
Physical opportunity - 
opportunity afforded by 
the environment involving 
time, resources, locations, 






“I don’t drive, so one of the questions I asked him [GP] where do these sessions 
take place, because if I need to go to [location] or somewhere to do it, it’s not 
easy you know. It adds another several hours to the day for me” [I-19 declined] 
Session times  
Social/work 
commitments  
 “It was a bad time of the day you know, effectively I lost a day’s work by the time 
I got up there and got back”                 [I-81, dropped-out] 
Social opportunity -  
opportunity afforded by 
interpersonal influences, 
social cues and cultural 
norms that influence the 
way that we think about 
 Employer 
support 
 “It is quite a commitment though. I work full time and I’ve been very lucky in 




 “ I said ‘do I need to do this prevention programme?, because I am quite happy 




things e.g. the words and 
concepts that make up 
our language 
to do you a lot of good, you’re already eating healthily and you’re losing weight’” 
[I-19 declined] 
Reflective motivation - 
reflective processes 
involving plans (self-
conscious intentions) and 
evaluations (beliefs about 







 “I think from my own diet management really I seem to have got myself back 
within the bounds or within the figures I should be” [I-115, dropped-out] 
Group-based 
sessions 











“I have a general idea you know. I listen to the radio and I watch television and 
you hear from programmes there about how to cope with diabetes and how to 
make your lifestyle better, so I thought what am I going to gain by doing some 
yet another class as it were” [I-40, declined] 
Family history Family history “My brother has it [type 2 diabetes]. It’s a nuisance and it affects him in a way 
which I thought well I don’t want to be in that situation. In fact, I thought I am 




sources to be 
less reliable  
“In a way I was happy to wait for more expert advice, because whilst I obviously 
used internet and google to check things out, you get a lot of information, some 
of which is conflicting. So it’s not always the best source” [I-18 completed] 
 Weight loss  “I’ve got to be fair and say I went more with the idea of trying to lose some 





 Saving NHS 
money 
“It’s a dreadful thing to think that I might be costing the NHS money because I 
am ill-disciplined, and that is really why I want to take it more seriously” [FG-32, 
waiting] 
Automatic motivation - 
Automatic processes 
involving emotional 
reactions, desires (wants 
and needs), impulses, 
inhibitions, drive states 
and reflex responses. 
 Fear of 
diabetes and 
complications  
“To be honest, I would hate to be diabetic. If I had to give myself injections, I just 
don’t know how I could handle that. I know people who have had it affects other 





Physical ability to participate in sessions of the NHS DPP, particularly group 
exercises, was identified as a key enabler for engaging with and completing all 
programme sessions. To this end some participants described being hindered by co-




Programme location, session times and transportation, contributed to both 
facilitators and barriers to engagement. Participants felt that session times, which 
run during working hours, were more accessible for those without work 
commitments. Social influences on uptake arose from a variety of networks 
including employers where some participants described employers allowing them 
to have time off work to attend sessions of the programme. Other participants, 
however, described making decisions to engage based on advice sought from 
healthcare professionals, particularly GPs and nurses. Some of these participants 
described practitioners advising them against participating based on their beliefs of 
the benefits of the programme and the availability of spaces on the programme.  
 
Motivation  
A variety of reflections influenced lifestyle changes and engagement with the NHS 
DPP. Participants’ perceived own ability of making dietary changes and increasing 
physical activity, without intervention from the NHS, influenced some to disengage 
from the national programme. These participants described making changes which 
had resulted in positive outcomes such as weight loss, lower HbA1c and blood 
pressure. Group-based sessions also appeared to be a deterrent to some who 
acknowledged this to be attributable to personal preference.  
 
Participants described making decisions to engage with the programme based on 
perceived potential health benefits as well as perceived reliability of alternative 
sources of help such as online information. Participants’ beliefs about the 




other observations, also influenced engagement. Whilst some participants with a 
family history of type 2 diabetes were more inclined to engage with the national 
programme others felt that their experience with the condition had given them 
enough information and knowledge to support them in making lifestyle changes 
and therefore chose not to engage. Emotional responses to diagnosis, particularly 
fear of diabetes and complications, served as motivators to making lifestyle 
changes or engaging with the programme. Participants also described being 
motivated by self-conscious intentions and goals such as losing weight or improving 
prognosis of co-morbidities such as arthritis. Finally, one participant in particular 
felt strongly that their reason for wanting to engage with the help offered by the 
NHS DPP was influenced by their view of the role of the NHS and that they should 
be doing everything they can to prevent additional burden to the health service. 
 
3.3.3.3 Theme 3: Feedback on the NHS DPP 
Feedback from participants who engaged with the national programme, including 
those who had dropped out, largely reflected the ‘one size does not fit all’ notion 
with some giving positive feedback and others giving negative feedback on the 
same aspects. Participants who had attended some sessions or had completed the 
programme described the location as accessible and session times as convenient 
whilst those who hadn’t engaged had opposing views including a lack of flexibility in 
programme delivery. Participants who had attended some sessions of the 
programme gave largely positive feedback and expressed positive outcomes 
achieved including raised awareness in making healthy dietary choices, weight loss, 
increased physical activity and reduced HbA1c. Some participants also reported 
positive outcomes with comorbidities such as blood pressure and arthritis. In terms 
of delivery, participants felt that the programme was well presented by 
knowledgeable non-healthcare personnel and felt that delivery was consistent 
throughout its duration.  
 
“Well the location was very good for a start, it was very near the doctors and I go to 





“I thought that the people that presented it, without being doctors, nurses, 
pharmacists whatever, did a very good job and I’m tempted to think they might also 
use a language that’s closer to that used by the participants than a medical 
professional” [I-18, attending] 
 
Participants also expressed the usefulness of resources offered by the programme 
including written materials and props which helped them to gain a better 
understanding of NDH and dietary choices. However, some expressed a preference 
for simple written materials instead of the book provided by the programme. 
Negative experiences appeared to centre on the notion that the duration of the 
sessions was too long, with some describing the 2-hour sessions as ‘heavy going’. 
Some participants also commented on aspects of the programme such as exercise 
sessions that seemed irrelevant to them due to their age and co-morbidities. Group 
activities also received both positive and negative feedback with participants liking 
activities such as weighing and others not taking to some of the activities. Most 
participants who completed the programme seemed to have a richer appreciation 
of the support and encouragement that the group-based sessions provided.  
 
“Only attended one session. Found it was very long, unnecessary and rather 
patronising” [Q161, dropped-out].  
 
“In the group I attended most of the people were 60 plus so the activities/exercise 
provided I think were for that age group and not mine” [Q-1, completed]. 
 
“A big benefit of the course was the group meetings. It wouldn't have meant 
anything to me if it hadn’t have been for that. I actually look forward to going every 
week and listening to what other people have done that week; what they found 
easy what they found difficult. I thought that was brilliant I think that interaction 
was what made it for me” [FG-91, completed] 
 




Participants discussed characteristics of services that could be delivered in the 
community pharmacy including a one to one alternative option of the NHS DPP. 
Participants who had completed the programme also felt that community 
pharmacy could be useful for providing post-intervention monitoring services to 
support maintenance of positive clinical outcomes. Suggested characteristics of the 
types of services community pharmacy could deliver are summarised in Table 3.7.  
Barriers and facilitators for engaging with community pharmacy-based DPS in 
particular NDH screening and prevention programmes were also identified. Barriers 
and facilitators mapped onto the COM-B are presented in Table 3.8. The table also 
presents summary phrases of these factors and  highlights those that have been 
taken forward for further COM-B analysis. The related target behaviour in this 
theme was ‘people with non-diabetic hyperglycaemia engaging with community 





Table 3.7 Potential intervention characteristics of community pharmacy-based services 
 
Type of service*  Illustrative quote  
One to one option “Possibly useful alternative to group sessions” [Q-166, dropped-out] 
Support after NHS DPP 
 
“I would welcome continuing support after the programme completed” [Q-152, completed] 
HbA1c monitoring “If technology is moving away from having to send blood samples away and having to wait days for 
them to come back to the surgery…  if modern equipment is able to do that in a pharmacy setting 
maybe there’s an opportunity that might work” [FG-11, attending] 
 
Private screening services “If there’d been some way I’d have even paid for it to monitor my health in some way, which is 
where I was thinking you know community pharmacy if you could pay them to test you when you’re 
35 (HbA1c)” [FG-25, waiting] 















Mapped codes Illustrative quotes Summary phrase  
Barriers  Facilitators 
 
Physical capability- 
physical skill, strength 
or stamina 
 
    
Psychological 
capability - knowledge 
or psychological skills, 
strength or stamina to 









 “There are just so many avenues you 
can get medical advice through 
nowadays, and it gets very confusing” 
[Q-25, waiting] 
A. Knowledge of support options 








“I’m not aware of all the different 
things that chemists do, I didn’t think 
they probably would measure your 
cholesterol and things like that I 
suppose it’s possible” [I-7, attending] 
B. Awareness/promotion (patients and 
public) 
 
Physical opportunity - 
opportunity afforded 
by the environment 
involving time, 
 Convenient “It sounds like a convenient way for 
people to access screening and advice 
on how they can best avoid developing 
full blown diabetes” [Q-94, attending] 
 
*Accessibility (location) 
Explored under the behaviour 
‘delivering community pharmacy-












“An excellent idea. Closer to home is a 
huge improvement. No long 1hour+ on 
cold wet days - that’s 1hr minimum - 
on my trip into [location]” [Q-48, 
declined] 
 
*Accessibility (location)  
Explored under the behaviour 
‘delivering community pharmacy-





 “Would there be a private room 
available or enough space if it’s a 
course and privacy and confidentiality. 
I hope it wouldn’t be held or reviewed 
at the shop counter” [Q-103, unknown 
participation status] 
C. Suitable consultation rooms (privacy 
and confidentiality)   
 Shorter waiting 
times 
 
“Probably far quicker than waiting for 
doctor’s appointment. Prevention 
screening services? Excellent idea if 
carried out by professionals targeting 
specific ailments include "Wellman 
Clinic" [Q127-waiting] 
 
*Accessibility (shorter waiting times) 
Explored under the behaviour 
‘delivering community pharmacy-






appointments   
 “Not sure if this would work as they 
always seem to be quite busy, unless it 




Explored under the behaviour 
‘delivering community pharmacy-
based diabetes prevention services’ 
(Ref 3d) 
Space challenges  
 
 “I feel the group setting is a good way 
forward for a prevention service and I 
am not sure if this can be provided by 








community pharmacy with limited 
space” [Q-110, completed] 
 
Explored under the behaviour 
‘delivering community pharmacy-
based diabetes prevention services’ 
(Ref 5) 
Lack of access to 
medical records 
 “I think the doctors have more 
accessibility to medical records for 
contacting people but the community 
pharmacy is always there for excellent 
advice“ [Q-26, completed] 
 
*Access to patient medical records 
Explored under the behaviour 
‘delivering community pharmacy-
based diabetes prevention services’ 
(Ref 6) 
Understaffed Extra resources 
e.g. 2 pharmacists  
“I don’t feel that community 
pharmacies have the resources to 
provide an effective diabetes 
prevention services as this would 
require lengthy consultations to cover 
the many aspects involved” [FG-11, 
attending] 
*Resources  
Explored under the behaviour 
‘delivering community pharmacy-
based diabetes prevention services’ 
(Ref 7b) 
Funding cuts Funding  “I think community pharmacy I think 
would be it’s not so much a 
commercial thing if you want would 
probably be a better option I’d love to 
see it but it’s going to take a lot of 
investment in time people and money” 
[I-18 completed] 
*Funding (resources) 
Explored under the behaviour 
‘delivering community pharmacy-
based diabetes prevention services’ 
(Ref 7b) 




pharmacy and the 
rest of the 
Diabetes 
prevention 
“You’ve got all sorts of people who 
have become involved with the surgery 
who weren’t before…same with the 
pharmacist, if it was within that 





influences, social cues 
and cultural norms 
that influence the way 
that we think about 
things e.g. the words 
and concepts that 





services must be 
linked to GP 
environment and they were all linked 
together and they had that interaction 
I think people would probably have 
more confidence” [FG-11, attending]  
 





 “I haven’t really had any experience 
with pharmacies…well I guess I’d have 
to trust them [to deliver DPS]. As I say I 
have no experience of ever going to 
them before, so I can’t judge them on 
no experience” [I-115, dropped-out] 





 “ If you go abroad I mean in other 
countries the pharmacist is usually the 
first port…even in European countries 
where you don’t pay for healthcare 
necessarily you go to a pharmacist you 
get advice” [FG-25, waiting] 
B. Awareness/promotion (patients and 
public) 
 
Prefers GP or 




 “Rather see the practice nurse as I 
know her” [Q-65, waiting] 
E. Healthcare professionals 

















“Having to wait at least 30 minutes in 
my pharmacy to collect prescriptions, 
they seem very disorganised with no 
system. I feel they would not be 
capable of providing this service 
efficiently” [Q-104, declined] 
F. Experience (receiving other 




(beliefs about what is 








able to deliver 
DPPs 
 “It is so detailed and comprehensive 
[NHS DPP] that I’m finding it difficult 
how a local pharmacy is going to be 
able to provide that sort of advice, 




Explored under the behaviour 
‘delivering community pharmacy-
based diabetes prevention services’ 
(Ref 10) 
 DPPs can be 
delivered by any 
trained personnel 
“I mean these courses were given by 
people who weren’t doctors or 
pharmacist and hadn’t had that 
amount of training, but they were 
trained to deliver this course and that 
was fine. I didn’t need to have 
somebody who’s got a degree” [FG-42, 
completed] 
*Training* 
Explored under the behaviour 
‘delivering community pharmacy-






“The staff are very capable for my use 
so far, and I see no reason why with 
training they [community pharmacy 
staff] would be unable to do so [deliver 





Explored under the behaviour 
‘delivering community pharmacy-






Potential to save 
GP time 
“That could actually save the doctors 
an awful lot of time and especially the 
climate at the moment is that hospitals 
doctors surgeries are at bursting 
point…it would be very useful for a 
chemist to take some of these more 
*General practice benefits  
 







simple things which are very important 
to the body on board and free the 
public from standing in queues and 
free the surgeries from having too 
many people to attend to” [I-7, 
attending] 
based diabetes prevention services’ 
(Ref 23) 
Automatic motivation 
- Automatic processes 
involving emotional 
reactions, desired 
(wants and needs), 
impulses, inhibitions, 







peace of mind 
“I think to be able to go in for peace of 
mind cos I know sometimes I feel that 
if I’ve gone too long and not eaten my 
blood sugar goes down” [I-13, 
declined] 
*Patient centred services (accessibility) 
Explored under the behaviour 
‘delivering community pharmacy-
based diabetes prevention services’ 
(Ref 3) 
 
*Links forward to Chapter 4, Table 4.3 






Generally, participants who were unable to engage with the current national 
programme due to various accessibility factors (e.g. time commitments) expressed 
a lack of knowledge of where to access alternative help. Therefore, with most 
participants also expressing a lack of knowledge about current community 
pharmacy-based public health services, it was felt that people with pre-diabetes 
would need to be informed about DPS provided in this setting to enable them to 
engage. Experiences with current community pharmacy services were largely 
medicine related and involved information provision or counselling. Apart from 
influenza vaccinations, there was a general lack of awareness of non-medicine 
related services, including diabetes screening, offered in this setting. Generally, due 
to the lack of awareness of current community pharmacy services and its public 
health role, participants felt that community pharmacy based DPS would need to 
be promoted sufficiently to the targeted population for it to be successful.   
 
Opportunity 
The community pharmacy setting was identified by the participants as accessible 
and convenient, particularly in terms of location and ease of making appointments. 
Participants felt that there is an opportunity for community pharmacy to deliver 
NDH screening and monitoring services with some expressing their willingness to 
attend and even pay for the services. Participants felt that the DPS delivered in this 
setting would be most appropriate for regular community pharmacy users due to 
established relationships. 
 
A number of barriers that would have to be overcome to deliver the services such 
as lack of access to medical records, time, funding and staff resources were also 
identified. Whilst some participants felt that, due to space challenges, community 
pharmacy would be unable to deliver group-based sessions, others discussed 
concerns about privacy and confidentiality, which were mainly based on the set-up 
of community pharmacies and the tendency for advice to be given over-the-





Most participants felt that the integration of community pharmacy DPS with 
general practice services could increase acceptability of service users. Participants 
also felt that delivering DPS in this setting could potentially decrease GP workload 
and thus decrease waiting times at general practices.  Other participants who were 
less keen on the idea of community pharmacy delivering DPS explained that the 
service would be better provided by the general practice alone due to their 
increased access to medical records and familiarity. However, some participants 
acknowledged their views were based on pre-conceived ideas of the role of 
community pharmacy and reservations about them providing services that 
traditionally would be otherwise provided by general practices.  
 
Motivation 
Motivations to access community pharmacy based DPS were largely reflective, 
where participants described basing decisions on their experiences and beliefs. 
Most respondents felt that delivering NDH screening and DPPs through community 
pharmacy was a good idea with some expressing that the setting could provide an 
alternative for those who do not like the group-based setting. Those who had either 
completed the national DPP and had managed to revert their HbA1c levels to 
normal ranges expressed that this setting could be useful for providing follow-on 
support and monitoring and would give them peace of mind due to ease of access.  
 
Participants acknowledged that community pharmacy has the potential to deliver 
DPS but considered appropriate training and qualifications of personnel delivering 
services as key determinants for enhancing their motivation to engage.  This 
indicated that participants were comfortable with the community pharmacy 
personnel delivering DPS as they felt it could be delivered by anyone providing they 
had the appropriate training. This aligned with other participant views about non-
healthcare professionals delivering the NHS DPP successfully.  
 
Willingness to participate in community based DPS was largely influenced by 
participants’ experience with other services in this setting, with those who had 




community pharmacy delivering diabetes prevention interventions. Additionally, 
some participants who had attended the national DPP were sceptical about 
community pharmacy being able to deliver DPS. These participants expressed that 
having attended the current national programme, which from their experience was 
a lengthy and comprehensive service, they were finding it difficult to envisage 
community pharmacy delivering a similar programme.  
 
 
3.4 Discussion  
 
This research highlights that a one-size fits all approach should not be applied when 
delivering the DPP and that alternative delivery approaches should be explored to 
maximize reach (131). Factors influencing engagement identified by this research 
not only highlight a potential role for community pharmacy in addressing 
accessibility barriers but could also inform pathways for signposting people with 
NDH into better suited DPP settings. This study also identifies important facilitators 
in the Capability (e.g. training) and Opportunity (e.g. time) domains of the COM-B 
theoretical behaviour change model that could be targeted when designing and 
implementing NDH interventions that could be delivered by community pharmacy 
teams.   
 
The experience of being diagnosed with NDH, largely described as a feeling of shock 
by the participants in this study, and the subsequent motivation to make lifestyle 
changes, highlights a timely opportunity for the provision of suitable interventions. 
Previous research has highlighted NDH as a ‘window of opportunity’ for healthcare 
professionals to support those identified to implement lifestyle changes (248). This 
research demonstrates scope for community pharmacy teams to deliver DPS for 
people diagnosed with NDH following screening as an alternative option to the 
current national programme. Community pharmacy was seen by people with NDH 
as a potentially accessible and convenient option, particularly for regular service 
users.  Previous research exploring views and perceptions of the public towards 




similar findings, identifying accessibility and convenience as positive aspects of 
community pharmacy (249-251). However, in line with previous research, our 
findings have shown that although the community pharmacy setting could be a 
favourable choice for people who are employed and regular service users (252, 
253), engagement could be hindered by lack of awareness of community pharmacy 
services and poor perceptions of the role and expertise of community pharmacy 
teams (249, 252, 254). Additionally, strong views of pharmacists as drug experts 
(255, 256), preference for general practice settings by patients  and lack of GP 
endorsement have also been highlighted by research as common hindrances to 
community pharmacy services uptake(253). 
 
In 2016, a review of community pharmacy clinical services in England highlighted 
similar behavioural constraints for accessing community pharmacy services 
including lack of awareness and expectation of the clinical care that pharmacy can 
and could deliver by patients, the public and other health care professionals (257). 
The report highlighted that raising awareness of community pharmacy services as 
well as increasing public perception and experience is central to changing 
behaviours. The review recommended building local peer relationships with other 
healthcare providers and using patient groups to raise awareness to people with 
different cultural backgrounds and age groups (257). 
 
This study demonstrates that engagement with community pharmacy based DPS 
could be influenced by perceptions of community pharmacy teams’ capability (in 
terms of training and qualification) to deliver such services. Although this research 
indicates that regular community pharmacy users are more inclined to perceive 
community pharmacy to be capable of delivering DPS, the findings show that most 
people with NDH would be willing to engage with services in this setting if 
community pharmacy teams received appropriate training. A systematic review 
examining the beliefs and attitudes of consumers towards pharmaceutical public 
health, has shown similar findings suggesting that although most service users view 
pharmacists as appropriate providers of public health advice, they have mixed 




satisfaction rates amongst those that had experienced community pharmacy based 
public health services and recommended the provision of training to increase 
pharmacists' confidence in providing these services. 
 
Other intervention characteristics such as programme content and delivery, 
seemed to influence retention of people with NDH following initial engagement. 
Characteristics such as session times and duration, were among factors identified 
by our study to influence those who dropped out of the national DPP. This reflects 
findings of the ComPoD study which evaluated an existing community-based DPP in 
parts of England (Exeter and Birmingham) and reported a similar proportion of 
people who had declined or dropped out (129, 130). The ComPoD study reported, 
amongst those willing but unable to engage with the programme, inconvenient 
session times as barriers. Previous qualitative research which identified organising 
suitable session times for a group as a challenge for providers identified the need 
for session time flexibility in programme delivery and ensuring sufficient physical 
access including transportation and parking (131).  
 
Finally, as this research suggests motivation to be an important factor influencing 
participation in DPPs, the provision of DPS in alternative settings to such as 
community pharmacy, which primarily serve to increase opportunity for 
engagement, could indirectly enhance motivation (188, 192, 259, 260). This study 
also identified motivational factors such as patients’ perceptions of their ability in 
making health changes and perceived reliability of alternative support options, as 
factors that have the potential to influence to engagement with the DPPs. Such 
factors would therefore need to be taken into account when considering the 
primary targets of the NHS DPP. It is also important that patients motivated to 
make lifestyle changes without the support of DPPs are well provided with 
evidence-based information and resources. 
 





This is the first study investigating influences of participation in NHS DPP and 
exploring the role of community pharmacy in diabetes prevention. Demographic 
characteristics, which largely consisted of an elderly population, including a small 
proportion of employed people and fewer men than women, sufficiently 
represented that of Norfolk which largely consists of a white British population with 
a relatively older age profile compared to the rest of England (261). Participation 
demographics reflected both national NHS DPP figures and previous research which 
demonstrate increased uptake with age and a significantly lower attendance in men 
(131, 133, 262-264). Additionally, participation rates reflected local figures which 
demonstrate a 56% (95% CI 53 to 60) uptake rate (attendance of initial session) 
since initiation of the programme in June 2016 (264).  
 
The mixed method, exploratory design enabled triangulation of findings to gain 
views of a wider NDH population. Using a theoretically informed approach to 
investigate the role of community pharmacy in diabetes prevention in this research 
presents a potential to inform development and implementation of services for 
people with NDH in this setting. The findings could also inform possible screening 
methods for signposting patients into better suited DPP settings.  
 
One of the limitations of the study was the lack of diversity thus providing a limited 
perspective from people of other ethnic backgrounds. Additionally, the exclusion of 
non-English speakers could have also created a literacy and language barrier to 
participation in both the NHS DPP and in this study, thus limiting the generalisation 
of findings to subpopulations (145). Another limitation was the low response rate 
to the questionnaire study which limited the number of questionnaires included in 
the analysis. With the majority of respondents constituting those who had 
expressed some interest in participating in the NHS DPP, social desirability may also 
be a bias in the responses received (265) i.e. the data is likely to represent people 






 The use of an unvalidated questionnaire incorporating agree/disagree Likert scale, 
a scale which research suggests achieve results with lower reliability and validity 




3.5 Conclusions  
 
Community pharmacy is an acceptable setting for the delivery of DPS and could be 
a possible alternative for people with work and social commitments, regular 
community pharmacy users and those seeking alternatives to the current national 
programme. This research outlines factors that could influence the implementation 
of services in this setting with regards to engagement. Opportunity to engage with 
community pharmacy-based DPS services could be based on its accessibility. 
Therefore, if community pharmacy were to provide DPS with flexible session times, 
which is possible given their extended opening hours, this could present a potential 
role for the setting in addressing some of the current barriers to engagement. 
Patient perceptions of the capability of community pharmacy to deliver acceptable 
DPS could be influenced by knowing that community pharmacy teams are 
appropriately trained to deliver the services.  In order to enhance motivation for 
people with NDH to engage with DPS, community pharmacy teams would need to 
build trusting relationships with this population and ensure endorsement by 
healthcare professionals such as GPs and nurses.  
 
This chapter provides evidence to inform development of an intervention as per the 
aims of the COM-B model in the BCW. The barriers and facilitators mapped to the 
COM-B components of this research were taken forward to describe the role of 
community pharmacy in diabetes prevention. Further work presented in Chapter 5 
and 6 seeks to refine these barriers and facilitators to assist the linking of the 
outcomes through the Behaviour Change Wheel (203, 207), to develop appropriate 
interventions and strategies that could increase participation in community 
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Intervention accessibility has been identified as an important influence for engaging 
with DPPs (131-133). Research investigating engagement with the NHS DPP has 
identified similar barriers, including lack of transportation, inconvenient location 
and session-times (Chapter 3). Such barriers may be addressed by community 
pharmacy involvement given its accessibility (Chapter 3).  
 
In England, however, with NDH primarily identified through routine primary care 
appointments or retrospective screening of general practice databases, the role of 
community pharmacy in the delivery of DPPs remains undefined (120, 155). 
Additionally, although community pharmacy delivers opportunistic screening 
interventions, there are no direct referral pathways to the NHS DPP from this 
setting (137), nor are there routine lifestyle interventions being delivered  for 
people with NDH. Therefore, with the NHS long term plan advocating involvement 
of community pharmacists in primary care networks for case finding and treating 
high risk conditions (115), it is important to establish a clear role for community 
pharmacy in delivering interventions for people with NDH. Additionally, there is a 
need to better understand the likely barriers and facilitators to delivering public 
health interventions in this setting.  
 
To date, with majority of qualitative research focusing on exploring barriers and 
facilitators to engagement from the perspective of people with NDH (132, 145, 146, 
238), very few studies have explored the views of those delivering the 
interventions.  Successful delivery of community pharmacy based DPS would 
require behaviour change from those delivering the interventions. Therefore, the 
study presented in this chapter focusses on behaviours of healthcare personnel 
that would be involved in delivering community pharmacy based DPS including GPs, 
pharmacists and commissioners (131) to inform the potential role of community 
pharmacy in the management of NDH within the primary care context.  The study 
applied the COM-B theoretical model to understand the target behaviour ‘the 




using the COM-B was intended to assist in identifying behavioural determinants 
which could serve as fruitful targets for community pharmacy-based interventions 




To explore the community pharmacy setting as an option for delivering DPS by 
eliciting views of stakeholders and using the COM-B to frame the data collection, 





1. To characterise the current and potential role of community pharmacy in 
the prevention of type 2 diabetes  
2. To describe the barriers and facilitators to delivering DPS in the community 





4.2.1 Study design  
 
This is a qualitative study that adopted a pragmatic epistemology to explore the 
study aims and objectives. The research employed semi-structured interviews and 
focus groups to explore views of multiple stakeholders including community 
pharmacy teams, GPs, nurses and commissioners (267). The study took place in 
Norfolk, UK, between January and March 2018. 
 
4.2.2 Ethics approval  
 
Ethics and governance approval was obtained from the Health Research Authority 




Ethics committee at the UEA before commencing the research. The study protocol 
can be found in Appendix 4.1, together with the ethics approvals (Appendix 4.2), 
ethics amendment approvals (Appendix 4.3) and research and development office 
approvals (Appendix 4.4).  
 
4.2.3 Rationale for study design  
 
A pragmatic and exploratory research design was used to address this research 
topic in which very little research had previously been undertaken (267, 268). 
Pragmatism, a philosophy that recognises that there are different ways of 
interpreting the world and research, suggests there to be multiple realities and 
hence that no single point of view can ever give the entire picture (269, 270). 
Pragmatic research therefore seeks to use whatever combination of methods 
necessary to find the answers to research questions. 
 
Exploratory research is often used to tackle research topics on which little or no 
previous research has been done (267). It is usually undertaken in a preliminary 
stage of an investigation to gain background information, produce insights of the 
situation being developed and generate ideas (267, 268). Since there is currently 
very little research investigating community pharmacy as a setting for the delivery 
of DPS, an exploratory research design was deemed appropriate. 
 
A mixture of focus groups and interviews was adopted. Focus groups were viewed 
as central to exploring the research topic in this group of participants who often 
work as a team to deliver services (242). However, to provide flexibility to potential 
participants and thus encourage participation, the interview option was made 
available to GPs, nurses and commissioners. This option also supports honest in-
depth accounts of experiences and opinions thus was considered suitable for 
obtaining accounts about community pharmacy and community pharmacy teams 





4.2.4 Study setting  
 
This study was set in primary care, specifically community pharmacy and general 
practice settings (271). General practices are private healthcare businesses whose 
role is to provide healthcare to local communities. Although the majority of general 
practices work to NHS contracts, follow NHS guidelines and see NHS patients, they 
do not compete for patients, or profit in the way competitive providers of 
healthcare do. General practices consist of multidisciplinary teams including 
general practitioners, nurses, pharmacists and healthcare assistants. These teams 
are responsible for both looking after patients with chronic illness and health 
promotion. Community pharmacies are also private healthcare providers working 
to NHS contracts in providing medicine related services such as dispensing and 
counselling. As part of their contract, community pharmacies also provide health 
promotion services such as smoking cessation programmes.  
 
In England, local health promotional services provided by both general practices 
and community pharmacies are commissioned by CCGs and local authorities (272). 
CCGs are groups of general practices which come together in an area to 
commission the best services for their patients and population. These groups 
therefore buy services for their local community from any service provider, 
including community pharmacy, which meets NHS standards and costs. 
Commissioners are usually supported by Clinical Support Units with external 
support, specialist skills and knowledge and may also consult Local Pharmaceutical 
Committees (LPCs), who represent all pharmacy contractors in a defined area, on 
services that could potentially be provided via community pharmacy. 
 
This study involved multiple stakeholders involved in both the provision and 
commissioning of local health promotional and preventative services in order to 
obtain a more complete perspective on a potential role of community pharmacy in 





4.2.5 Study Participants   
 
Eligible participants were community pharmacy personnel, GPs and nurses working 
in Norfolk, UK. Community pharmacy personnel included pharmacists and 
registered technicians and healthcare assistants involved in the delivery of public 
health services (273). GPs, nurses and other pharmacists were only eligible if they 
were working for general practices participating in NDH screening and referral to 
the NHS DPP and had a special interest in diabetes. Individuals involved in 
commissioning and negotiating services for community pharmacy in Norfolk were 
also eligible to participate in the study. These included individuals working for the 
CCG, the LPC, NHS England, Public Health England and the East of England strategic 
clinical network.  
 
4.2.6 Participant identification and approach 
 
4.2.6.1 Gatekeeper consent  
Community pharmacy: Gatekeeper consent was sought from area managers 
(responsible managers for a group of pharmacies in a defined area) of multiple 
pharmacies or pharmacist managers for independent pharmacies. Area 
managers/pharmacist manager were sent an e-mail (Appendix 4.5) asking them to 
circulate an invitation letter (Appendix 4.6) and a participant information sheet 
(Appendix 4.7) to pharmacists in their area/store. Where gatekeepers were unable 
to do this, consent was sought from the gatekeepers to contact community 
pharmacies via telephone before sending research documents to interested 
persons. 
  
General practice: GP practice participants were approached through the Norfolk 
and Suffolk Primary and Community Care Research and Development teams (R and 
D) office (Appendix 4.5). These are teams set up in each CCG to support research 
that aims to develop new treatments and knowledge for better healthcare. 




information sheet (Appendix 4.7), was e-mailed to practice managers by the R and 
D officers asking them to forward it to GPs and nurses in their practice.  
 
Commissioners: Commissioners were identified through the Norfolk and Suffolk 
Primary and Community Care Research and Development (R and D) office and/or 
existing contacts with CCGs and Local Pharmaceutical Committee (LPC) (Appendix 
4.5).  Potential participants were approached via e-mail which included an 
invitation letter (Appendix 4.6) with an attached participant information sheet 
(Appendix 4.7).  
 
4.2.6.2 Expression of interest and follow-up  
Individuals who were interested were asked to complete an online expression of 
interest form (Appendix 4.8) which contained options for their availability. 
Participants were given two weeks to respond to the e-mail and followed up either 
via e-mail (Appendix 4.9) or a follow-up telephone call. All participants who 
volunteered to participate in the study were sent a reminder e-mail at least three 




The study aimed to conduct two focus groups and a maximum of 12 interviews. For 
community pharmacy participants, initial recruiting involved convenience sampling 
followed by purposive sampling. This was to ensure a good representation of 
community pharmacy personnel from various chains and independent pharmacies. 
Participants were therefore selected to obtain a diversity of views using job titles 
and workplace representation (242). The size of the focus groups consisted of five 
to eight participants to ensure a group composition that facilitated a rich discussion 
(242).  
 
Convenience sampling was used to recruit commissioners, GPs and nurse 
participants whilst ensuring representation of practices in Norfolk. All GPs, nurses 




option, hence focus groups were only conducted with community pharmacy 
participants. The number of interviews conducted was determined by availability of 
participants and data saturation. In this study data saturation was determined 
when there was no additional data expressed in new data (244).   
 
4.2.8 Incentives and reimbursement  
 
Participants involved in focus groups and interviews conducted outside of working 
hours were reimbursed for travel costs and received a £30 voucher for 
participating. General practices were reimbursed at £80 per hour for GP time and 
£23.21 per hour for nurses’ time for interviews conducted during working hours in 
line with advice from the Norfolk and Suffolk R and D team. Participating 
commissioners offered to participate without payment.  Refreshments were 
provided for the focus groups. 
 
4.2.9. Data collection  
 
4.2.9.1 Data collection procedure 
Semi-structured interviews were conducted at the UEA or participants’ workplace 
by the main researcher (TK) and lasted up to a maximum of 30 minutes. Focus 
groups were held at the UEA and facilitated by the main researcher (TK) and 
another member of the research team (MT/HA) and lasted approximately 60 
minutes. Both interviews and focus groups were digitally audio recorded and a 
semi-structured topic guide was used to facilitate the discussions. Written consent 
was obtained for both the focus groups and interviews (Appendix 4.11).  
 
4.2.9.2 Topic guide 
A topic guide facilitated the conduct of both interviews and focus groups, and this is 
summarised in Table 4.1. The full version can be found in Appendix 4.12. The topic 
guide was designed to gain information about the current and potential role of the 
community pharmacy in diabetes prevention. It also explored the main barriers and 
facilitators of delivering a community pharmacy-based DPP. It was developed based 




underpinned by the COM-B model proposed by Michie et al. (192). However, the 
structure was not restricted to this in order to allow emergence of unanticipated 
topics. The topic guide was tailored to the appropriate healthcare professional 




Table 4.1 Topic guide summary 
 
Research topic        Issues discussed  




 Experience and challenges with the management of patients with NDH  
 Engagement with the delivery of current NDH services  
   
 
Community pharmacy services   Experience and views about current community pharmacy services  
 Views on current primary care based public health services e.g. NHS Health Checks  
 Current challenges and impact of services  
 
Community pharmacy-based 
diabetes prevention  
 Views on the role of community pharmacy in diabetes prevention (screening and lifestyle interventions)  
 Capability: barriers and facilitators for using community pharmacy personnel to deliver services e.g. skills and 
training  
 Opportunity: barriers and facilitators for using the community pharmacy setting for the delivery of DPS 








4.2.10 Data Analysis  
 
4.2.10.1 Thematic analysis  
Interviews and focus group recordings were transcribed verbatim by the main 
researcher (TK) or a paid contractor. The transcripts were then uploaded to NVivo 
11 and checked for accuracy by listening back to the original recording. To provide 
an iterative process of analysis Braun and Clarke’s six phases of thematic analysis, a 
method for identifying, analysing and reporting themes within data was conducted 
(274). This approach was adopted because it can be used to analyse data from 
different types of communication media, providing a flexible approach to analyse 
data from both audio recorded interviews and focus groups (275). Processes taken 
to conduct thematic analysis in the study were similar to those presented in 
Chapter 3. 
 
In summary, the transcribed data was re-read and inductively coded by the main 
researcher (TK). The coding process was then discussed with another member of 
the research team (HA) to assist the development of themes. Relationships 
between the codes were sought in order to develop subthemes and subsequent 
themes by the main researcher (TK) and another member of the research team 
(HA). Subthemes and themes were then reviewed by another member of the 
research team (MT). Any disagreements were resolved by consensus following 
discussion, referring back to the coded and original transcripts. Transcripts were 
again revisited to develop a richer description of the themes and to identify 
representative extracts to use in the written analysis. Extracts were selected to 
ensure a balanced representation of participant characteristics in terms of 
engagement with the NHS DPP and study involvement (questionnaire, focus groups 
and interviews). Theme descriptions and extracts were discussed by the main 
researcher (TK) with another member of the research team (MT).  
 
4.2.10.2 COM-B analysis 
To facilitate the COM-B analysis of the target behaviour, themes associated with 




community pharmacy teams’) were identified by the main researcher (TK) and 
another member of the research team (MT). Respective codes from the themes 
were then separated into barriers and facilitators and mapped onto the three 
categories of the COM-B. Mapping was carried out independently by the main 
researcher (TK) and two other members of the research team (HA and MT). 
Following this the mapping was further analysed by another member of the 
research team (HF) who has a psychology background and experience in using the 






Two focus groups with community pharmacy participants and nine interviews with 
GPs, nurses and commissioners were conducted. One focus group consisted of a 
mixture of four pharmacists and three technicians and the other consisted of four 
pharmacists and one pre-registration pharmacist.  Participant characteristics are 
summarised in Table 4.2. Thematic analysis identified five main themes, and these 
were as follows: ‘Management of non-diabetic hyperglycaemia and associated 
challenges’, ‘The community pharmacy setting’, ‘Awareness of community 
pharmacy services’, ‘Relationships and communication’ and ‘Delivery of community 
pharmacy services’. The first theme sets the context for the current management of 
people with NDH in primary care which is largely carried out in the general practice 
setting and the subsequent themes relay the factors associated with the delivery of 
DPS in the community pharmacy setting.  What follows aims to provide a 
commentary on the first theme along with illustrative quotes to provide context 
and a COM-B analysis of the subsequent themes with respect to the target 







Table 4.2 Participant characteristics 
 
Characteristic  Total (N=21) N (%) 
Gender   




Pharmacist (registered) 8 (38.1) 
Pharmacist (pre-registration) 1 (4.8) 
Pharmacy technician  3 (14.3) 
General practitioner  3 (14.3) 
General practice pharmacist 1 (4.8) 
Nurse  3 (14.3) 
Commissioner (pharmacist)   1 (4.8) 
Commissioner (non-healthcare professional) 1 (4.8) 
 
Place of work  
 
Pharmacy chain 9 (42.9) 
Independent pharmacy  3 (14.3) 
General practice  7 (33.3) 
Commissioner (Local Pharmaceutical Committee-non-healthcare professional)   1 (4.8) 




4.3.1 Thematic analysis 
 
4.3.1.1 Theme one: Management of non-diabetic hyperglycaemia and associated 
challenges 
Despite the implementation of the NHS DPP, there was a variation in its utilisation 
by participants working in general practices who described using different risk 
management protocols and expressed a variety of associated challenges. GP and 
nurse participants described providing diet and lifestyle advice using, but not 
limited to, leaflets and face to face or telephone consultations. Personnel 
responsible for annual monitoring and reinforcement of lifestyle advice also varied 
and included healthcare assistants, nurses and GPs. Although most GPs and nurses 
felt that patients were largely receptive to their advice, some felt unable to deliver 
personalised support due to time constraints. These participants relayed that the 
overwhelming numbers of people with NDH identified in their practices had led to 
reactive rather than proactive screening and management.  
 
“When pre-diabetes first became a thing we went from being really proactive about 
it, thinking gosh we’ve got to stop these people from becoming diabetic and we 
were talking to them bringing them in for face to face consultations. Then we 
realised it was too many people and we couldn’t sustain that. So now we send them 
a letter which is a bit of a cop out” [P15-GP] 
 
Experience with referral to the NHS DPP was varied amongst GP and nurse 
participants who largely welcomed the programme as a referral option that saved 
them time and allowed them to focus on management of other conditions. 
Although some participants mentioned receiving positive feedback from patients 
who had engaged with the programme, most seemed to have very little knowledge 
about the content of the programme.  
 
“It is a good option I do feel because of the time element and obviously we’re really 




they say, ‘yes I will go on the diabetes prevention’, that does then reduce that, not 
burden, but it transfers that responsibility over” [P18-Nurse] 
 
Nurse participants felt that uptake amongst their patients was low and was largely 
affected by location of the programmes and transportation means. Some 
participants felt that the programme could have better uptake if it was being 
delivered within their practice due to familiarity and location. Apart from 
accessibility factors, other barriers to participation included social and work 
commitments, group-based sessions and patients’ perceptions that they had 
adequate knowledge and capability to make changes themselves. From experience 
with their patients, some participants felt that engagement was noticeably low 
amongst people with co-morbidities and those from low socioeconomic 
backgrounds. 
 
“The other thing is a lot don’t like groups…the minute I found that I say oh you know 
it’s a group session, they say, ‘oh no I don’t want to go, I don’t do groups” [P16-
Nurse] 
 
4.3.2 COM-B analysis  
 
Four themes: ‘The community pharmacy setting’, ‘Awareness of community 
pharmacy services’, ‘Relationships and communication’, and ‘Delivery of 
community pharmacy services’ all contributed to various degrees in the Capability, 
Opportunity and Motivation domains of the COM-B analysis. What follows is a brief 
description of each theme and the results of the COM-B analysis in relation to the 
target behaviour ‘community pharmacy teams delivering DPS’. The separation of 
the codes in each theme into barriers and facilitators and mapping to the COM-B is 
detailed separately in Table 4.3 together with the descriptions of Capability, 
Opportunity and Motivation. The codes in each COM-B component have been given 






Table 4.3 COM-B analysis of barriers and facilitators to delivering community pharmacy-based diabetes prevention services 
COM-B components with 
definitions 
Mapped codes Illustrative quotes Summary phrase* 
Barriers Facilitators 
Physical capability – 
physical skill, strength or 
stamina 
 
   Practical training “I think if the CCG is commissioning a 
service then they should be able to provide 
us with the practical training” [P4-
Pharmacist] 
1a. Training (practical) 
Psychological capability – 
Knowledge or psychological 
skills, strength or stamina to 
engage in the necessary 
mental processes 
 Inadequate training to 
deliver services  
 
 
 Knowledge of support 
staff 
 
 Consultation skills  
 
 Coaching and behaviour 
change skills 
“I think we need to be very mindful that 
when we’re training our staff it’s not just 
about how you use the equipment. We have 
to up-skill them on consultation skills as 
well, because if people are to be utilising us 
more, they also need to feel that they’re 






(communication skills)  




 “You need the skills to be concentrated 
because if like say for example in the past 
we [GP practice] used to provide smoking 
cessation services, but we felt that we were 
not dealing with enough number of services 
so that our skills would remain at a high 
level” [P14-GP] 
2b. Experience 
(service delivery)  
Physical opportunity – 
opportunity afforded by the 
environment involving time, 
resources, locations, cues, 
physical affordance 
 
  Accessibility 
 
“It’s about access as well. I think access is 
very important because I’ve had customers, 
they would have gone to the GP otherwise if 
we weren’t closer… one of them had to go 
in a wheelchair on the bus to go all the way 
to the surgery whereas they could just leave 
the house go in the wheelchair to the 






done and then go home, so for them it’s 
easy access” [P1-Pharmacist] 




“How easy would it be to actually do things 
like mass screening in community pharmacy 
and the answer is really really 
easy…community pharmacy could be 
picking up pre-diabetics and you know 
giving the intensive lifestyle advice, weight 
management etc. you know that’s such a 
piece of cake” [P20-Commissioner] 
3b. Accessibility 
(setting) 
  CP screening for NHS 
DPP could deliver faster 
referrals than surgeries 
 
“ I think it could only be a good thing for 
everybody because the delay in patients 
getting appointments in a busy practice 
means that if they are able to go via the 
pharmacist then they would get the referral 
quicker than perhaps waiting for an 
appointment to see somebody here to then 
be referred into the system” [P18-Nurse] 
3c. Accessibility 
(shorter waiting times) 
  Appointment systems 
with shorter waiting 
times than general 
practice 
 Walk in services  
“Actually, booking appointments, I think, 
works for a lot of people even if they have 
to wait ten minutes. I think that’s better 
than what they have to wait at the doctors 
surgery’s” [P12-Pharmacy technician] 
3d. Accessibility 
(appointments) 
  A time-flexible 
alternative  
“I think it’s again going back to 
individualisation…some patients would 
chose not to engage in the prevention 
programme, they may feel I don’t want to 
go to my GP surgery, I can’t ever get an 
appointment or I don’t have time to go 
there because their lifestyle and choices and 
things. So if they are willing to engage with 
3e. Accessibility 




their local pharmacy I would say its surely 
better that they engage with somebody and 
receive that advice and education that they 
need than getting signposted to somewhere 
that they are not going to follow-up with 
and not get any education at all” [P18-
Nurse] 
 Time pressure barrier 
to delivering diabetes 
prevention services 
 Pharmacist time 
constraints hindering 
delivery of services 
 “I can see this eruption this volcano 
erupting and suddenly not only will general 
practice be overwhelmed but so will the 
pharmacist delivering one to one because 
its very time consuming” [P16-Nurse] 
 
4a. Time (availability)  
 Time pressures leading 
to low quality service 
delivery 
 Delivery of public health 
services need adequate 
time 
 
“With diabetes our main problem is that we 
don’t have time of such for these kind of 
things we do them of course but there are a 
lot of time restraints that limit of us to the 
sort of quality that we may be able to give 
our patients with the services” [P9-Pre-
registration pharmacist] 
4b. Time (delivery) 
 Space challenges 
 
 “In terms of other barriers some 
pharmacies it would be their consultation 





 Lack of access to 
medical records 
 “The only thing I would say is that I don’t 
see how a pharmacy can help with 
medication reviews and tell patients they 
shouldn’t be taking certain drugs when they 
don’t have access to their blood results for 
some cases [laughter]” [P16-Nurse] 
6. Access to patient 




 Funding cuts a barrier 
to CP delivering more 
services 
 
 Future CP services would 
need to be well funded 
 
“You know what 6% shaved off! I mean that 
6 seems like a small number but that’s big 
money you know because it’s paying for 
your staff to be able to deliver these 
services so that’s what it comes down 
to…we’re in this difficult situation right 
now… we want to be doing more we want 
to be involved more and like we’re tied, 
really we’re tied to the dispensary, we’re 
tied to these prescriptions” [P8-Pharmacist] 
7a. Funding (cuts)  
 Lack of resources to 
deliver beneficial 
services 
 “To give those services out and be beneficial 
to the patients a second pharmacist is 
always good...I mean we’ve got a second 
pharmacist in in our pharmacy for at least 4 
days a week haven’t we but they said you 
know they are trying to that is getting 




 Current CP services not 
Integrated in primary 
care 
 Pharmacists cannot 
deliver DPS without 
general practice  
 Perceives CP diabetes 
prevention services as 
fragmentation of 
primary care services  
 Integration in primary 
care 
 Commissioning model 
and integration 
fundamental 
 CP and GP need to work 
together more 
 General practice should 
refer patients into new 
CP services 
“The issue with all community pharmacy 
services at the moment is that they are not 
integrated at the end of the day they are an 





 Current follow-up 
systems not sufficient 
 Effective 
communication, 
feedback and referral 
“You need the IT solutions etc. to be able to 
pass that information back to the GP 
practice, because at the moment it’s not an 
8b. Integration 




 Lack of feedback from 
CP services hindering 
referrals 
 Poor feedback from GP 
practice following CP 
referrals 
 IT systems not merged 
with GPs hindering GP 
referrals, follow-up 
and leading to 
duplication of work  
systems to general 
practice are needed for 
the delivery of services 
 IT connectivity 
fundamental for CP-GP 
integrated services 
integrated system. So IT connectivity and 
read write abilities etc. are kind of 
fundamental I think to the integration of 
community pharmacy service going 
forward” [P20-Commissioner] 
 
Social opportunity – 
opportunity afforded by 
interpersonal influences, 
social cues and cultural 
norms that influence the 
way that we think about 
things e.g. the words and 
concepts that make up our 
language  
 
 Challenges in funding 
services traditionally 
provided by general 
practice  
 No dedicated budget 
pot for commissioning 
CP services 
 “One of the problems at the moment with 
the way that commissioning happens in the 
NHS in primary care is if we are 
commissioned to do something that is a job 
that traditionally might have been done by 
the GP practice, how do you release that 
money?. You are not going to de-
commission the GP practices, you’re not 
going to take money away from them etc. 
so how do you then fund that work that is 
being transferred to community 
pharmacy?” [P20-Commissioner]  
7c. Funding 
(commissioning) 






envision primary care 
as primary medical 
 “I think the biggest barrier to developing 
community pharmacy services is the fact 
that commissioners at a local level do not 







care (which doesn't 
include CP) 
  Increased awareness 
 Targeted awareness  
 CP services awareness - 
responsibility of all HCP 
including CP 
 
“I think the diabetes prevention programme 
would be another good service we provide 
though provided we create the awareness 
so that people would know we are doing 




(patients and public) 
 Patient barriers - only 
wanting to engage 
with prescription 
services 
 Need positive promotion 
of CP i.e. not as cheaper 
alternative but accessing 
right level of care 
 Patient need to move in 
with the times and start 
using other HCP more 
rather than expecting to 
see GP 
 
“I think also the raising of awareness of 
pharmacy need to be in a positive way, 
because you know the stuff that I’ve seen 
around pharmacy has been you know 
doctors too busy so go and see your 
pharmacist, or medicines are costing too 
much money go buy them cheaper in the 
pharmacy, and so I’m not 100% sure that 




(patients and public) 
 Ethical challenges with 
promoting CP services 
 
 “Then again there’s another point with 
private companies like [pharmacy multiples] 
trying to advertise for services. It’s like this 
is a health thing do I really advertise it like 
I’m advertising for maybe perfume or milk? 
There’s that ethical aspect” [P6-Pharmacist] 
9a. 
Awareness/promotion 
(patients and public) 
 Lack of awareness of 
CP services (GP) 
 GP only aware of 
pharmacist role in 
medication 
 “I think that GP’s don’t understand, have no 
idea what pharmacists know and what 
pharmacists could do in community 
pharmacy… it’s just a lack of knowledge 







 Lack of knowledge of 
CP role and skills  
 Sceptical if prevention 
service is feasible in CP 
setting 
 Sceptical if CP is the 
best setting for 
delivery of diabetes 
prevention advice 
 “I mean if they’ve got the appropriate 
resources then I can’t see any major 
disadvantages, but whether it’s feasible to 
provide all these services in a pharmacy 
setting I am not so sure, and whether one 
person can do all these things am not so 
sure” [P14-GP] 
10. Feasibility  
 Sceptical about follow-
up following screening 
in CP 
 
 CP public health 
screening services with 
no follow-on 
programmes wasting 
primary care resources 
 “In terms of screening I can’t see any reason 
why it can’t be done outside of the surgery 
setting but I am a bit sceptical about how 
that would be dealt with in by the 
pharmacist. Meaning is it going to be a case 
of them just doing a blood test and then if 
they’ve got an HbA1c of 42 say oh go and 
see your GP or whether they can then give 
any focused advice about that or whether 
they would be empowered to do the 
necessary referrals to the say for example 
the diabetes prevention programme” [P14-
GP] 
10. Feasibility  
  Commissioning for 
outcomes better model 
of demonstrating impact 
of service 
 
“They need to know what we they are 
commissioning and commissioning for 
outcomes… unless you can say what you are 
going to deliver and performance manage it 
then you know it’s always going to be 
questionable as to the impact that you’re 
providing” [P20-Commissioner] 
11.   Demonstration of 
impact (positive 




 Commissioning CP 
services difficult due to 
multiple contractors 
 
 “Obviously we’ve got yes some big 
providers like [name of pharmacy 
multiples]… but we’ve also got individuals 
and if you were an evolving care 
organisation…an accountable care 
organisation and you wanted to 
commission something like that from 
community pharmacy….how do you 
manage it…in an area might be 30, 40, 50, 
60 different contractors… so you need a 





 Competing interest in 
delivering services 
 Competing interest 
with GP practices for 
services 
 “With regards to services moving out of 
primary care, if GPs provide the screening 
services then we get...as I said to you earlier 
we get kind of paid for it and it’s a source of 
income. So even though it might not be a 
huge source of income but because of the 
precarious state a lot of GP are around the 
country even smaller reduction in their 




 Competing interest 
affecting CP-GP 
relationships 
 “There is some competition between 
services especially the flu vaccination…  
there’s been quite a lot of inappropriate 
advertising from both sides in the past few 
years to try to get patients so that’s 
something that kind of ruins the 







 GP perceiving that CP 
has an ulterior motive 
for providing services 
 
 Perceives CP delivering 
pre-diabetes advice as 
stepping on GPs toes 
 
 
 DPP would need to be 
positively promoted to 
practices to ensure they 
don't see it as challenge 
upon their services 
“Our satisfaction rates are have always 
been high in spite of whatever the 
newspaper say… and that's because we feel 
that the patients feel that we are doing 
what we are doing for them rather than for 
any other ulterior motive. I guess when they 
going to see a pharmacist even if they are 
very altruistic, even if they want to be just 
doing good for the patients, there always 
the suspicion if is it really just for me or is it 
because they are after their bottom line 
yeah so I don’t know” [P14-GP] 
13. Competing 
interests  
  Pre-diabetes education 
not efficient use of GP 
time 
 
“We were referring patients to the health 
trainer…anyone who was diagnosed with 
[pre-] diabetes was sent her way because 
it’s not actually it’s not efficient use of our 





* Not carried forward 
-related to general 
practice teams hence 
not directly linked 
main research 
population  
 GP practices not 
referring patients to CP 
public health services  
 “There is an awful lot of surgeries that can't 
engage because they are busy as well and 
can't and don’t want to engage but they are 
not necessarily referring patients to 
community pharmacy” [P20-Commissioner] 
14.  GP 
endorsement/referrals   
 Potential patient 
resistance because 
historically they would 
see a nurse or a GP for 
diabetes services  
 GP endorsement of CP 
services would positively 
influence uptake 
 GP endorsement of CP 
DPP would be important 
“If the GP’s were to promote pharmacy 
then I think a lot more people will be more 
willing to uptake services” 
 [P1-Pharmacist] 
14.  GP 




for instilling confidence 
in patients 
  CP could help reduce GP 
workload  
 
“I think that’s good because from our point 
of view as primary care and GP practice 
were trying to reduce our footfall as much 
as possible in terms of patients coming into 
the surgery for things that can be dealt with 
by pharmacies” [P18-Nurse] 
15. GP workload  
 CP time pressure 
leading to 
unwarranted referrals 
to general practice 
 
 CP public health 
screening services 
creating more referrals 
and workload for 
general practice 
 “ If they are doing those things we need to 
see it…referring back if we need to 
something the only problem with that is 
that its more workload for us but it’s only 
the same as someone getting a private 
medical and then we have to deal with that 
so” [P15-GP]  
15. GP workload 
 Fear of overwhelming 
working environment 
that CP DPS could 
create in primary care  
 “I can see this eruption this volcano 
erupting and suddenly not only will general 
practice be overwhelmed, but so will the 
pharmacist delivering one to one” [P16-
Nurse] 
16. CP workload 
(prescription service) 
** 
 Poor relationships with 
pharmacy multiples 
 




 Good referral systems 
depending on 
relationships 
“I suppose because we have got our own 
pharmacy we just work through …yes so we 
know them all so they are employed by the 
practice so we’ve got pharmacy patients 
and dispensary patients so it’s all done 
within the practice”  [P13-GP] 
17. Relationships 
(community pharmacy 




  GPs need to have 
confidence in pharmacy 
team ability to deliver 
DPP 
 
“It’s you know trying to build the confidence 
of the doctors in us as well and our teams 
because at the end of the day if we do 
something like this it’s unlikely it’s going to 
be us that’s delivering the service it’s going 
to be our healthcare team so they have to 











 CP need to build trust 
with GPs 
“Yeah I mean I guess there ought to be a bit 
more kind of trust in between, I think it’s 
mostly a trust issue. If GPs are to trust that 
what they are doing they are doing it 
properly and then the GPs don’t have to 
take up the extra burden but not be paid for 




and general practice) 
 Potential resistance 
from general practice 
because historically 
patients go to a GP 
setting for diabetes 
services 
 
 “I would imagine that there could 
potentially be some resistance from 
obviously places like us as a GP setting, 
because historically it would always be that 
you came to your GP and you know if the 
GP or the practice nurse or whoever would 
see you and diagnose you and give you 
advice and so on” [P18-Nurse] 
GP resistance  
 
*  Explored under 
relationships (Ref 17) 
 
 GPs perceiving to be 
better than 
pharmacists at giving 
pre-diabetes due to 
extensive knowledge 
of diabetes and 
 “I think the background knowledge is very 
important but what is also important is the 
experience behind it. I mean it will be very 
difficult for a pharmacist to replicate the 
experience which a GP will have because 
diabetes is not just diabetes, its kidney 
disease, its heart disease, its peripheral 
GP resistance  
 
*  Explored under 








 GPs perceiving to be 
better placed to give 
pre-diabetes 
opportunistic advice 
due to links with co-
morbidities in patients 
the consult  
vascular disease and we see it day in and 
day out. I think a pharmacist will be adjunct 
to this but I don't think pharmacists will be 
able to do this all on their own.” [P14-GP] 
 
 
Reflective motivation – 
reflective processes 
involving plans (self-
conscious intentions) and 
evaluations (beliefs about 





 Use pharmacy skill mix 
to deliver diabetes 
prevention services 
CP public health 
interventions don’t have 
to delivered by 
pharmacists 
 
“We are supposed to be utilising and 
making best use of the skills mix … because 
as much as we get frustrated with the 
monotony of our role as do our dispensers 
and our healthcare assistants so 
introducing these things can make them 
feel challenged and provide opportunities 
for growth” [P8-Pharmacist] 
18. Skill mix 
Dispensary role of 
pharmacist hindering 
scope to deliver more 
services 
Pharmacy workload 
hindering delivery of 
services 
Appropriate allocation of 
resources 
 
“Our employers have to be on-board 
properly. We need the support unless this 
can be done by a designated member of 
staff, but if it’s on the pharmacists again 
then that would be a problem because as it 





resources)   
Inadequate training 
leading to lack of 
confidence 
Self-efficacy of staff in 
delivering services 
enhanced by training 
and experience 
 
“I think it’s imperative that you know the 
services are standardised across the board 
that will instil confidence ok for us and also 
for the patients you know you don’t want 
your patient to come in and you don’t know 
what you’re doing” [P4-Pharmacist] 
20. Self-confidence 




Confidence of patient 
and GPs on CP delivering 
services enhanced by 
training and experience 
Lack of structure to 
deliver particular 





experience created by 
unstructured delivery 









“ If you get people come marching through 
your door to speak to your pharmacist, and 
as you were saying you’ve got your 
methadone addicts, and you’ve got your 
morning after, and you’ve got your MUR’s, 
it sometimes as a pharmacist you don’t 
know where your backside is really because 
you're everywhere”  [P6- Pharmacist] 
 




 Implementation of 
service with GP to 
alleviate tensions caused 
by competing interests  
“ The worry is if the GP’s think oh you’re just 
taking their job away…so it’s trying to make 
sure that we get a good conversation going 
with the GP’s and actually come up with a 
good way to actually implement the service 
with them” [P2-Pharmacist] 
22.  General practice 
support 
 Delivering pre-diabetes 
lifestyle advice does not 
require one to have a 
medical degree 
 
“As a GP I mean I do do an awful lot of it 
[lifestyle advice] opportunistically within the 
consultation because it relates to so many 
things… blood pressure and anything but 
you don’t need a medical degree to give 
lifestyle advice”  
[P13-GP] 
Training beliefs  
* Not carried forward 
– explored under 
capability 
Automatic motivation – 
Automatic processes 
involving emotional 
reactions, desired (wants 
GPs will only endorse 
services if there 
something in it for 
them 
 “If obviously the doctors have got QOF 
targets and they will be paid for a similar 
thing then they’re not going to be sending 






* Numbered phrase taken forward for further COM-B analysis in Chapters 5 and 6
and needs), impulses, 
inhibitions, drive states and 
reflex responses  
people to me if they can get that money 
isn’t it” [P5-Pharmacist] 
 CP diabetes prevention 
services would bring in 
financial benefits 
 
“So cost wise in providing the service I think 
it would be cheaper for the NHS  for us to 
do it [deliver DPS] than to get the GP 
surgery’s to do that…also hopefully they will 
channel a little bit of money you know from 
there into the community pharmacy so that 
they can provide us with a extra hands that 
we need” [P1-Pharmacist] 







intimidated by GPs - 
affecting relationships 
 
 “I think as pharmacists we can find it you 
know really difficult to talk to GP’s 
sometimes… I think of what I used to be like 
with consultants, they seemed you know 
they were up here…that’s a personality 
thing sometimes and I think it would be the 






4.3.2.1 Theme two: The community pharmacy setting 
This theme largely discussed physical characteristics of the community pharmacy 
setting such as accessibility in relation to engagement of people with pre-diabetes 
with DPS. The barriers and facilitators identified in this theme related to delivering 
DPS in the community pharmacy setting with respect to time and resources. As 
such, a majority of barriers and facilitators associated with the theme were mapped 
to the physical opportunity domain of the COM-B.    
 
4.3.2.2 Theme three: Awareness of community pharmacy services 
This theme considered the societal role of community pharmacy in public health 
and primary care. The theme, largely discussing the level of awareness of 
community pharmacy services by the public, patients and other healthcare 
professionals, identified barriers and facilitators which were primarily mapped to 
the social opportunity domain of the COM-B.  
 
4.3.2.3 Theme four: Relationships and communication  
This theme discussed current challenges with communication between community 
pharmacies and other primary care teams, particularly general practices and how 
relationships play a role in enhancing and hindering communication and delivery of 
services. Whilst certain aspects of this theme related to physical resources that 
could enable efficient and effective communication between community pharmacy 
and general practices, much of the theme identified interpersonal influences 
behind the poor communication and relationships between the two primary care 
settings. Therefore, most of the barriers and facilitators relating to this theme were 
mapped onto the opportunity and motivation domains of the COM-B.  
  
4.3.2.4 Theme five: Delivery of community pharmacy services 
This theme examined the practical aspects of delivering public health services, 
including DPS, in the community pharmacy setting. The theme considered the 
capability of community pharmacy teams to deliver the services, the physical 




engage with delivering the services. Hence the theme contributed to all three 
domains of the COM-B.  
 
Capability 
Training was identified as the main enabler for enhancing the capability of 
community pharmacy teams to deliver DPS. Most participants felt that whilst 
pharmacists have adequate knowledge to deliver NDH education and interventions, 
other members of the community pharmacy team, e.g. technicians, would need a 
sound theoretical understanding of NDH and its management. Pharmacist 
participants felt that this was crucial as it would give such members more 
autonomy and subsequently lead to less pharmacist intervention. 
 
Other training requirements highlighted by the participants included coaching, 
behaviour change skills and consultation skills. These skills were seen as important 
for supporting people with NDH in the making desired lifestyle changes. In general, 
all participants including general practice participants and commissioners felt that, 
with sufficient training, any personnel including community pharmacy teams could 
deliver DPS. 
 
“I think if the CCG is commissioning a service then they should be able to provide us 
with the practical training” [P4-Pharmacist] 
 
“I’m sure we’ve had consultations whether it be with a healthcare assistant or a 
nurse or a doctor where we think, ‘that could have been a little bit better’, and so I 
would want to ensure that when people are coming into our pharmacy that they’re 
having a positive experience with the member of staff who is delivering the services 
to them” [P8-Pharmacist] 
 
Physical opportunity  
The community pharmacy setting was identified as well-placed for delivering NDH 
screening services that could afford a faster referral pathway into the current 




the NHS DPP alone would make no difference to their current NDH management 
procedures and would therefore be acceptable. Additionally, these participants also 
felt that community pharmacy delivering DPPs as a follow-up from screening would 
be a good thing and would not conflict with them as they had no capacity to deliver 
such services. Accessibility was identified as an enabler for engagement of people 
with NDH with DPS, with setting characteristics such as location, provision of walk-
in services and faster appointment systems considered as important factors.  
 
“Well for a start we are more accessible. We open seven days a week…it’s not like 
Monday to Friday the GP’s…they [patients] can come in over the weekend and see 
someone as well. It might be a good thing [to deliver DPS]” [P5-Pharmacist] 
 
In considering the practical delivery of DPS by community pharmacy teams, 
participants raised various barriers and facilitators. Community pharmacy 
participants identified time as a key factor in delivering the services. These 
participants felt that delivering public health interventions requires adequate time, 
which when compromised, often lead to low quality, “tick box” services. The 
feasibility of delivering DPS in the setting also considered factors such as space and 
resources with most participants acknowledging the inadequacy of most 
consultation rooms in the community pharmacy setting and some referring to them 
as ‘cupboards’. 
 
“Our main problem is that we don’t have time for these kind of things [delivering 
public health services]. We do them of course, but there are a lot of time restraints 
that limit the sort of quality that we may be able to give our patients” [P9-Pre-
registration pharmacist] 
 
Participants also identified the lack of access to full patient medical records in 
community pharmacy and IT systems which are not merged as barriers to efficient 
communication and referrals between the community pharmacy and general 
practice settings. Community pharmacy participants expressed frustration to the 




they have no way of knowing the outcomes of recommendations and referrals they 
make to general practices. Additionally, participants felt that current public health 
services receive very few referrals from general practices and proposed that this 
mainly stemmed from the poor communication and referral systems between the 
two settings. In confirmation of this, some general practice participants admitted to 
not referring their patients to community pharmacy services due lack of feedback. 
A common ground reached by the majority of the participants was that in order to 
successfully deliver services in a community pharmacy setting, future services 
would require good referral, communication and feedback systems. 
  
“You need the IT solutions etc. to be able to pass that information back to the GP 
practice because at the moment it’s not an integrated system. So IT connectivity 
and read write abilities etc. are kind of fundamental I think to the integration of 
community pharmacy service going forward” [P20-Commissioner] 
 
“It’d be nice to know they’ve done it [DPS], but equally they are doing something 
which we don’t seem at the moment to be able to provide because at the moment 
we don’t have the resources so that’s great” [P15-GP] 
 
Finally, a major concern highlighted by community pharmacy participants and 
commissioners was the current funding cuts in community pharmacy and the lack 
of a dedicated budget for commissioning services in this setting. Community 
pharmacy participants, considering the current strain in funding and resources, felt 
that sufficient reimbursement would be required to account for the time and 
resources invested in delivering future services. 
 
“The problem is the chicken and egg. Does pharmacy develop and staff itself for 






Social opportunity  
Community pharmacy was considered to have potential to increase patient centred 
care by providing service users with more choice. Participants felt community 
pharmacy could potentially increase reach to regular pharmacy users due to the 
settings’ propensity for normalising care and the non-judgemental and anonymous 
environment it provides. It was also seen as suitable for accommodating an 
individualised intervention as an alternative to the current group intervention 
offered in the national DPP, in particular for regular service users. 
 
“I think another benefit [of community pharmacy-based DPS] is also that they 
develop that link with their pharmacist. I guess perhaps that would be it, that if 
you’ve got somebody that’s on quite a few medications anyway they’re used to 
going to the pharmacist, it’s not a big deal” [P19- GP practice pharmacist] 
 
“I think perhaps it de-medicalises it. It’s not a surgery so patients perhaps, I think, 
would engage better if it’s in community pharmacy” [P13-GP] 
 
Although community pharmacy participants considered the delivery of DPS as part 
of their public health role, they felt there is a general lack of awareness of this role 
amongst patients, the public and other primary care teams. This resonated amongst 
general practice participants who, although aware of medicine related services 
provided in community pharmacies such as Medicine Use Reviews, seemed 
unaware of the range of public health interventions delivered in this setting. 
Community pharmacy participants felt that this lack of awareness hindered 
referrals and consequently affected service uptake.  
 
 “I am not really aware of anything apart from that we do have a pharmacy as part 
of our practice. We have a very good team there and the pharmacist there does 
quite a lot of education with patients, but not specifically for pre-diabetes in 





“I think most of the services we do we haven’t really publicised to our customers, so 
you have somebody walking into the pharmacy they don’t have an idea of what 
other services we do, apart from dispensing” [P4-Pharmacist] 
 
The need to raise awareness of the role, skills and services provided by community 
pharmacy to both general practices and the public was therefore seen as crucial for 
service uptake. Participants felt that all healthcare professionals have a role to play 
in raising awareness of community pharmacy services to patients and the public. 
However, commissioners and community pharmacy participants expressed some 
concerns over current NHS promotional campaigns as they felt that the message 
around promoting community pharmacy had so far presented the community 
pharmacy as a cheaper alternative to general practice. These participants expressed 
the need for more positive promotion centred on accessing the right level of care.  
 
“I think we’ve probably all got some responsibility to make services aware, so the 
chemist obviously themselves they could have posters” [P18-Nurse] 
 
“If you change the message to, ‘you’re still going to get primary care services you’re 
just accessing it at a more appropriate place’, it’s a different message and it might 
drive behaviours to change because as a patient if you get told you are going to see 
the cheap alternative you might not want to go there” [P21-Commissioner] 
 
The delivery of DPS by community pharmacy as part of the primary care team was 
also discussed. Community pharmacy participants felt that service endorsement by 
key members of the primary care team involved in the diagnoses of the majority of 
NDH cases, in particular GPs and nurses, was crucial to service uptake. However, 
community pharmacy participants felt that endorsement of, and referral to, 
community pharmacy services by general practices was largely dependent on 
working relationships between general practice and community pharmacy 
personnel. In general, where community pharmacies were independent or co-
located with general practices, participants described amicable and positive 




agreed referral pathways in patient management as well as regular communication 
between the two parties. In these cases, GPs or nurses described not only referring 
patients to the community pharmacy for services such as new medicine services but 
also described a culture that promoted inter-professional learning. However, 
regardless of proximity, practices which were attached to chain community 
pharmacies or were a dispensing general practice (practices that dispense 
medicines they prescribe to patients living remotely from a community pharmacy) 
described negative working relationships, poor communication and lack of trust for 
community pharmacies. Most community pharmacy participants attributed the 
poor relationships to competing interests, in particular public health interventions 
such as influenza vaccinations and NHS Health Checks.  
 
“There has to be a working together you know. If we’re going to be delivering a 
service, then the GP surgery needs to be selling it to the patients, because if patients 
believe something’s been endorsed by their doctor then they are a lot more likely to 
do it” [P8-Pharmacist] 
   
“In an ideal world they [community Pharmacy] are joined to us [General Practice], 
we live in the same building, but it’s definitely a them and us” [P17-Nurse] 
 
With reference to community pharmacy’s involvement in delivering DPS such as 
screening and lifestyle programmes, although some participants were sceptical 
about the feasibility of delivering the services in this setting, most participants, 
including commissioners, felt that the ability for community pharmacy to deliver 
public health interventions had been proven by current services which were 
demonstrating positive outcomes. 
 
However, some participants felt that the delivery of DPS in community pharmacy 
could generate resistance from both GPs and patients. General practice participants 
described how such services, particularly screening which mainly refer to general 
practice for confirmatory tests, could potentially create extra workload for them as 




NDH management in their practices who perceived that community pharmacists 
delivering prevention programmes as taking resources and services outside of 
primary care and into the hands of private contractors. This is despite the fact that 
general practices, like community pharmacies, are also private NHS contractors. 
One GP in particular felt disadvantaged or somewhat cheated by current 
community pharmacy screening services which refer patients at high risk of CVD or 
diabetes to them as they felt that community pharmacy was getting paid to do the 
easy part whilst general practices were left to deal with the long-term management 
of the conditions for no extra payment. For this reason, the participant felt that 
there is a need for community pharmacists to be empowered to do thorough NDH 
screening tests requiring no referral for confirmatory tests and that community 
pharmacy teams should also be empowered to either refer straight into the NHS 
DPP or provide follow-on preventative services. Although this view was not 
expressed by all the general practice participants, community pharmacy 
participants also acknowledged the lack of services following screening in this 
setting. 
  
“I would imagine that there could potentially be some resistance from obviously 
places like us as a GP setting because historically it would always be that you came 
to your GP, but I think we have to all move and change with the times you know. We 
need to stop working so segmentally and start working more collaboratively and 
recognising that actually we can all help each other” [P18-Nurse] 
 
“If GPs are to trust that what they [community pharmacy teams] are doing, they are 
doing it properly and then the GPs don’t have to take up the extra burden but not be 
paid for it, then I think it would work well…with regards to services moving out of 
primary care, I mean, if GPs provide the screening services we get kind of paid for it 
and it’s a source of income. So even though it might not be a huge source of income 
but because of the precarious state a lot of GPs are around the country even smaller 





With respect to funding, commissioners stated that the funding of services 
traditionally delivered via general practices was a major challenge which was 
somewhat enhanced by the under-representation of pharmacists in CCGs. They also 
expressed that most commissioners envision primary care as primary medical care, 
which does not include community pharmacy, and thus do not prioritise it. 
Commissioners felt that currently there is poor integration of community pharmacy 
contractual elements with general practices on a national level which hinders the 
delivery of community pharmacy services as part of the primary care team. These 
participants felt that in order to deliver DPS as part of the primary care team, 
community pharmacy services would need to have a commissioning model that is 
integrated into both parties. All in all, participants felt that future services would 
have to embrace more integration and encourage the development of positive 
working relationships between community pharmacy and general practices. 
 
 “I think the biggest barrier to developing community pharmacy services is the fact 
that commissioners at a local level do not see it as priority… when they talk about 
primary care they talk about primary medical care. A lot of commissioners here 
know that I would say actually you mean primary medical care, we are talking 
about primary care” [P21-Commissioner] 
 
Motivation 
Community pharmacy participants identified various enablers for increasing 
motivation of delivering DPS as part of the primary care team. Financial incentives 
were identified as a key source of motivation, with community pharmacy 
participants expressing that such services would bring some much-needed funding 
into community pharmacy following recent funding cuts. Community pharmacy 
participants also felt that future services should offer financial benefits for general 
practices as an incentive for them to endorse community pharmacy services and 
avoid competing services between the two settings. 
  
“So cost wise in providing the service, I think it would be cheaper for the NHS though 




channel a little bit of money you know from there into the community pharmacy so 
that they can provide us with extra hands that we need” [P1-Parmacist] 
 
“It will depend on, if obviously the doctors have got QOF targets and they will be 
paid for a similar thing then they’re not going to be sending people to me if they can 
get that money isn’t it” [Quality and Outcomes Framework - a reward and incentive 
programme for all GP surgeries in England, detailing practice achievement results] 
[P5-Pharmacist] 
 
However, pharmacy participants did acknowledge that in order for general 
practices to endorse community pharmacy-based services, positive and strategic 
promotion would be required in order to avoid them seeing the services as a threat. 
These participants felt that it was community pharmacy’s responsibility to engage 
with such promotion as they perceived that community pharmacy needs general 
practice support rather than the other way around. This said, some participants felt 
that community pharmacists may be intimidated by GPs and hence struggle to build 
positive working relationships with general practices.  
 
“The worry is if the GP’s think oh you’re just taking their job away…so it’s trying to 
make sure that we get a good conversation going with the GP’s and actually come 
up with a good way to actually implement the service with them” [P2-Pharmacist] 
 
“I think as pharmacists we can find it really difficult to talk to GP’s sometimes… I 
think of what I used to be like with consultants, they seemed you know, they were 
up here… that’s a personality thing sometimes and I think it would be the same” [ 
P19- GP practice pharmacist] 
 
Self-efficacy, which could be enhanced by adequate training and experience, was 
seen as fundamental for motivating community pharmacy teams to deliver DPS. 
Some participants felt that it was also important for other members of the primary 
care team, particularly GPs and nurses, to have confidence in the community 




since patients are usually more receptive to nurse and GP advice, referrals from 
these healthcare providers would increase uptake and patients’ confidence in 
community pharmacy services. Community pharmacy participants particularly 
expressed that referrals from practices would address the fluctuations seen in the 
uptake of their current services which often lead to lack of concentrated skills and 
subsequent de-skilling of the pharmacy teams. 
 
The biggest barrier to motivation stemmed from pharmacists feeling overwhelmed 
in their current role. Participants felt that their dispensary role and the current lack 
of working structure, due to the provision of largely walk-in services, could be a 
barrier to them engaging in the delivery of DPS. To this extent participants felt that 
extra resources and improved utilisation of current skill mix, particularly 
technicians, would be required to deliver the services.  
 
“It doesn’t need to be pharmacists necessarily, we’ve got technicians, we’ve got skill 
mix there… and in health checks most of the health checks are not done by 
pharmacists. The pharmacists does the risk communication but most of the work, 




This study highlights the potential for community pharmacy to deliver diabetes 
prevention services and presents factors in terms of Capability, Opportunity and 
Motivation at both local and national levels that could facilitate implementation. 
The study identified fundamental factors that could enhance opportunity for 
community pharmacy teams to deliver diabetes prevention services including time, 
resources and funding. Such factors, particularly lack of time and funding have also 
been identified as major hindrances in delivering public health interventions in 
previous research (276, 277).  
 
The need for integration of community pharmacy services in primary care has also 




identified as both physical (e.g. integration of IT systems with general practices and 
access to patient medical records) and social opportunities (e.g. lack of awareness 
of community pharmacy role and skills by both patients and other healthcare 
professionals), highlight the importance of considering potential impact of physical 
and social contexts when developing interventions. Previous research has also 
identified social interactions and relationships between the community pharmacy 
and general practice teams as key for successful delivery of services by community 
pharmacists (37). In England, the integration of community pharmacy within 
primary care including the development of positive working relationships between 
GPs and community pharmacists has also been identified as central for the 
provision of clinical services (257). In 2019, NHS England introduced primary care 
networks (PCNs) as part of the NHS Long Term Plan to provide structure and 
funding for services designed to meet local needs (123). General practices, typically 
covering 30,000 to 50,000 patients are a major part of these network. It is therefore 
important that community pharmacy teams closely work with such networks when 
developing future interventions that are successful in meeting local needs.  
 
However, although most factors identified by this study in relation to integration 
would need to be addressed in developing future interventions, the extent to which 
they would influence behaviours (i.e. delivering diabetes prevention services) needs 
further clarification. For example, the extent to which community pharmacy teams 
would require access to medical records needs to be further investigated. This is 
because, although the identification of NDH is largely undertaken in general 
practice settings, most diabetes prevention interventions are conducted in non-
clinical community settings (85). Additionally, with research suggesting that the 
majority of people with NDH are prescribed a combination of a lipid-lowering and 
anti-hypertensive drugs (278), community pharmacy could already have sufficient 
information to identify individuals eligible for focused diabetes prevention 
interventions.  
 
The importance of considering the impact of future community pharmacy services 




in this study. The findings suggest current community pharmacy screening 
interventions such as NHS Health Checks (279), which refer individuals with NDH to 
general practice services for HbA1c testing, to be potentially adding to general 
practice workload. A recent report on understanding general practice pressures has 
highlighted changing relationships of general practices with the wider healthcare 
system as a contributor to workload and has highlighted referrals and 
communication as factors that take a significant amount of time in general practice, 
both for medical and administrative staff (280). It is important therefore that future 
community pharmacy services should seek to reduce pressure on general practice 
rather than increase it. Additionally, evaluation of the NHS Health Check service has 
shown poor attendance amongst people referred to general practice services 
following screening in community pharmacy (137). The evaluation also 
demonstrated that almost half the people referred to other lifestyle interventions 
following community pharmacy services were unwilling to engage. This 
demonstrates that whilst some people are willing to engage with screening services 
and lifestyle advice in the community pharmacy setting, they may not necessarily 
be willing to engage with other primary care services. It is therefore important that 
community pharmacy is empowered to provide robust screening and follow-up 
services in this population.  
 
With current guidelines for the diagnosis and referral into NHS DPP screening 
requiring HbA1c testing, community pharmacies need to be empowered to 
undertake more thorough diabetes screening that does not necessarily need to 
refer individuals to general practice services (120). Previous research conducted in 
Australian community pharmacies has demonstrated that risk assessments 
followed by fasting plasma glucose tests resulted in fewer referrals to General 
Practice and greater uptake by patients (281). Additionally, more recent research 
conducted in Norwegian community pharmacies has further demonstrated the 






Recent systematic review evidence evaluating the effectiveness and analytical 
quality of point of care testing performed in community pharmacy, including blood 
glucose testing, found tests conducted in this setting to have satisfactory analytical 
quality and has recommended their use to allow easier access to various screening 
tests (282). There is therefore a potential for community pharmacies in England to 
be involved in delivering comprehensive screening tests without requirement for 
referral to other primary care teams for confirmatory tests. With previous research 
also demonstrating that screening for NDH with appropriate intervention appears 
to be cost effective (125), there is an opportunity for community pharmacy to 
deliver lifestyle interventions for those that are unwilling to engage with other 
primary care lifestyle interventions. The provision of diabetes prevention lifestyle 
interventions in community pharmacy services for people with NDH, although not 
commonly explored in research, has been implemented in other countries such as 
the USA. The national DPP in the USA has highlighted a significant role for 
community pharmacy not only in raising awareness of NDH and screening but also 
in delivering DPPs (160).   
 
This study has highlighted training and the appropriate use of pharmacy skill mix as 
key factors that could enhance the capability and motivation respectively for the 
community pharmacy teams to deliver quality DPS. The pharmacy workforce, the 
third largest workforce group in the NHS, consisting of pharmacists and pharmacy 
technicians has in recent years had its potential to contribute to the delivery of 
public health services identified (257). The use of technicians, trained as lifestyle 
coaches, in the delivery of DPS has particularly been identified as a viable option in 
terms of cost and availability in the USA (160). In order to enhance their capability, 
this research has highlighted that technicians would not only need theoretical 
training on NDH and its management but would also need to develop skills such as 
consultation, coaching and behaviour change skills to support people with NDH in 
making lifestyle changes. In recent years, the increasing involvement of pharmacists 
and pharmacy technicians’ in direct patient care has highlighted that theoretical 
training is not enough. This has led to the development of multifaceted training 




research has indicated that training not only increases pharmacists’ confidence in 
providing public health services but is also more likely to lead to a positive impact 
on customer attitudes and health outcomes (258). Therefore, future services in 
community pharmacy should seek to invest in the development of this workforce in 
terms of training in order to increase availability of services.  
 
This research has highlighted various motivations for both community pharmacy to 
deliver services or general practices to refer into community pharmacy-based DPS, 
including financial incentives. Additionally, the development of positive and trusting 
working relationships as well as the elimination of perceived competing interests 
between community pharmacies and general practices have been highlighted as 
fundamental for the delivery of future community pharmacy services (257).  
 
Finally, these study findings add to an emerging body of research applying the 
COM-B model to assist a theoretically based approach of developing interventions. 
The application of the COM-B has also demonstrated success in identifying barriers 
to engagement in a recent study reported by Handley et al. which aimed to design a 
tailored DPP among women with recently diagnosed gestational diabetes (247). In 
the study, the findings of the COM-B analysis led to the development of a tailored 
DPP which addressed barriers to engagement by identifying suitable intervention 
strategies to increase both social and material supports such as social networks, 
health coaches and community resources. Therefore, in the same vein, the findings 
of this research form a foundation for the development of community pharmacy 
based DPS. Further research to assist the development of interventions with 
strategies to enable the successful delivery of DPS in this setting are presented in 
Chapters 6 and 7 of this thesis.   
 
4.4.1 Strengths and limitations 
 
This is the first study exploring community pharmacy for delivering DPS from the 
perspective of multiple stakeholders. Data collected was contextual and involved a 




for people with NDH. Although this study was conducted in the context of exploring 
the role of community pharmacy in diabetes prevention, its findings could be 
applied to the development of other health promotional interventions in this 
setting. The incorporation of theory using COM-B, which forms the hub of the BCW 
will enable the identification of behaviour change techniques which could assist the 
development and implementation of interventions in this setting. Additionally, 
although the COM-B has been designed for use by researchers without psychologist 
background, our analysis benefited from the involvement of a psychologist with 
experience of applying the COM-B in designing interventions.  
 
A limitation of the study was the lack of participants who are directly involved in 
commissioning the current NHS DPP. Additionally, the use of two different data 
collection methods, although useful for triangulation, generated two different types 
of data where interviews with general practice participants and commissioners 
generated in depth data whilst focus groups with community pharmacy participants 
generated superficial data. Arguably, more ground was covered with general 
practice participants than community pharmacy participants, thus inadvertently, 
this may have caused an imbalance in the data. Furthermore, the community 
pharmacy background of the main researcher could have influenced perspectives 
on analysis and presentation of the findings. On reflection, the novelty of the views 
expressed by general practice participants and commissioners might have stood out 
more to the main researcher than those of community pharmacy participants due 
to familiarity with current challenges associated with delivering community 
pharmacy services. Therefore in order to minimise bias, analyst triangulation was 
used to provide multiple perspectives in interpretation of results (284). At 
significant points during the process of data analysis, the main researcher (TK) 
regularly met with members of the research team [MT and HA] to discuss data 
interpretation. Additional discussions were also held with the wider research team 









This research has highlighted a potential role for community pharmacy in delivering 
DPS for people with NDH due to its accessibility. In order to enhance this 
opportunity, investment is needed to ensure adequate time, resources and funding. 
New models of services should also seek to integrate community pharmacy services 
in primary care to facilitate better communication (referrals and feedback) with 
general practices and prevent competing interests. However, in order to sufficiently 
manage primary care workload and resources, community pharmacy teams should 
be sufficiently enabled to deliver holistic interventions which require minimal 
referral to general practices.  
 
To enhance the capability and motivation of community pharmacy to deliver such 
services, multifaceted training involving coaching and behaviour change skills and 
the appropriate use of pharmacy skill mix are required. Whilst incentives would 
motivate both community pharmacy providers to deliver the services and general 
practices to refer patients to the services, promotion of the services to patients, 
public and other healthcare professionals could enhance engagement. The lack of 
clarity of the extent to which some of the factors identified by this study could 
affect the delivery of DPS in the community pharmacy setting requires further 















Chapter 5: Validation of barriers and 
facilitators for delivering community 
pharmacy-based diabetes prevention 



























5.1 Introduction  
 
Previous research, conducted in people with NDH, has indicated that community 
pharmacy could serve as an acceptable option for delivering DPS in people who fail 
to engage with the current NHS DPP due to accessibility (Chapter 3). Additionally, 
research conducted in primary healthcare personnel and commissioners indicated a 
potential for delivering interventions which mirror the NHS DPP in community 
pharmacy settings (Chapter 4). This research identified a number of enablers for 
delivering the services including collaboration with general practice teams (Chapter 
4), a finding supported by a growing recognition that public health interventions 
delivered in community pharmacy should be integrated into local primary care 
networks (257).  
 
Findings from previous research were analysed using the COM-B theoretical model 
and thus could potentially inform the development of interventions to assist 
community pharmacy teams with delivering accessible DPS to people with NDH. 
This could be achieved through the application of the Behaviour Change Wheel 
framework (188, 192). However, as this work was conducted in a small number of 
practitioners there is a need to triangulate these findings in a larger number of 
professionals before proceeding with further development. At the same time, it is 
important to elicit practitioner views on the current NHS DPP and this can be done 
using the APEASE criteria (192). The APEASE criteria can be used to make context-
based decisions when designing or evaluating interventions. The criteria recognises 
that an intervention design is more than effectiveness as all behaviour change 
operates within a diverse range of social contexts, affordability, practicability, 
effectiveness, acceptability, sustainability and equity. The APEASE criteria could 
therefore be useful for establishing a contextual understanding of views on the NHS 
DPP to ensure that interpretation of views on the community pharmacy role in 









To assess the acceptability and practicality, from a primary care practitioner’s 
perspective, of the NHS DPP and the potential role of community pharmacy in 
diabetes prevention.   
 
5.1.2 Objectives  
 
 To examine the perceived role of community pharmacy in diabetes 
prevention. 
 To triangulate findings from previous qualitative work in a larger group of 
practitioners. 
 To conduct a context-based evaluation of the existing NHS DPP. 
 
 
5.2 Methods  
 
This research involved distributing a questionnaire to community pharmacists as 
well as GPs and nurses involved in the management of NDH. The project was 
undertaken in collaboration with five fourth year pharmacy students from the UEA. 
Ethics approval was obtained from the Health Research Authority (IRAS ID 252420) 
and UEA Faculty of Medicine and Health Sciences Ethics committee prior 
commencing the research.  The study protocol can be found in Appendix 5.1, 
together with the ethics approvals (Appendix 5.2) and ethics amendment approvals 
(Appendix 5.3).  
 
5.2.1 Questionnaire rationale 
 
The use of questionnaires was adopted in this study as the most efficient way, in 
terms of time and cost, to obtain data from a sample covering a wide geographical 
distribution (28). It also provided anonymity and thus had the potential to 
encourage honest answers. Having previously conducted qualitative work in this 




evaluation, a questionnaire approach was deemed appropriate to further progress 
this study.  
 
5.2.2 Participant recruitment 
 
Details of the initial 27 sites across England that had implemented the NHS DPP were 
obtained from the NHS website. Following this, sites whose lead organisation for 
implementing the programme was a CCG (and not a County Council) were selected for the 
study (285). County councils are authorities representing local governments and are 
responsible for providing majority of public services including education, transport planning 
and social care. CCGs were the preferred recruiting pathway due to the direct link and 
governance that they have over General Practices in their area. Ten areas whose lead 
organisation were CCGs were selected for the study. The procedures for recruiting sites 
and recruiting GPs, nurses and pharmacists are summarised below: 
 
5.2.2.1 GPs and nurses   
Figure 5.1 presents a flow diagram of the recruitment process of GPs and Nurses. R 
and D departments in the selected ten areas were contacted via e-mail asking them 
to assist in distributing an ‘initial approach letter’ (Appendix 5.4) to a nominated 
lead for the NHS DPP in the identified CCGs.  
 
The initial approach letter requested that the NHS DPP lead e-mail an invitation 
letter (Appendix 5.5) to each practice in their area that participates in the NHS DPP. 
Where the CCG did not have a member of staff responsible for this programme 
then the R and D department was asked to e-mail the invitation letter (Appendix 
5.5) directly to each practice involved in referring patients to the NHS DPP. The 
invitation letter, sent to practice managers, contained a copy of the participant 
information sheet (Appendix 5.6) and a link to an electronic version of the 
questionnaire (Appendix 5.7). Practice managers were asked to forward this 
directly to GPs and nurses in their practice with a special interest in diabetes. To 
improve response rates, follow-up e-mails (Appendix 5.8) were sent to practices 
two weeks after initial e-mails were sent, and phone calls made a week after to 





















Areas selected for the initial implementation of 
the NHS DPP (n=27) 
Excluded (n= 13) 
- Areas with County Councils as lead organisation 
Potentially eligible sites (n=14)   
Excluded (n= 4) 
- Population already studied (1) 
- Member practices >80 (3) 
 
R & D contacted to assist recruitment (n=10) 
Excluded (n= 2) 
- R & D with capacity to get involved with research 
- NHS DPP undergoing recommissioning  
R & D mail research information to NHS DPP CCG 
lead (n=7) 
R & D mail research information directly to practice 
managers (n=1) 
NHS DPP CCG lead mail research information to 
practice managers (n=7) 
Practice managers forward research information 




5.2.2.2 Community pharmacists 
Figure 5.2 presents the recruitment process for community pharmacists. In the 
CCGs identified above, the R and D departments were also asked to e-mail an 
invitation letter (Appendix 5.9), participant information sheet (Appendix 5.6) and a 
link to an electronic version of the questionnaire (Appendix 5.7) to all community 
pharmacies in their area. As above, this e-mail was re-sent two weeks after as a 
follow-up to increase the response rate. Depending on the response rate, a week 
after the follow-up e-mail the research team called the pharmacies in these areas 
using telephone numbers readily available on the NHS Choices website. If 
pharmacists had already completed the questionnaire then no further action was 
taken and the participant was thanked for their involvement. However, if they had 
not completed the questionnaire the research team highlighted the study to them 
and resent the information and questionnaire link to them. No further follow-up 
occurred after this point.   
 
Where R and D departments did not have the capacity or contact list to enable 
dissemination of the questionnaire, LPCs were approached to assist dissemination 
of the research information. Where LPCs were also unable to assist in disseminating 
the questionnaire, pharmacies in these areas were contacted using telephone 































Areas selected for the initial 
implementation of the NHS DPP (n=27) 
Excluded (n= 13) 
- Areas with County Councils as lead organisation 
Potentially eligible sites (n=14)   
Excluded (n= 4) 
- Population already studied (n=1) 
- Member practices >80 (n=3) 
R & D contacted to assist recruitment 
(n=10) 
- R & D had no capacity to get involved with research (n = 2) 
- R & D had inadequate contact details for community pharmacies (n=7) 
R & D mail research information to 
community pharmacies (n=1) 
LPCs contacted to assist with 
recruitment  
LPCs mail research information to 
community pharmacies (n=4) 
LPCs with no capacity to get involved with 
research (n=5)  
Researchers phone individual pharmacies 




5.2.3 Sampling and sample size  
 
To gather data from practices with substantial experience of referring into the NHS 
DPP, participants from the 27 areas where the programme was first implemented 
were recruited. Purposive sampling based on CCG deprivation scores and diabetes 
prevalence data was used to select 10 areas to target from the first wave sites with 
the aim of achieving an even representation of deprivation and diabetes prevalence 
across England (286). Based on the assumption that 10 areas with the lowest 
number of practices and led by an NHS organisation (i.e. CCG rather than the 
County Councils leading NHD DPP implementation) were to be selected, a potential 
recruitment sample of 400 practices was expected. With two potential practitioners 
in each practice (one GP and one nurse), it was estimated that this would yield a 
potential sample size of 800 practitioners.  
 
Estimating a response rate of 10% (287) we expected a final sample size of 80 
questionnaire responses. This yielded a confidence interval around a proportion of 
10% (3.4-16.6) which is deemed an appropriate range. Community pharmacists 
were sampled using a convenience sample; however, the target for responses was 




5.2.4 Piloting  
 
Prior to distribution to the main sample, the questionnaire was e-mailed out to one 
GP, one nurse and one pharmacist who had participated in previous qualitative 
research for piloting (Chapter 4). The practitioners were asked to complete the 
questionnaire and provide feedback on the structure of the questions and the 
relevance of the contents to their everyday practice. Two out of three practitioner 
completed the questionnaire. Both practitioners felt that the questionnaire 
statement were easy to understand and were relevant to the practice. As a result, 
no changes were made to the questionnaire following piloting.    
 
5.2.5 Data collection  
 
Data collection was undertaken using an electronic questionnaire (Appendix 5.6) 
that was distributed to eligible participants. The electronic questionnaire was 
hosted online by JISC Online Surveys (288). The questionnaire consisted of five 
sections. The first section gathered participant demographics and current 
management of NDH. The second section evaluated the existing NHS DPP using the 
APEASE criteria as described above. The third section examined practitioners’ views 
on the perceived role of community pharmacy in diabetes prevention. The fourth 
section asked for any additional comments.   
 
The questionnaire was estimated to take approximately 10 minutes to complete as 
the majority of questions consisted of a Likert scale response from strongly agree to 
strongly disagree. It was anonymous with consent confirmed by ticking a box on the 
first page of the questionnaire.   
  
5.2.6 Incentives  
 
Participants were given the option of entering a prize draw to win a £50 voucher. 
Following completion of the questionnaire, participants were directed to a second 
questionnaire (Appendix 5.10) to enter their details for entry into the prize draw. 




remained anonymous. Ten entries into the prize draw were selected to receive a 
gift voucher of £50 using random name picking. Successful participants were 
notified by e-mailed and sent vouchers by post or electronically.   
 
5.2.7. Data analysis  
 
Questionnaire data were analysed quantitatively. A descriptive analysis of 
participants’ demographics and work setting characteristics was carried out using 
SPSS. Data were also explored to describe current experience with managing NDH. 
Median (IQ) was employed to examine how the NHS DPP was rated by practitioners 
using aspects of the APEASE criteria as this was a Likert scale. Similarly, appropriate 
statistical tests were employed to examine practitioners’ perceptions on feasibility 
of community pharmacy activity in the management of NDH. Summarised 
responses to open ended sections of the questionnaire were coded and mapped to 
the COM-B framework (192).  
 
 
5.3 Results  
 
In total seven CCGs, one R & D office and four LPCs assisted with disseminating the 
questionnaire. Of the 761 community pharmacies and 383 general practices who 
received the research information, 96 healthcare professionals completed the 











Table 5.1 Questionnaire participant characteristics  
 
Characteristics  N Measure  Classification Response 
     
Replied 160* % (n)  60 (96) 
     
Male  96 % (n)  57.3 (55) 
Age (years) 96 Mean (sd) 
 
44 (11.8) 
Profession 96 % (n) Pharmacist 84.4 (81) 
   GP 7.3 (7) 
   Nurse 8.3 (8) 
Years of practice  96 Mean (sd) 
 
16.3 (11.6) 




5.3.1 Community pharmacy setting characteristics 
 
Pharmacists reported dispensing a median (IQ) of 6,500 (5000, 9900) prescription 
items per month. A quarter of pharmacist respondents reported having an accuracy 
checking technician, the majority of whom were routinely involved in checking 
prescription items, (n=19, (90.5%)). Most pharmacists reported having a 
consultation room (n=80, (98.8%)) and delivering locally commissioned services 
(n=69, (85.2%)). Reported community pharmacy services, including diabetes 











Table 5.2 Types of commissioned services delivered in community pharmacies 
 
Type of service  Details (Summarised from open ended responses) 
 
Medication related services Healthy start vitamins 
Emergency Supply Services 
Nutrition and dietetic vouchers 
Palliative care supply 
Medicines management service 
Blister pack and Monitored Dosage System scheme  
Minor ailment scheme Urinary tract infection treatment 
Minor eye conditions 
Impetigo treatment 
Oral candidiasis 
Seasonal rhinitis  
Screening services Blood pressure monitoring 
Diabetes checks 
Latent TB screening and treatment   
Weight management services Help-to-Slim 
Sexual health services Emergency hormonal contraception 
Chlamydia test and treatment 
STI screening  
Condom distribution (C-card scheme) 
Pregnancy testing 
Smoking cessation services Nicotine replacement therapy 
Varenicline patient group direction 
Drug user services Supervised methadone and buprenorphine 
consumption 




Pneumococcal vaccination (PPV) 
Meningitis vaccination 
Travel vaccinations 
Others  Anti-coagulation services  
Falls prevention project  
Carpel Tunnel service 




5.3.2 General practice setting characteristics and NHS DPP evaluation  
 
General practitioners and nurses reported having a median (IQ) patient list size of 




practice. Approximately two-thirds (n=9, (60.0%)) of the practices reported opening 
longer hours e.g. evenings and weekends. Just over half of the general practices 
were co-located with a community pharmacy (n=8, (53.3%)) and a fifth (n= 3, 
(20.0%)) reported having a dispensing practice.   
 
Most GP and nurse respondents (n=13, (86.7%)) had a special interest in diabetes. 
Practitioners reported using a combination strategy to manage NDH including 
referral to NHS DPP (n=12, (80.0%)), face to face lifestyle advice (n=13, (86.7%)), 
written information (n=11, (73.3%)) and signposting to online information sources 
(n=6, (40.0%)). Table 5.3 presents findings of the evaluation of the NHS DPP using 
the APEASE criteria. Generally, practitioners agreed that the service was acceptable 
and that referring patients to the programme was easy for them. They also felt that 
the programme had no unwanted/unintended consequences. However, 
practitioners seemed uncertain about the availability of NHS funding to deliver the 
programme long term. Neither were they certain of the programmes’ effectiveness, 








Table 5.3 NHS DPP evaluation using the APEASE criteria 
 
Criteria Questionnaire statement Median (IQ)* 
Affordability  
 
There are adequate funds to continue delivering the service in the future  3 (3,3) 
Practicability  
 
Referring patients to the programme is easy for me  4 (3,5) 
Effectiveness and cost-effectiveness  
 
This programme is good use of NHS money 3 (3,4) 
Acceptability  
 
The programme is an acceptable service for these patients  4 (3,4) 
Side effects/safety  
 
The NHS DPP has not had any unwanted/unintended consequences  4 (3,4) 
Equity  This programme does not disadvantage any groups of people 3 (3,4) 











5.3.3 Delivery of community pharmacy-based diabetes prevention services: COM-
B analysis of questionnaire statements and open-ended section 
 
Practitioner’s views on the delivery of community pharmacy-based DPS in primary 
care are presented in Table 5.4. The questionnaire statements are presented under 
the domains of the COM-B together with the domain definitions. Each statement 
has a reference linking it to the COM-B analysis of barriers and facilitators 
conducted in the previous chapter (Chapter 4, Table 4.3). Twenty-three 
participants, including 19 pharmacists, three nurses and one GP responded to the 
open-ended section of the questionnaire. Responses associated with delivering 
community pharmacy-based DPS were mapped onto the COM-B framework. The 
following section describes the responses to the questionnaire statements 
supported by illustrative quotes from the open-ended sections. The descriptions 
are presented in the categories of the COM-B and represent views across the 




















Table 5.4 Practitioners views’ regarding delivery of community pharmacy-based diabetes prevention services  
 
 Questionnaire statement Median (IQ)* 
 
GPs and Nurses  Community pharmacists  
   Agree and strongly agree (N (%)) 
Ref no. and 
summary phrase 
Capability (physical skill, knowledge or psychological skills, strength or stamina to engage in the 
necessary behaviour) 
 
1.Training Community pharmacy teams would need additional training to 
deliver diabetes prevention services  
4 (4,4) 12 (80.0) 65 (80.2) 
1.Training Once trained, community pharmacy teams would be capable of 
delivering pre-diabetes screening services  
5 (4,5) 
 
12 (80.0) 76 (93.8) 
1.Training Once trained, community pharmacy teams would be capable of 
delivering one-off diet and lifestyle advice for people with pre-
diabetes following screening  
5 (4,5) 12 (80.0) 76 (93.8) 
1.Training Once trained, community pharmacy teams would be capable of 
delivering ongoing diet and lifestyle advice for people with pre-
diabetes following screening 
5 (4,5) 
 
10 (66.7) 76 (93.8) 
Ref no. and 
summary phrase 
Physical opportunity (opportunity afforded by the environment involving time, resources, locations, cues, physical affordance) 
3. Accessibility The community pharmacy is an accessible setting for delivering 
diabetes prevention services  
5 (4,5) 
 
10 (66.7) 79 (97.5) 
3. Accessibility Diabetes prevention services in this setting would likely have shorter 
waiting times than the NHS DPP 
5 (4,5) 
 
6 (40.0) 71 (88.8) 
3. Accessibility Community pharmacy is an acceptable setting for the delivery of 
diabetes prevention services for people unable to engage with the 
NHS DPP 
4 (4,5) 11 (73.3) 72 (88.9) 
4. Time Community pharmacy teams could create time to deliver diabetes 
prevention services  
4 (3,4) 5 (33.3) 44 (55.0) 
 
5. Suitable 
consultation rooms  
Consultation rooms in community pharmacies are adequate for 
delivering services  





6. Access to 
medical records 
Community pharmacy has adequate access to patient medical 
records to facilitate the delivery of diabetes prevention services  
3 (2,4) 1 (6.7) 45 (55.6) 
7. Funding  Community pharmacy would need extra funding and resources to 
deliver diabetes prevention services  
5 (4,5) 
 
10 (66.7) 79 (97.5) 
8. Integration Current IT systems are enough for communication and feedback 
with general practice  
3 (2,4) 3 (13.3) 31 (38.3) 
 
Ref no. and 
summary phrase 
Social opportunity (opportunity afforded by interpersonal influences, social cues and cultural norms that influence the way that we 
think about things) 
8. Integration Community pharmacy diabetes prevention services should be 
integrated with general practice  




Diabetes prevention services in this setting would need to be 
promoted to both patients and practitioners  
4 (4,5) 11 (73.3) 71 (88.8) 
9.Awareness/prom
otion 
GPs and nurses have adequate knowledge of services provided in 
community pharmacy 
3 (2,4) 10 (66.7) 25 (30.9) 
 
10. Feasibility It is feasible to implement diabetes prevention services in 
community pharmacy 





Community pharmacy diabetes prevention services would need 
referral from general practice  
3 (2,4) 
 
5 (33.3) 24 (29.6) 
15. GP workload Any new services in community pharmacy should minimize creating 
additional workload for general practice 
4 (4,5) 10 (66.7) 64 (79.0) 
17. Relationships Successful delivery of diabetes prevention services in community 
pharmacy depends on positive relationships with general practices   
4 (4,5) 11 (73.3) 69 (85.2) 
17. Relationships  Community pharmacy teams could be trusted to deliver diabetes 
prevention services properly  
4 (4,5) 9 (60.0) 75 (93.8) 
 
Ref no. and 
summary phrase 
Motivation (reflective processes involving plans (self-conscious intentions) and evaluations (beliefs about what is good and bad) 
23. General 
practice benefits  
GP practices would need to be reimbursed appropriately for 
referring patients to diabetes prevention services in community 
pharmacy and acting on their feedback 
3 (3,4) 8 (53.3) 28 (34.6) 




5.3.3.1 Capability  
Training was viewed as essential for the enablement of community pharmacy 
teams to deliver DPS (Median, 4). Practitioners strongly agreed that once trained 
community pharmacy teams would be able to deliver interventions including one-
off or ongoing diet and interventions (Median, 5).  
 
“Need better training … for scheme to work” [P21-Pharmacist] 
 
However, with community pharmacy services in England being provided by multiple 
contractors, there were concerns around standardisation of services to ensure high 
quality service delivery.  
 
“Concern that not all community pharmacies would provide same level of service” 
[P32- Pharmacist] 
 
5.3.3.2 Physical opportunity  
Participants were largely positive about the involvement of community pharmacy in 
diabetes prevention and felt that services in this setting could target people who 
are willing but unable to engage with the current national programme (Median 
(IQs), 4 (4, 5)). The community pharmacy setting was viewed to be accessible 
(Median (IQs), 5 (4, 5)) and convenient for delivering DPS by most practitioners. 
However, although current facilities e.g. consultation room, were generally deemed 
adequate for the provision of the services (Median (IQs), 4 (3, 5)), a larger 
proportion of this view was held amongst pharmacists (77.8%) than general 
practitioners and nurses (20%).  
 
The setting was also perceived to have potential for affording shorter waiting times 
than the current national DPP (Median (IQs), 5 (4, 5)). This was supported by 
qualitative responses by general practice respondents highlighting location, session 
times and transportation and work commitments as common barriers for 




noticeably low amongst people living in deprived areas. To this end it was 
highlighted that community pharmacy’s involvement in delivering DPS could 
enhance engagement amongst this population.  
 
“We are a rural practice. Poor public transport therefore difficult to get to. Also, our 
local courses are only done in working hours. Not suitable if you have a job.” [P58-
GP] 
 
 “It would be a great opportunity to play a big role in this important area of disease 
prevention and treatment.  Community pharmacy is easily accessible to all and at 
times when other services are unavailable.”  [P2-Pharmacist] 
 
 “Approx. 90% of my clients decline DPP, I have a very deprived client group but they 
do engage with the pharmacy so this would be excellent to implement in my area” 
[P24-Nurse] 
 
However, practitioners were uncertain with regards to whether current primary 
care IT facilities and current access to patient medical records in community 
pharmacy are sufficient to enable successful service delivery and communication 
(Median (IQs), 3 (2, 4)). Additionally, most respondents agreed that community 
pharmacy would need to be funded and appropriately resourced to enable the 
delivery of the services (Median (IQs), 5 (4, 5)).   
 
“Community pharmacy is severely underfunded…If remunerated correctly Pharmacy 
can play a vital role in diabetes prevention…before any service is considered funding 
must be addressed.”  [P8-Pharmacist] 
 
5.3.3.3 Social opportunity 
Delivering DPS in community pharmacy, was viewed to be feasible (Median (IQs) 4 
(4, 5)), with most practitioners perceiving that community pharmacy teams could 
be trusted to deliver the services successfully (Median (IQs), 4 (4, 5)). Overall 




practice and eliminate any competition between the two settings (Median (IQs) 4 
(4, 5)). Positive working relationships between general practices and community 
pharmacists were perceived to be crucial for the successful delivery of the services 
(Median (IQs) 4 (4, 5)).  
 
“This has to be seen as complementary to GP services and not in competition. 
Where GP's feel threatened at loss of income they will rail against a service” [P31-
Pharmacist]  
 
There was uncertainty as to whether community pharmacy services would require 
referral from general practices (Median (IQs) 3 (2, 4)). Respondents were also 
uncertain if GPs and Nurses had adequate knowledge of current community 
pharmacy services to enable referrals (Median (IQs) 3 (2, 4)). It was therefore of no 
surprise that practitioners felt that there would be a need to raise awareness of 
community pharmacy-based DPS to both patients and other practitioners (Median 
(IQs) 4 (4, 5)).  
 
With regards to transfer of workloads between the community pharmacy and 
general practice settings, most respondents felt that community pharmacy-based 
DPS should avoid creating additional work for general practices (Median (IQs) 4 (4, 
5)). However, there was a concern that the transfer of workload from general 
practice to community pharmacy could create pressure on community pharmacy if 
the service was not appropriately resourced. 
 
“No one seems to realise that the workload in the community pharmacies is 
increasing. More services are being "dumped" on the community pharmacy teams 
in order to relieve the pressures GPs are facing but it seems like there is no adequate 
reimbursement” [P3-Pharmacist] 
 




Although some participants involved in referring patients to the NHS DPP were 
uncertain about the current benefit and uptake of the programme, they highlighted 
the need for good local service for people with NDH. 
 
“We refer patients to NHS DPP but not sure if of benefit or uptake we have a very 
good local service called Diabetes essentials for these patients” [P9- Nurse] 
 
Delivering DPS in community pharmacy was viewed as something that could be of 
benefit to both community pharmacists and general practices. Although 
participants seemed uncertain as to whether general practices ought to be 
reimbursed for referring patients to community pharmacy-based DPS and acting on 
their feedback, respondents felt that DPS could save GP time as well as contribute 
to quality of framework (QOF) points. Quality of Framework is an incentivised 
scheme for all general practices in England, designed to outline and reward 
appropriate resourcing and good practice (308).    
 
“[With] regards [to] payment to the GP's for referring and acting on feedbacks, I 
think this type of service would be of benefit in two ways. One, the time saved for 
doing this at the surgery and also they will gain QOF rewards which result in 
financial gain anyway. So I don't think this should be sold to the GP's with financial 
payments but benefits to them” [P26- Pharmacist] 
 
Some respondents also felt that offering incentives to individual pharmacists rather 
than employers could motivate community pharmacists to deliver the services. This 
would be different from the current structure which reimburses pharmacy 
contractors, who often employ pharmacists to deliver community pharmacy 
services.   
 







5.4 Discussion  
 
This research highlights the NHS DPP to be an acceptable and practical intervention 
for managing NDH by primary care practitioners. The study also confirms previous 
research findings suggesting a potential role for community pharmacy in delivering 
DPS that mirror the NHS DPP (Chapter 3 and 4), with likely capacity highlighted by 
its current involvement in delivering a wide range of locally commissioned services. 
Although previous research (Chapter 3 and 4) indicated a need for increased access 
to patient medical records to deliver DPS, this study highlights an uncertainty 
towards the extent to which community pharmacies would require access to 
patient medical records. Research evidence demonstrates that community 
pharmacy could have sufficient patient information to provide targeted lifestyle 
interventions to people with NDH (278). Therefore, with the current majority of the 
NHD DPP being delivered by non-healthcare personnel and outside general practice 
settings, it seems reasonable to suggest that community pharmacy would not 
require additional access to patient medical records for the provision of DPS.  
 
The study findings also highlight funding uncertainties with regards to the cost-
effectiveness and long-term affordability of the NHS DPP and the need to ensure 
sufficient funding/resources to deliver community pharmacy-based DPS. A recent 
evaluation of the NHS DPP has indicated the programme as likely to be both cost 
effective and cost-saving (156). Additionally, with current evidence ranking type 2 
diabetes risk factors amongst the top five contributors to premature death in 
England (289), NHS England has committed to double the funding for the NHS DPP 
over the next five years (123). However, despite the highlighted plans to expand 
the current NHS DPP, there is still some concern with regards to appropriate 
resourcing (290). Therefore, with current demands for the programme outstripping 
supply in many areas of England since its introduction in 2016 (123) there is a need 
to explore other pro-active approaches for the management of NDH. The 
continuing shortfalls in GPs and nurses coupled with the increased practice sizes, 
also calls for extended roles to be played by other community care providers such 




Another concern raised by this study and previous research (Chapter 4), is ensuring 
the delivery of standardised quality services in community pharmacies, given the 
multiple contractors involved. These concerns could be addressed by the 
implementation of recent community pharmacy initiatives which seek to promote 
the delivery of standardised care. For example, the introduction of the Healthy 
Living Pharmacy initiative, a tiered commissioning framework for delivering health 
and wellbeing services tailored to local requirements (291) and the pharmacy 
quality scheme which remunerates community pharmacies for meeting specified 
quality criteria including public health (292), provides a platform for the provision 
of standardised services. Additionally, the proposed Integrated Care Systems (293), 
where NHS organisations work together with local Councils to meet the needs of 
the local population, giving commissioners the option to commission services 
through a single contract would require a shared vision and agreement on common 
clinical protocols which would further eliminate differences in provision of services. 
The provision of well-co-ordinated preventative services would therefore 
demonstrate commitment to improving the health and wellbeing of local 
communities and aligned patient centred values by primary care providers (290).  
 
This research further highlights the need for the provision of integrated primary 
care services and positive working relationships between community pharmacy and 
general practices. In recent years, a growing recognition that integrated primary 
care services is one way of ensuring efficient use of NHS resources, has led to the 
development of sustainability and transformation partnerships (STPs) (294, 295). 
These plans, which include strengthening of prevention and early intervention, 
recommends that providers and commissioners collaborate and manage the 
collective resources available for NHS services for their local populations. 
Therefore, building on the groundwork of the STPs, more integrated models 
including community pharmacy could facilitate meeting the demands on current 
DPSs whilst ensuring efficient use of resources. 
 
The provision of integrated DPS through various primary settings including 




The findings of this study show an uncertainty as to whether the current 
programme has equity (i.e. the extent to which an intervention may reduce or 
increase the disparities in health between different sectors of society) and suggests 
lower engagement amongst people living in deprived regions. With evidence 
suggesting the risk of developing type 2 diabetes to be up to four times higher in 
Black, Asian and Minority Ethnic groups (296) there is need to widen patient choice 
and target inequality. Moreover, with findings from a recent evaluation study 
suggesting that people of low socioeconomic status or ethnic minority groups may 
gain fewer health benefits per intervention than obese individuals, it is important to 
ensure that the NHS DPP does not contribute to widening health inequalities (156). 
Community pharmacy provides one strategy of targeting these population 
subgroups. With 99.8% of the population living in areas of highest deprivation 
estimated to have access to a community pharmacy within 20 min walk, the setting 
has potential to increase accessibility to these population subgroups (141). 
Additionally, with community pharmacy staff largely reflecting local populations 
with respect to ethnicity, culture and language, this setting has potential to 
increase engagement in particular population subgroups.  
 
This study highlights variations in the current use of the NHS DPP in the 
management of NDH, also validating previous findings suggesting that DPS should 
not follow a “one-size-fits-all” approach (Chapter 3). Future designs of DPS 
delivered in the community pharmacy setting would therefore need to consider the 
development of tailored services that would increase uptake amongst people not 
engaging with the current programme. With evidence indicating capacity concerns 
with regards to suitability of consultation rooms for group-based interventions, 
perhaps community pharmacy would need to consider delivering a one to one 
intervention as highlighted by previous research (Chapter 3). 
 
5.4.1 Strengths and limitations  
 
This research promotes the development of an understanding of the role of 




the NHS DPP in primary care. This study, which included 8 regions in England, 
confirms that barriers and facilitators for delivering DPS in community pharmacy 
identified in previous research (Chapter 4) could be generalised across England. 
These research findings, which have been analysed using the COM-B theoretical 
framework, provide a basis for the development of interventions which could 
promote the provision of DPS by community pharmacy teams.  
 
A limitation to this study was the small sample size and low response rates from 
general practitioners and practice nurses which precluded further statistical 
analysis comparing responses of community pharmacy and general practice 
respondents. Another limitation of this study was the use of agree/disagree Likert 
scale, which research suggests to achieve results which have lower reliability and 
validity due to acquiescence and cognitive burden (266). However, despite this 
limitation, the use of the Likert scale was deemed appropriate for this study as it 
assisted the design of a universal method of data collection that could encompass 





This research validates previous findings on the barriers and facilitators for 
delivering community pharmacy-based diabetes prevention services. The research 
also suggests that the provision of primary care integrated community pharmacy-
based DPS could play a role in increasing equity of the current national programme 
particularly people living in areas of deprivation. However, with limited available 
evidence for lifestyle interventions in this setting, further research is needed to 
investigate both feasibility and cost-effectiveness of diabetes prevention services in 
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Community pharmacy has been identified as a potential setting for delivering 
accessible diabetes prevention services (DPS) for people with non-diabetic 
hyperglycaemia (NDH) (Chapter 3 and 4). Previous research has highlighted several 
interventions that could be delivered in the community pharmacy setting including 
one to one lifestyle programmes that mirror the NHS Diabetes Prevention 
Programme (NHS DPP) (Chapter 3, 4 and 5). These interventions; however, need 
prioritising to assist with the development of community pharmacy-based DPS. 
 
Previous research has also identified several factors that could influence the 
engagement of people with NDH with community pharmacy-based DPS (Chapter 3) 
and the delivery of DPS by community pharmacy teams (Chapter 4 and 5). 
Theoretical analysis of the identified factors has been performed using the COM-B 
model (188, 192) to provide a better understanding of behaviours that would need 
changing (both for people with NDH and community pharmacy teams) to facilitate 
both delivery and engagement. These factors, however, also need prioritising in 
order to identify key COM-B components (behaviours) influencing both 
engagement with, and delivery of, DPS. The prioritisation of these components is 
central to the identification of behaviour change interventions that could facilitate 
successful implementation of community pharmacy DPS. This development would 
employ the Behaviour Change Wheel (BCW)) to identify interventions and policies 
that would facilitate implementation (192).  
 
The Nominal Group Technique (NGT) is one of the most commonly used consensus 
methods applied in research directed at the identification of research priorities 
(297). The technique, originally developed by Delbecq et al. (298), is a structured 
consensus method that aims to achieve a general agreement or convergence of 
opinion around a particular topic (297). The NGT comprises of highly structured 
face to face group discussions that empower participants to voice their opinions 




This study adopted a NGT approach to prioritise types of DPS that could be 
delivered in a community pharmacy setting and to prioritise COM-B categories that 
would likely influence engagement with and delivery of community pharmacy-
based DPS. This study also employed the BCW to facilitate the selection of 
appropriate intervention functions, policy categories and behaviour change 




To identify interventions and policies most likely to facilitate successful 
implementation of community pharmacy-based DPS. 
 
6.1.2 Objectives  
 
1. To identify and describe intervention characteristics of DPS that could be 
delivered in the community pharmacy setting.  
2. To identify COM-B categories most likely to enhance engagement with 
community pharmacy-based DPS in people with NDH.  
3. To identify COM-B categories most likely to enable the delivery of 
community pharmacy-based DPS by community pharmacy teams. 
4. To identify the intervention functions, BCTs and policy categories that are 




6.2. Methods  
 
6.2.1 Study design and ethics approval   
 
This research adopted a modified NGT method comprises of two group discussions 
with stakeholders to prioritise factors for enhancing engagement with and delivery 
of community pharmacy-based DPS (239). The research also applied the BCW to 




facilitate successful implementation of community pharmacy-based DPS. Ethics 
approval was obtained from the Health Research Authority (IRAS project ID: 227930 
and 233631) and the Faculty of Medicine and Health Sciences Research Ethics 
committee at the UEA before commencing the research. The relevant study 
protocols can be found in Appendix 3.1 and 4.1, together with the ethics approvals 
(Appendix 3.2 and 4.2), ethics amendment approvals (Appendix 3.3 and 4.3) and 
research and development office approvals (Appendix 3.4 and 4.4). The research 
was conducted between February and March 2019.  
 
6.2.2 Rationale for using the Nominal Group Technique method and the 
Behaviour Change Wheel  
 
This research used an adapted NGT to identify key priorities for the development of 
community pharmacy-based DPS (299-301). The NGT, often used in health services 
research to explore opinions of health professionals, lay people and carers’ views, 
was identified as appropriate for this research which is exploring the views of 
multiple stakeholders (300). The NGT was considered to be more suitable for this 
research than the Delphi technique, another commonly used consensus method 
applied in research (297). The Delphi technique comprises of multi-stage self-
completed questionnaires with individual feedback and is often used for the 
development of guidelines (297). This technique, although useful for determining 
consensus from a large group of experts, was not viewed as appropriate for this 
research which included people with NDH. Furthermore, as this research was also 
not seeking to achieve consensus for the development of guidelines with health 
professionals, the Delphi technique was not seen as appropriate. An advantage of 
using the NGT over the Delphi technique is the provision of prompt results. The 
multi-stage process of the Delphi technique can take weeks to conclude.  
 
The original NGT comprises of four key stages: silent generation, round robin, 
clarification and voting (ranking) (298, 302). Over the years, variations in the use of 
the NGT, often influenced by available research, participant time or the level of 




exclusion of ‘generation of ideas’, often due to the availability of adequate ideas 
from literature reviews (301), preliminary qualitative research or surveys (300) and 
expert opinions (299). Another common variation is in relation to ranking where 
various methods to prioritise ideas have been used including the allocation of 
scores (303) and Likert scale rating (299) and re-ranking (300). Re-ranking, often 
consisting of the revision of original ranking, has often been employed to explore 
the extent to which discussions influence participants’ views.   
 
This study, in contrast with the classic NGT, excluded the silent generation of ideas 
and included the re-ranking of ideas. As this study was built on previous findings 
which identified barriers and facilitators for engagement with and delivery of 
community pharmacy-based DPS (Chapter 3 and 4), the generation of ideas was 
deemed unnecessary. Additionally, due to the inclusion of multiple stakeholders in 
this research, re-ranking was seen as an important element in determining how 
discussion would alter views of stakeholders following discussion.  
 
The rationale for using the BCW has been documented in the theory chapter 
(Chapter 2). The selection of intervention functions, BCTs and policy categories was 
guided by the APEASE criteria, a set of principles designed to assist in making 
strategic judgements in consideration of the context (192). The APEASE criteria 
therefore consider how factors such as affordability, practicability, effectiveness 
and cost-effectiveness, acceptability, side-effects/ safety and equity, may affect the 
development and implementation of interventions. 
 
6.2.3 Participant recruitment  
 
This research involved multiple stakeholders including people with NDH, healthcare 
personnel and commissioners.  
 
6.2.3.1 People with non-diabetic hyperglycaemia  
Participants were eligible if they had completed the questionnaire in the previous 




 Expressed an interest to participate in further qualitative studies (Appendix 
3.11) 
 Not participated in a previous qualitative study for this research 
 
6.2.3.2 Healthcare personnel and commissioners   
Eligible participants were community pharmacists, pharmacy technicians, 
healthcare assistants, general practitioners, nurses and commissioners. Participants 
were eligible if they had expressed an interest (Appendix 4.8) in the previous study 
to participate in latter phases of the research (Chapter 4) 
  
Eligible individuals were contacted via e-mail which included a participant 
information leaflet (Appendices 3.8 and 4.7) and details about scheduled date and 
times for the group discussions. Participants’ e-mail addresses were obtained from 
completed expression of interest forms (Appendices 3.11 and 4.8) or from existing 
contacts with the Norfolk Clinical Commissioning Group (CCGs)   
 
6.2.4 Sampling and sample size  
 
Two separate group discussions, one with people with NDH and another with 
healthcare personnel and commissioners, were planned for the conduct of this 
research. The aim was to obtain groups consisting of 5 to 12 participants, ensuring 
diversity to help generate richer discussion (302, 304).  People with NDH were 
purposively sampled, with priority given to people who had not engaged with the 
NHS Diabetes Prevention Programme (DPP). Other stakeholders were also 
purposively sampled to ensure a mix of professional backgrounds. 
 
6.2.5 Data collection 
 
6.2.5.1 Nominal group technique procedure  
The modified NGT consisted of three main stages involving individual responses 
(initial ranking), group discussion and individual re-ranking.  
 




Questionnaire content: Types of community pharmacy-based DPS and factors that 
could influence both engagement with and delivery of the services identified from 
previous research (Chapter 3 and 4) were summarised in an electronic 
questionnaire format (Appendix 6.1). The questionnaire was divided in three main 
sections: 
 
 Section 1: Participant consent and demographics.   
 Section 2: Target services and uptake. These questions were based on 
summarised statements of the six factors likely to influence engagement 
with community pharmacy-based DPS (Chapter 3, Table 3.8). 
 Section 3: Delivery of community pharmacy services. These questions were 
based on summarised statements of the factors influencing delivery of 
community pharmacy-based DPS (Chapter 4, Table 4.3). 
 
Of the twenty-four factors that had been identified in the previous research to have 
potential in influencing delivery of DPS in community pharmacy, only nineteen 
were included in section three of the questionnaire. The five factors that were 
excluded from section three of the questionnaire were time, funding, accessibility, 
awareness/promotion and feasibility. Two of these factors, time and funding, were 
identified as central for delivering DPS and thus were excluded on the basis that 
DPPs are already a nationally funded intervention. Two other factors, accessibility 
and awareness/promotion, which had been identified from research exploring both 
engagement and delivery, were viewed as factors more likely to influence 
engagement than delivery hence were included in section two of the questionnaire. 
Lastly, feasibility was seen as inappropriate for further exploration in this study as 
services based on this research would require feasibility testing in future. The 
decision to include/exclude factors from previous chapters was based on existing 
literature and discussion amongst the research team (TK, JS, MT). 
 
Questionnaire distribution: Participants who had expressed an interest in 
participating and had confirmed availability were sent an e-mail describing the NGT 




participants were asked to select one factor from each COM-B category which they 
perceived to be most important for enhancing engagement with and delivery of 
community pharmacy-based DPS. Participants were also asked to select one or 
more DPS which could be delivered in a community pharmacy setting.  
 
The questionnaire was distributed at least one week before the scheduled day for 
the discussion and participants were asked to complete it at least one day before. 
This was to ensure that participants could still recall their rationale for the ranking 
at the time of the group discussion. The questionnaire was designed to take 
approximately five to ten minutes to complete and responses were anonymous. 
 
Stage 2: Group discussion 
Responses to questionnaire statements were summarised in a graphical format and 
presented as PowerPoint slides and/or handouts on the day of the discussion. This 
was done primarily to identify statements on which consensus had been reached 
and therefore which required less discussion.  
 
On the day of the focus group and following the obtaining of written consent 
(Appendix 3.9 and 4.11), the purpose for conducting the research and process of 
the discussion was re-iterated to the participants. Following this, topics were 
introduced and discussed in turn. Participants were asked to expand on their 
responses or viewpoints to the group in a ‘round robin’ fashion. Participants were 
also given the opportunity to discuss the rationale behind their ranking with the 
group in order to highlight any ambiguities in the statements that may have 
affected response and therefore subsequent consensus (300, 301). 
 
The discussions were facilitated by two members of the research team, one who 
took the lead in introducing topics (TK) and another who took field notes and 
assisted in ensuring progression of the discussions (MT) (305). The discussions were 
digitally audio recorded. They were held at the UEA and lasted approximately 50 





Stage 3: Individual re-ranking  
Following the group discussion participants were immediately asked to complete a 
questionnaire, exactly the same as the one completed in stage 1. Participants were 
again asked to select their top preferences following the opportunity to reconsider 
their ranking in light of other participants’ views. The re-ranking process was 
anonymous and could only be linked to previous responses by matching participant 




Participants involved in nominal group discussions received a £30 voucher for 
participating and were reimbursed for travel costs where appropriate. 
Refreshments were provided prior to the discussions.  
 
6.2.7 Analysis   
 
6.2.7.1 Participant demographics, characteristics of community pharmacy-based 
diabetes prevention services and COM-B categories.  
SPSS statistics (version 23; IBM Corp) was used to perform analyses of participant 
demographics with percentages used to describe the data. Similarly, a descriptive 
analysis of participant ranking was performed, where ranking was described in 
percentages and factors with highest percentage were ranked as most important 
for engaging with or delivery of community pharmacy-based DPPs.  
 
To obtain a deeper understanding of the ranking, analysis of the qualitative data 
was performed. Qualitative data were transcribed verbatim by a paid transcription 
contractor, loaded in NVivo 11, and then checked by a member of the research 
team (TK) by listening back to the original recording. The data were then coded 
inductively by a member of the research team (TK). Codes and associated extracts 
describing characteristics of the types of services that could be delivered in a 
community pharmacy setting were used to support and provide a deeper 




extracts associated with engagement with and delivery of community pharmacy-
based DPS were also selected and mapped to relevant COM-B categories (242). 
 
The coding and mapping were conducted by a member of the research team (TK) 
and then discussed with another member of the research team (MT). Any 
disagreements were resolved by consensus following discussion and referral to 
original data. The selected extracts aimed to provide deeper understanding of the 
rationale behind the ranking and a good representation of participant responses. 
Extracts related to the COM-B categories that were prioritised from the ranking 
were selected to represent the rationale behind the ranking. Additionally, extracts 
relaying strategies that could bring about desired behaviour changes in the target 
behaviours (engaging with and delivery of community pharmacy-based DPS) were 
particularly sought to assist the identification of intervention functions and 
behaviour change techniques.  
 
6.2.7.2 Identifying intervention functions, policy categories and behaviour change 
techniques 
Strategies within selected COM-B categories identified from the discussion were 
used to identify intervention functions and policy categories most likely to facilitate 
behaviour change. Following this, BCT linked to the selected intervention functions, 
were selected from a taxonomy of 93 BCTs (220). The selection of intervention 
functions and policy categories involved the application of the Behaviour Change 
Wheel and followed the guidance provided by Michie et al. (192). Similarly, the 
selection of BCTs followed the recommendations of Michel et al. by aiming to 
identify the most frequently used BCTs relevant to the intervention functions.  
 
The selection process was carried independently by two members of the research 
team (TK and MT). The selected intervention functions, policy categories and BCTs 
were then discussed by the two members of the research team (TK and MT). 
Discussions were guided by the researches experience and expertise and 
considered the APEASE criteria, primarily practicability, acceptability and equity. 




team (HF) with a psychology background. Any disagreements were resolved by 
consensus, referring to the original ranking and transcripts.  
 
 
6.3 Results  
 
Fifteen participants completed the questionnaire prior to the group discussion, 
twelve of whom participated in the group discussions and questionnaire re-ranking. 
Three participants, two people with NDH and one nurse, could not make it to the 
group discussion due to unforeseen circumstances.   
 
Two group discussions were conducted, one with people with NDH (n=3) and 
another with healthcare personnel and commissioners (n=9). Participant 
characteristics are detailed in Table 6.1. The group discussion with healthcare 
personnel consisted of a mixture of community pharmacy and general practice 
personnel, and a representative from the CCG. Participants had a median working 
experience of 8.6 (1.8, 9 (IQs)) years. Engagement characteristics of people with 





Table 6.1 Participant characteristics 
 




Gender    
Female  N (%) 13 (86.7)  10 (83.3) 
Healthcare providers and commissioners  
Pharmacist N (%) 3 (20) 3 (30) 
Technician   1 (6.7) 1 (8.3) 
Dispenser  1 (6.7) 1 (8.3) 
General practitioner   1 (6.7) 1 (8.3) 
Nurse   2 (13.3) 1 (8.3) 
Healthcare assistant   1 (6.7) 1 (8.3) 
Commissioner  
 
 1 (6.7) 1 (8.3) 
People with pre-diabetes (Engagement status)  
Waiting  N (%) 2 (13.3) 1 (8.3) 
Completed   2 (13.3) 1 (8.3) 




6.3.1 Types of diabetes prevention services that could be delivered in community 
pharmacy  
 
The selection of services that could be delivered in community pharmacy is 
presented in Table 6.2. Since participants were asked to select more than one 
option, it was unclear which service was most preferred. Participants perceived 
community pharmacy to have potential for delivering alternative one to one DPP as 
well as NDH screening and monitoring services. Although the ranking of the services 
did not alter following group discussion, views of participants altered in favour of 
providing private screening and monitoring services. This was despite being very 
minimal discussion about private screening services in the discussion. The text 
below presents a narrative summary of discussions related to types of services that 





Table 6.2 The selection of potential community pharmacy-based diabetes 
prevention services 
 
Type of service*  Stage 1: Initial 
ranking (N=15) 
Stage 3: Individual 
re-ranking (N=12) 
n (%) 
One to one DPP  6 (40.0) 5 (41.7) 
FPG plus referral to GP for confirmatory HbA1c 
test  
8 (53.3)                                 6 (50.0) 
HbA1c plus referral to NHS DPP 6 (40.0)                          4 (33.3) 
Monitoring services post NHS DPP e.g. BP  8 (53.3)                                 5 (41.7) 
Private screening and monitoring services  2 (13.3)            
     
6 (50.5)              




Training and cost were the two main factors considered by participants when 
selecting types of screening services that could be delivered by community 
pharmacy teams. Over half of the participants selected screening and monitoring 
services that used the fasting plasma glucose (FPG) test. This was primarily due to 
familiarity with using the test in current community pharmacy screening services. 
Consequently, the employment of HbA1c testing, which was perceived to require 
additional training for community pharmacy, was not favoured amongst the 
participants. 
 
“The fasting plasma glucose obviously some pharmacies already do the health 
checks, so you know that training is already out there…with the HbA1c… that’s 
obviously going onto a much you know next level again with that”. [P6, pharmacist] 
 
Participants also considered the use of point-of-care-test (POCT) to be a better 
option for the community pharmacy setting. This was primarily due a lack of 
current arrangements and facilities for conducting laboratory analysis for venous 
blood tests in this setting. Although generally the FPG POCT was favoured due to 




direct referrals to the current NHS DPP, the HbA1c POCT would need to be 
employed. Participants considered direct referrals to the NHS DPP through 
community pharmacy, without confirmatory screening tests by general practices, to 
be a more efficient use of time and NHS resources. 
 
“We [NHS DPP] normally go for HbA1c tests rather than fasting plasma glucose and 
a lot of GP practices do actually do HbA1c testing”. [P12, commissioner] 
 
Participants also felt that community pharmacy has the potential to deliver 
alternative one to one DPPs and monitoring services to support the maintenance of 
health outcomes following completion of the NHS DPP. These services were 
perceived to be a natural progression of current screening services such as the NHS 
Health Check. Participants felt that, similarly to the NHS DPP, these services would 
need to provide ongoing support to enable the monitoring of clinical outcomes 
such as weight loss and blood glucose. However, participants felt that community 
pharmacy could modify the current delivery of the NHS DPP with respect to 
intervals for monitoring. Participants felt that monitoring could reflect the level of 
risk presented by patients in order to reduce cost. Community pharmacy 
participants related that such modifications could mirror current blood pressure 
screening services which provide different action points based on specified cut off 
points.   
 
“We do blood pressure checks as it is and with our ones at least there’s kind of cut 
off points for what your next advice would be… I think that’s something with this as 
well. If you have got people who are borderline you give the advice and obviously 
the people that are you know much higher risk you probably want to see a lot 
sooner um and especially as you were saying you know doing the tests do[es] cost 
money”. [P6, pharmacist] 
 
However, participants felt that monitoring services delivered following completion 
of the NHS DPP should provide more regular monitoring (3-6 months) compared to 





“Well I do think the follow-up is actually more important because once you finish 
the programme it stops because they’re delivering it elsewhere and you’ve gone into 
the past as far as they’re concerned and if it means that I’ve got to make a doctor’s 
appointment to find out what my blood pressure and everything else is then that’s 
not as easy as going into the pharmacy. So the follow-up of people who’ve been on 
the programme by a pharmacist would be I think very valuable” [P3, patient]. 
 
6.3.2 The development of community pharmacy-based DPS using the Behaviour 
Change Wheel 
 
The following section presents the application of the BCW to the findings of this 
research. The section will focus on two behaviours:  
 Behaviour one: people with NDH engaging with community pharmacy-
based DPS  
 Behaviour two: Community pharmacy teams delivering DPS as part of the 
primary care team  
 
For each behaviour, COM-B domains prioritised from the questionnaire-based 
ranking are first presented. Secondly, for each selected domain, suggested 
strategies for bringing about change identified from the group-based discussion are 
then presented. Thirdly, the selection of intervention functions, policies and 
behaviour change techniques for each selected COM-B category is presented and 
discussed.  
 
6.3.3 Prioritising factors influencing behaviour one 
 
Six barriers/facilitators, mapped to categories of the COM-B model, were identified 
by previous research to have potential for influencing engagement of people with 
NDH with community pharmacy-based DPS (Chapter 3, Table 3.8). Table 6.3 
documents the ranking of these factors before and after the NGT discussions. 




From the ranking, awareness/promotion (psychological capability) and 
integration/collaboration with GP (social opportunity) were identified as the most 
important influences of engagement with community pharmacy-based DPS. 
Participants also suggested strategies that could be used to promote community 
pharmacy-based DPS and enhance collaboration between community pharmacy 
and general practice. The suggested strategies together with their illustrative 
quotes are summarised in Table 6.4. The text that follows is the qualitative analysis 
related to the selection of awareness/promotion (psychological capability) and 






Table 6.3 Ranking of factors influencing behaviour one 
 











(Chapter 3, Table 3.8) 
NGT Questionnaire statement                        N (%)  
 
A. Knowledge of support options 
(capability) 
Knowing that community pharmacy is an appropriate place to 
access the service 
 
3 (20%) 2 (16.7%) 
 
B. Awareness/promotion  
(capability) 
Being aware that the services are available in community 
pharmacies 
 
6 (40%) 5 (41.7%) 
** 
C. Suitable consultation rooms 
(physical opportunity) 
Having the assurance that the service would be private and 
confidential 
 
1 (6.7%) - 
 
D. Integration/collaboration with 
GP (social opportunity) 
Making sure that the service is provided in collaboration with 
general practice 
5 (33.3%) 5 (41.7%) 
** 
E. Healthcare professionals 
(motivation) 
 
Having a recommendation from a GP or nurse - - 
 
F. Experience with community 
pharmacy services (motivation)   








Table 6.4 Suggested strategies for behaviour change (behaviour one) 
 
COM-B domain Summary 
statement  
Strategies generated from stage 
group discussion (Stage 2) 







Availability of community 
pharmacy DPS  
 
“It’s almost like there ought to be hand-outs, leaflets almost to give to people 
or even a poster in the doctors surgery that says are you aware that you can be 
tested for diabetes at your local [pharmacy multiple] chemist or whatever. It is 
even something like that either that or the chemists themselves have some 
poster or leaflets”. [P1, patient] 
“We can add something to the letter [NHS DPP invitation letter] to say you 
contact your pharmacy as well that can be added easily” [P12, commissioner] 
Training and experience of 
community pharmacy personnel  
“Well in my doctors surgery they’ve got certificates up on the wall showing who 
does what and what qualifications they’ve got. I mean they don’t necessarily 
have to have a qualification but they could have something up to say that 
they’ve met these competencies i.e. can take a blood pressure, take blood, 
couldn’t they a tick box just to show…some sort of sign up that said all of our 
health care assistants and technicians have done this training” [P1, patient] 
Diabetes risk factors  
 
“It’s raising awareness because had I not have been for my ‘MOT’ as [P1] called 
it, I wouldn’t have ever thought about the fact that I might have [pre-] 
diabetes” [P3, completed]. 
Social 
opportunity 
D. Making sure 




General practices referral of 
patients to community 
pharmacy-based DPS  
 
“Obviously most patients they do listen to their GP’s and they do listen to them 
very well. So I’d just say if they were to refer them to the service I think people 
would definitely come if they were being made aware that… you can go to a 
community pharmacist if you can get an appointment then people would, they 
generally come and use us”. [P5, pharmacist]  
Community pharmacy 
communicating clinical outcomes 
to general practice   
“If you were in the pharmacy and they picked up that you were actually really 
bad or your blood test was really bad then you want to know that you can then 
be possibly even fast tracked into the doctors to get the whatever needs to be 





6.3.3.1 Increasing awareness/promotion (psychological capability)  
Increasing awareness/promotion, mapped to the psychological capability category 
of the COM-B, was identified to be important in influencing engagement. This was 
primarily due to participants perceiving there to be a lack of knowledge of non-
medicine related services delivered in community pharmacy settings. Participants 
therefore felt that it was important for community pharmacy-based DPS to be 
promoted amongst both patients and the general public. 
 
Strategies suggested by participants to raise awareness were mainly in relation to 
the content of the messages. Participants felt that as well as informing people of 
the availability of DPS in community pharmacy, promotional messages would need 
to raise awareness of the training and experience of the teams in order to increase 
patient trust and likelihood for engagement. Participants also felt that promotional 
messages would need to raise awareness of type 2 diabetes risk factors. This was 
due to participants with NDH perceiving their diagnosis to be coincidental, with 
most of them associating their diagnosis with visiting the general practice for 
‘something else’. Therefore, these participants felt that most members of the public 
would need some knowledge of what the risk factors for type 2 diabetes are before 
engaging with DPS.  
 
Participants felt that promotional messages could be conveyed through simple 
means such as posters and leaflets displayed both in community pharmacy and 
general practice settings. The inclusion of community pharmacy-based DPS as an 
option in diagnosis letters sent from general practices was also seen as a viable 
means of raising patient awareness. 
 
6.3.3.2 Collaboration with general practice (social opportunity) 
The provision of integrated services, mapped to social opportunity category of the 
COM-B, was also perceived to be important for increasing engagement. Strategies 
for enhancing collaboration between community pharmacy and general practice 





Participants felt that collaboration would avoid current multiple screening 
appointments that occur between community pharmacy and general practice, 
hence saving both patients’ time and increasing the likelihood of engaging. 
Considering this, communication between community pharmacy and general 
practice teams was seen as crucial for integrating services and maintaining 
complete and up-to-date medical records.  Communication of clinical outcomes 
between the two settings and the provision of reassurance of collaboration was 
seen as important for instilling patient trust in community pharmacy based-DPS and 
facilitating engagement. Additionally, patient referrals from general practice to 
community pharmacy-based DPS where appropriate, was perceived to have 
potential in enhancing patient centred care. 
 
6.3.4 Selecting intervention functions, policy categories and behaviour change 
techniques (behaviour one) 
 
Selected intervention functions, policy categories and BCTs change techniques 
associated with engaging with community pharmacy-based DPS are presented in 
Table 6.5. The selection was targeted at strategies for behaviour change identified 
from the qualitative NGT data.  Education and enablement were identified to be the 
main intervention functions for raising awareness whilst environmental 
restructuring was identified as a key intervention function for enhancing 

















component   
Summary 
statement  
Strategies generated from group 













CP DPS  
Raising awareness of availability of 








Adding objects to the 
environment   
Raising awareness of training and 





Adding objects to the 
environment  





and marketing  





D. Making sure 




General practices referring patients to 
community pharmacy-based DPS  
Environmental 
restructuring 
Guidelines Prompts and cues 
 
 
Community pharmacy reassuring patients 
that results from interventions will be 










6.3.4.1 Increasing awareness/promotion (psychological capability)  
Education, which primarily functions to increase knowledge and understanding, 
was identified as appropriate for raising awareness of diabetes and its risk factors 
amongst patients and members of the public. Furthermore, the provision of 
information about health consequences, was identified as the most appropriate 
intervention (BCT) for delivering knowledge and understanding. 
 
Enablement, an intervention function which goes beyond education in increasing 
means or reducing barriers to increase capability, was identified as the most 
appropriate for increasing awareness of both community pharmacy-based DPS and 
the training/experience of community pharmacy teams. Interventions (BCTs) 
identified as suitable for increasing such awareness were social support and adding 
objects to the environment. Social support, particularly from other primary care 
providers such as general practices, was perceived to be important for raising 
awareness to both regular and non-regular community pharmacy users. 
Participants highlighted that support offered by general practices could involve 
including community pharmacy-based DPS as an option in letters sent out to people 
with NDH. Additionally, primary care settings, including community pharmacy, 
could raise awareness by adding objects to their environment such as posters, 
leaflets and qualification certificates.  
 
Policies identified to support education and enablement were service provision and 
communication. Increasing awareness is an important element in delivering the 
NHS DPP (295). The NHS DPP has employed the use of communication, using print, 
electronic and even media, as means for raising awareness. Similarly, community 
pharmacy-based DPPs could also employ similar means of raising 
awareness/service promotion.   
 
6.3.4.2 Collaboration with general practices (social opportunity) 
Environmental restructuring, which involves changing physical and social contexts, 




based DPS in collaboration with general practice. The provision of guidelines in the 
form of protocols and standard operating procedures was therefore identified as a 
policy that could support environmental restructuring. Such protocols installed in 
clinical systems could ensure that service delivery is integrated and that integrated 
communication forms are available for use between the two settings. 
 
The intervention (BCT) identified as most appropriate for enhancing environmental 
restructuring was the use of prompts and cues in both community pharmacy and 
general practice settings. On screen prompts were identified as a means through 
which healthcare assistants, nurses and GPs could be reminded to inform people 
identified with NDH about community pharmacy-based DPS. Similarly, when 
delivering community pharmacy-based DPS, prompts could be added to documents 
or on IT systems to remind healthcare providers to inform patients that the service 
is provided in collaboration with general practice and reassure them that clinical 
outcomes from the intervention would be communicated to them accordingly.  
 
6.3.5 Prioritising factors influencing behaviour two 
 
Nineteen factors, mapped to categories of the COM-B model, were identified from 
previous research to have potential for influencing delivery of community 
pharmacy-based DPS (Chapter 4 and 5). Table 6.6 presents the ranking of these 
factors (presented under their COM-B categories) before and after the discussion. 
From the ranking, five factors (theoretical training, adequate staffing levels, 
demonstration of impact, skill mix and workload) within all three categories of the 
COM-B, were identified as most important in influencing delivery of community 
pharmacy-based DPS.  
 
Views of participants concerning training requirements for community pharmacy 
did not alter following discussion. However, following the discussions, participants’ 
ranking changed in favour of staffing levels, workload, skill mix and the importance 




including potential strategies for enhancing delivery of the selected factors, has 

















Table 6.6 Ranking of factors influencing behaviour two 
 
Questionnaire statement and summary statement (From chapter 4, Table 4.3) Phase 1 (N=15) Phase 3 (N=12) Selected  
% (n) 
Capability:  Which ONE of the following could most likely increase capability of community pharmacy teams to deliver diabetes prevention services? 
 
 
1a. Training (practical) 2 (13.3%) 1 (8.3%) 
 
1b. Training (theoretical knowledge) 11 (73.3%) 9 (75%) 
** 
1c. Training (communication skills) - - 
 
2.  Experience (service delivery) 2 (13.3%) 2 (16.7%) 
 
Physical opportunity:  Time and funding are key factors needed to deliver diabetes prevention services. Please select ONE additional factor most likely to 
increase the opportunity to deliver such services 
 
5. Suitable consultation rooms (space) 3 (20%) 1 (8.3%) 
 
6. Access to patient medical records 1 (6.7%) 1 (8.3%) 
 
7b. Adequate staffing levels 10 (66.7%) 10 (83.3%) 
** 
8b. Merged IT facilities 1 (6.7%) - 
 
Social opportunity: Which ONE of the following is most important for the implementation of community pharmacy diabetes prevention services as part 
of primary care? 
11. Demonstration of impact (positive health outcomes) 7 (46.7%) 9 (75%) 
** 
13. Competing interests 4 (26.7%) 2 (16.7%) 
 















15. GP workload (reducing GP workload) 3 (20%) 1 (8.3%) 
 
16. CP workload (not to affect prescription services) - - 
 
Motivation:  Financial incentives are a key factor that could increase motivation to deliver diabetes prevention services. Please select ONE additional factor 
that would most likely motivate community pharmacy teams to deliver such services? 
 
 18. Skill mix 3 (20%) 5 (41.7% 
** 
19. Workload (appropriate allocation of resources)  4 (26.7%) 5 (41.7%) 
** 
20. Self-confidence enhanced by training 3 (20%) 1 (8.3%) 
 
21. Structure of service delivery  2 (13.3%) - 
 
22. General practice support 3 (20%) 1 (8.3%) 
 





Table 6.7 Suggested strategies for behaviour change (behaviour two) 
 
COM-B domain Summary 
statement  
What needs to happen for the 







diabetes and its 
management 
Providing theoretical training 
using online resources 
“So again you know if you’re got people in the pharmacy they can sit down and do 
that online or do it at home or something and you know you’re then giving them 
the knowledge of that as well without kind of having to go too much into extra 
resources for training” [P6, pharmacist] 
 
Standardising training across 
primary care 
 
“I think that you obviously do need the training cos you all need to sing off the 
same hymn sheet…within the sort of GP land we all sort of pretty much sing off 
the same hymn sheet because we all have the same regulations the same 
guidelines that we’re following so I think that’s just something that’s expanded 
out to the community” [P10, nurse] 
 
Providing regular updates on 
training  
 
“I went to my own GP practice to have the NHS health check and it was just like oh 
what’s going on it was so it was so different… I said ‘have you been doing this long 
she said oh yes I had my training 5 years ago and I thought it shows…I only had 
mine two years before.  So, if you’re going to do it, it should be regular updates or 
one person from the pharmacy is sent for the regular update to then share with 







Providing adequate resources 
to enable the delivery of DPS  
 
“I mean staff is definitely you know especially in kind of the current climate in 
community pharmacy that’s usually an issue with kind of delivering services. I 
mean it’s not just the staff to be there to be able to do the service, it’s the staff to 
be able to do all the other jobs within the pharmacy at that point as well” [P6, 
pharmacist] 
 
Ensuring that multiple team 
members are trained to deliver 
“I think over the years we’ve had um like a certain group of people in the team 




DPS in order to increase 
accessibility or availability of 
services 
team and when it comes to healthy living you have one person you know as a lead 
in the team when they are not in it means the service cannot be provided… so 
having everybody in the team trained… would mean that you have so many 
people available to do the service” [P4, pharmacist] 
Social 
opportunity  




Reporting clinical outcomes to 
commissioners  
 
“From a commissioning point of view yes that’s really important [reporting 
outcomes] and obviously the outcomes from the NDPP have been positive um I 
think the average patient who does lose weight lose an average of 4kg” [P12, 
commissioner] 
 
General practice sharing clinical 
progress data of individuals 
referred onto the NHS DPP 
through community pharmacy  
 
“So that would be good for GP’s to collaborate with the pharmacies to share this 
data um cos then they might ah that patient who I referred onto the programme 
has benefitted from it” [P12, commissioner] 
 
Community pharmacy 
personnel informing patients of 
previous positive outcomes to 
enhance programme adherence  
“It is effective as well so when I go to meetings with GP’s nurses they always say it 
is effective and you can inform your patients about this as well cos if a patient 
isn’t aware if it’s effective or not then they might be less likely to attend opposed 
to as if it is effective you will lose weight if you adhere to the programme then it 
will be more likely to um go onto it yes” [P12, commissioner] 
 
Motivation 17. Using whole 
CP skill mix 
Delivering community 
pharmacy services through 
trained healthcare assistants or 
technicians  
“I think any of those could do it if they’ve had the training because obviously when 
you’re in hospital although you’ve got the trained nurse in the background it’s 
usually the health care assistant that comes and does your blood pressure while 
you’re in bed” [P2, patient] 
 
18.  Adequate 
staffing levels 
(workload) 





6.3.5.1 Theoretical training (psychological capability) 
Theoretical training in NDH and its management was perceived to be important for 
enhancing the capability of community pharmacy teams to deliver DPS. Participants 
felt that training would need to be targeted at all team members including 
healthcare assistants (HCAs). This was due to the key patient facing role that HCAs 
play in promoting community pharmacy services. 
  
Highlighted strategies for the provision of the theoretical training, included the use 
of online training platforms. Participants also highlighted the importance of 
providing training through external sources rather than employers who often 
cascade training through one trained team member. This, participants felt, would 
avoid passing on ‘bad practice’. Standardisation of training across primary care and 
the provision of regular updates was also identified as a strategy that could 
enhance the delivery of up-to-date and collaborated services.  
 
6.3.5.2 Adequate staffing levels (physical opportunity) 
Adequate staffing levels were identified as key for increasing the opportunity of 
community pharmacy teams to deliver DPS. Although participants felt it beneficial 
for community pharmacy teams to take the ‘strain off’ general practice, participants 
felt that community pharmacy would require appropriate investment in people 
resources to carry this out. Therefore, the availability of multiple trained team 
members was highlighted as central for service delivery and maintaining the 
accessibility of community pharmacy services.  
 
6.3.5.3 Community pharmacy skill mix and workload (reflective motivation) 
The involvement of the whole team in delivering DPS was identified as a key 
motivation for the provision of services by pharmacists. Pharmacists, who described 
feeling ‘under pressure’ with the delivery of current services including dispensing, 
reported that the provision of future interventions requiring minimal pharmacist 





6.3.5.1 Impact (social opportunity) 
Participants also felt that the demonstration of impact, with regards to patient 
clinical outcomes from community pharmacy based-DPS, would enhance 
community pharmacy involvement in delivering primary care services. 
Communication of service clinical outcomes to commissioners was identified as an 
important determinant of securing funding as was communication of clinical 
outcomes with general practice in increasing patient referrals. Participants also felt 
that feedback on the progress of people referred to the NHS DPP from community 
pharmacy would also increase motivation of community pharmacy teams to 
continue delivering the services 
 
6.3.6 Selecting intervention functions, policy categories and behaviour change 
techniques (behaviour two) 
 
Selected intervention functions, policy categories and BCTs associated with 
delivering community pharmacy-based DPS are presented in Table 6.8. The 
selection was guided by strategies for behaviour change identified from the NGT 









Summary statement  Strategies generated from stage 




function (s)  
Selected policy 





knowledge of NDH 
and its management 




Service provision Information about social, 
environmental and health 
consequences  
Demonstration of behaviour and 
instruction of how to perform the 
behaviour  




Guidelines  Instruction on how to perform a 
behaviour 
 
Standardising training across 
primary care 





7a. Adequate staffing 
levels (funding)  
Providing adequate resources to 
enable the delivery of DPS  
 
Enablement  Fiscal measures  Action planning  
 
Review of outcome goals 
 
Ensuring multiple team members 
can deliver DPS in order to 




Action planning  
 








Communication of clinical 
outcomes by community 
pharmacy) 
 
Modelling   Communication and 
marketing 





  Communication of clinical 
outcomes by general practice  
Modelling Communication and 
marketing 
Demonstration of the behaviour   
  Informing patients of service 
clinical outcomes (by community 
pharmacy) 
 
Modelling Communication and 
marketing 
Demonstration of the behaviour   
Motivation  17. Using whole CP 
skill mix 
Delivery of DPS by trained 
healthcare assistants or 
technicians  
 
Incentivisation  Guidelines  Feedback on behaviour  
Feedback on outcomes of behaviour  
18.  Adequate staffing 
levels (workload) 
 




6.3.6.1 Theoretical knowledge of NDH and its management (psychological capability) 
Education, which serves to increase knowledge and understanding, and training 
which serves to impart skills, were identified as appropriate intervention functions 
for the provision of theoretical knowledge about NDH and its management in 
primary care. Interventions (BCTs) identified to enable the delivery of education 
and training were information provision, demonstration of behaviour and 
instruction of how to perform a behaviour. As suggested by participants, 
community pharmacy personnel could utilise online training packages to increase 
knowledge and understanding about NDH and its management. Additionally, 
community pharmacy teams could shadow general practice personnel when 
delivering DPS in order to improve skills.  
 
The provision of guidelines in the form of standard operating procedures was 
identified as policies that could support the delivery of up-to-date and standardised 
education and training for all DPS providers in primary care.  
 
6.3.6.2 Adequate staffing levels (physical opportunity) 
Enablement was identified as an appropriate intervention function for ensuring 
adequate resources for delivery of DPS. Since the delivery of the NHS DPP is 
currently funded by NHS England, fiscal measures and environmental planning were 
identified as policies that could enhance enablement. Therefore action planning by 
the funding bodies, involving consideration of the role of community pharmacy in 
delivering DPPs was identified as an intervention (BCT) that could ensure adequate 
resources for the provision of DPS. Additionally, the incorporation of interventions 
that regularly review goals and outcomes of community pharmacy-based DPS was 
identified as central for ensuring appropriate use of resources. 
 
6.3.6.3 Skill mix (reflective motivation) 
Incentivisation was identified as the intervention function which would best 




Incentivisation encompasses interventions which are designed to create an 
expectation of reward and can be supported by the production of guidelines. 
The majority of primary care public health services are incentivised with financial 
rewards. Service providers often provide feedback to commissioners at the point of 
delivery in order to receive incentives. In community pharmacy such feedback is 
provided through report platforms such as PharmaOutcomes®. Similar means of 
reporting outcomes to receive incentives from commissioners could also be 
employed delivering community pharmacy-based DPS.  
 
6.3.6.4 Demonstration of impact (social opportunity)  
In order to promote the delivery of community pharmacy-based DPS within primary 
care, community pharmacy would have to demonstrate the impact made by the 
services (BCT). This could be achieved by the provision of information about clinical 
and patient outcomes to commissioners.  
 
Modelling, an intervention function which involves the provision of an example for 
people to aspire and imitate, was identified as a means through which community 
pharmacy could demonstrate such health outcomes. Policies such as 
communication and marketing were identified as appropriate for supporting the 
reporting of clinical outcomes to commissioners, general practices and patients. 
 
 
6.4 Discussion  
 
This research highlights important service characteristics that need consideration 
when developing community pharmacy-based DPS. The findings also identify 
potential interventions and policies that could facilitate both engagement with, and 
delivery of, DPS by people with NDH and community pharmacy teams respectively.  
 





This study verifies the potential for community pharmacy to deliver a range of 
interventions in NDH including one to one DPPs and ongoing monitoring. One of 
the key factors that would need consideration when designing such services is the 
types of tests used for assessing glycaemic states. This research particularly 
highlights views and opinions of stakeholders over the use of HbA1c and FPG tests in 
community pharmacy settings with regards to their affordability, acceptability and 
practicability.  
 
The current service specification for the NHS DPP recommends the use of either a 
HbA1c test (venous or POCT) or FPG test (venous only) for assessing glycaemic 
status, provided the same test is conducted throughout the programme (85). The 
use of HbA1c in clinical practice has several advantages over the use of FPG. Firstly, 
there is no requirement of fasting with the HbA1c test and secondly the results 
provide an indication of glycaemic control over a period of three months (306). 
Therefore, although there is no primacy for the use of HbA1c in clinical practice, 
most service providers, including the current NHS DPP providers, opt for the use of 
the HbA1c POCT rather than the FPG.  
 
The involvement of community pharmacy in delivering integrated DPS in primary 
care would therefore require personnel to conduct similar tests. This research 
indicates the use of POCT devices to be more favourable for community pharmacy 
use than venous blood tests. POCT devices have been recommended for use in 
community settings due to increased accessibility for patients and the convenience 
of providing instant results for both the patient and the provider (32, 307).  
Previous research conducted in Norway and Canada demonstrated delivery of 
HbA1c POCT to be feasible for implementation in community pharmacies and 
indicated successful performance of quality controls on HbA1c instruments by 
pharmacists (162, 308).  
 





This research has identified raising awareness of community pharmacy-based DPS 
and providing collaborated services in primary care as factors that could facilitate 
patient engagement. A recent systematic review exploring pharmacists’ and GPs’ 
views of community pharmacy services in the UK, also highlighted the lack of 
awareness of extended services in this setting as a barrier to successful uptake 
(254). The review also highlighted the need for collaborative working between 
community pharmacists and GPs to achieve better integration within patient 
primary care pathways.  
 
This research goes beyond the findings of the review by Hindi et.al. to identify 
practical and affordable interventions to facilitate the promotion of community 
pharmacy-based NDH and collaboration in primary care. The interventions which 
included social support and marketing and information materials (e.g. leaflets, 
posters and letters) follow the current means in raising awareness of services in 
community pharmacy and promote equity through the involvement of other 
primary care providers. 
 
The use of prompts and cues in both community pharmacy and general practice 
settings have been identified as an intervention likely to be effective for the 
provision of collaborative primary care. Prompts and cues, a common behaviour 
change technique used in healthcare settings, is also likely to be an acceptable, 
practicable and affordable intervention. Prompts and cues, which act as reminders 
of recommended standards of clinical practice or guidelines, have been associated 
with improved delivery of preventative healthcare services (309). Research also 
shows that embedding such reminders in the flow of care and providing easy access 
to information is likely to improve patient care (310). Such reminders could occur at 
the point of decision making in general practice to prompt practitioners to inform 
eligible patients about community pharmacy DPS. Additionally, the reminders could 
also occur during consultations in community pharmacy to prompt service 
providers to inform patients about service collaboration (311). In community 




dispensing systems which are currently used when delivering public health services 
such as NHS Heath Check and Emergency Hormonal Contraceptive services (312).  
 
6.4.3 Delivery of community pharmacy-based diabetes prevention services  
 
This research highlights the importance of providing standardised and up-to-date 
training across primary care settings delivering DPS. Previous chapters have 
highlighted that standardising community pharmacy services not only ensures the 
delivery of quality services but could also improve patient trust (Chapter 3, 4 and 5). 
Therefore, in order to facilitate the provision of collaborative services in primary 
care, training for community pharmacy personnel delivering DPS would need to 
align with training provided for NHS DPP providers at a local level. 
 
The current NHS DPP service specification recommends all providers ensure 
delivery of interventions is by health professionals or suitably trained and 
competent individuals and that training should be routinely monitored and updated 
(85). Additionally, although the current service specification does not specify the 
type and level of qualification, training and/or competence required to deliver DPS, 
it suggests that qualification levels align with accredited training packages e.g. the 
Royal Society of Public Health qualifications (85). Current training for community 
pharmacy, is mostly provided by the Centre for Pharmacy Postgraduate Education 
(CPPE) (313). The training aims to offer continuing professional development 
through face-to-face workshops, on-line or distance learning programmes. 
However, although CPPE provides training for the delivery of public health services, 
there are currently no training packages specifically focused on the management of 
NDH in community pharmacy. Therefore, in order to deliver DPS, community 
pharmacy would need to identify or develop suitable training packages that meet 
the standards set out in the service specification. Previous research has 
demonstrated the combination of both face to face and online training to be 
adequate for enabling implementation of DPS such as HbA1c monitoring in 
community pharmacy (162). Such training, which closely resembles the current 




practicable and affordable. However, the cost of training would need to be 
considered when developing community pharmacy-based DPS.  
 
This research also suggests that adequate resources and appropriate use of skill mix 
can increase both the opportunity and motivation of community teams to deliver 
DPS. In recent years, an increased strain on primary care services such as general 
practices, has produced an expansion on clinical and public health services provided 
through community pharmacy (123, 254). However, as identified by previous 
research (Chapter 5) (254), this has led to community pharmacy teams feeling 
under pressure from the increased workload. Therefore, if community pharmacy is 
to play an extended role in primary care, workforce restructuring is central. A 
recent report on clinical services provided by community pharmacy also highlighted 
the need to develop community pharmacy workforce capacity to include models of 
practice that best utilise the community pharmacy skill mix (257). Therefore, the 
development of community pharmacy teams and restructuring of skills, beyond the 
current capacity, would need to be undertaken to enable community pharmacy to 
take on new roles.  
 
The reporting of clinical outcomes between community pharmacy and general 
practice as well as to both patients and commissioners has been identified as a key 
factor for enhancing patient retention, commissioning and integration of 
community pharmacy-based services in primary care (314). Previous research 
indicates that community pharmacy interventions demonstrate positive clinical 
outcomes in interventions including patient education and health/lifestyle 
interventions with significant reductions demonstrated in blood pressure and HbA1c 
(281, 314).  However, research also indicates a lack of evidence directly linking 
specific community pharmacy-based interventions to particular clinical outcomes 
(314).  
 
In recent years the commissioning of services has adopted an outcomes-based 
approach which has more emphasis on the results of interventions (338). An 




get reimbursed for the on-going support element following patients completing a 
12-week period without smoking (315). Current commissioning therefore aims to 
develop services specifications that focus on producing improved outcomes for 
patients, rather than reimbursing providers for activity (316). Thus, providers are 
required to determine the best service delivery models to meet the outcomes and 
cost envelope specified by the commissioner. Therefore, for community pharmacy 
to deliver DPS there is a need to focus more effort on reporting clinical outcomes 
rather than the delivery activity. With previous chapters highlighting poor 
representation of pharmacy in commissioning groups, regular reports to 
commissioners could potentially increase recognition of the contributions made by 
community pharmacy in the current NHS (particularly in increasing reach to harder 
to reach groups) and thus increase opportunities for funding.  
 
Finally, in this research the prioritisation of factors important for delivering 
community pharmacy-based DPS altered following discussion. The main factors 
altered were those concerned with the need for adequate staff, appropriate 
allocation of resources and the importance of demonstrating impact. These 
changes in ranking could indicate the importance of including multiple stakeholders 
when developing integrated services. For example, views concerning the need to 
demonstrate impact could have altered following clarification of the commissioning 
process by one of the participants. Similarly, views concerning the importance of 
resourcing could have altered following clarification from community pharmacy 
teams concerning the pressures in current service delivery. The changes in ranking 
could also indicate that the discussion in the NGT process could have highlighted 
ambiguities and misunderstandings in the questionnaire statements subsequently 
affecting later consensus. This finding highlights the importance of the role of 
community pharmacy representation in primary care commissioning groups.  
 
6.4.4 Strengths and limitations 
 
The research employed modified consensus methods which enabled the 




DPS in community pharmacy. Additionally, the use of data obtained from the 
qualitative discussion also provided a richer understanding of the prioritisation.  
 
Building on the findings of previous studies, this research has considered the views 
and perceptions of multiple stakeholders including people with NDH, 
commissioners, community pharmacy and general practice personnel, to build a 
model for community pharmacy-based DPS. The application of the BCW framework 
to the findings of this research has enabled the identification of possible 
interventions that could be implemented to facilitate the delivery of community 
pharmacy-based DPS.  
 
A limitation of this study was the inclusion of only a small number of participants in 
conducting the NGT. The number of participants precluded further ranking of 
factors such as types of services that could be delivered in the community 
pharmacy setting to identify the main priorities. Furthermore, the multiple factors 
that had to be prioritised, precluded clear ordering with regards to ranking the 
factors. Although this research considered the findings using the APEASE criteria 
some of the criteria such as cost-effectiveness were outside the scope of this 





Community pharmacy has potential to deliver a wide range of DPS including on-
going lifestyle and monitoring interventions. In order to facilitate patient 
engagement, such services would need to be provided in collaboration with general 
practices and would need to be promoted to both patients and members of the 
public. To enable delivery of integrated services in primary care, training for 
community pharmacy teams would need to be standardised at a local level and 
efficient communication of clinical outcomes with commissioners and general 
practices established. Practical and acceptable interventions that could be 




identified including the use of prompts and cues and the display of posters and 
leaflets in various primary care settings.  Further work is needed to inform and 




































7.1 General discussion 
 
The aim of this PhD was to characterise the current and potential role of 
community pharmacy in the prevention of type 2 diabetes and to explore 
community pharmacy as an option for delivering DPS in England. To achieve this 
aim, the BCW framework was employed to firstly, define and understand the 
problem that community pharmacy could potentially address by delivering DPS and 
secondly, to inform the design and implementation of potential interventions that 
could enable delivery of the services.  
 
This chapter presents a discussion of overall findings from the PhD which have been 
summarised in a logic model. The MRC guidance recommends the use of a logic 
model to graphically present the theory of an intervention i.e. how an intervention 
produces its outcomes (226). A logic model is a diagrammatic representation of the 
relationships between an intervention’s context, resources/inputs, 
activities/outputs and intended outcomes impact (317, 318). Due to variations in 
the nature of interventions, there are no standard definitions for ‘context’ or 
‘outcome’ (317). For example, the community pharmacy setting may be part of the 
context for a diabetes prevention intervention. Alternatively, if an intervention is 
designed to change the community pharmacy culture to facilitate the provision of 
diabetes prevention interventions (as is the case for this research), then the 
community pharmacy is part of the intervention not the context.  Additionally, 
when developing a logic model for exploratory interventions, where an intervention 
(e.g. DPP) is being delivered in a new setting (e.g. community pharmacy), some 
aspects of how the intervention might work or processes that could occur may be 
largely unknown due to uncertainties in participant responses (317). Therefore, in 
such cases there may be gaps in logic models which can be specifically explored 
during process evaluation, with the findings contributing to a more complete logic 






This chapter adopts the use of a logic model to graphically present the theory 
underpinning the delivery of community pharmacy-based DPS. The logic model has 
been populated with findings from each chapter of the thesis. Since the nature of 
the interventions proposed by this research are exploratory, certain aspects of the 
behaviours explored are somewhat incomplete and would require process 
evaluation in order to produce a complete model. Below are the definitions used 
for the sections of the logic model (318, 319).  
 
 Background: a summary of existing literature outlining the problem being 
addressed by this PhD. 
 Assumptions: a hypothesis of the causes of the problem and possible 
solutions.  
 Outcomes: the ultimate aims of the intervention i.e. an indication of 
changes that need to be observed. This consists of short, medium- and long-
term outcomes.  
 Activities and outputs: activities needed to be undertaken in order to 
achieve the outcomes and by whom. 
 Inputs: resources required to facilitate the implementation and 
performance of activities. 
 Target population: the population affected with respect to delivering and 
receiving the intervention. 
 
What follows is therefore a discussion of the components of the logic model 












7.1.1 Background: ‘an update of evidence’  
 
This section consists of a discussion of the research evidence that formed the 
rationale for selecting ‘low engagement in DPPs’ as a research problem that needs 
addressing. The evidence discussed is summarised in the ‘Background’ section of 










  Table 7.1: Logic model - background 
 
‘State of the nation’  
 Increasing prevalence of type 2 diabetes and NDH in England. 
 5-10% of people with NDH will develop type 2 diabetes within a year. 
 Individual and societal costs associated with type 2 diabetes.  
 
‘Potential solution’  
 Early identification of NDH followed by intensive diet and lifestyle interventions may 
delay or prevent progression to T2D.  
 NHS England has implemented a national DPP in light of this evidence.  
 
‘The problem’ 
 Evidence shows that the impact of implementing a national DPP could be 
undermined by poor uptake amongst people with T2D.  
 Progress report on the NHS DPP has indicated that of those referred onto the 
programme, 49% attend the initial assessment meeting. 
 The report also indicates that between 36% and 55% of people referred into the NHS 
DPP decline the service and between 26% and 50%, do not progress onto the group-





A review of the literature, conducted at the beginning of the PhD, highlighted poor 
engagement in DPPs as a potential ‘problem’ with current diabetes prevention 
interventions that could be addressed by community pharmacy (Chapter 1). The 
evidence suggested that although DPPs are an effective intervention for delaying or 
preventing development of type 2 diabetes in people with NDH (100), the potential 
impact of implementing such programmes on a national level could be undermined 
by poor uptake (78). In England, a national programme was implemented in 2016, 
to tackle the increasing prevalence of type 2 diabetes (115). Analysis of the 
projected impact of the NHS DPP suggested potential for the programme to be 
both cost-effective and cost-saving, provided assumptions of uptake were met 
(128, 156). However, uncertainties in the projected uptake of the programme were 
highlighted as the biggest risk of implementing the programme nationally (128). 
Furthermore, the programme was shown to create less value for money for low 
socioeconomic status and ethnic minority groups, a factor that could contribute to 
widening health inequalities (156).  
 
The progress report of the NHS DPP, published in 2018, included an initial report on 
programme uptake and suggested that amongst those referred into the NHS DPP, 
49% attend the initial assessment (264). Furthermore, a more recent report on 
programme uptake, published within an updated service specification in 2019, has 
indicated that between 36% and 55% of people referred into the NHS DPP decline 
the service and between 26% and 50%, do not progress onto the group-based 
sessions (124).  
 
In response to the low service uptake, in 2019, NHS England announced plans to 
implement a digital stream of the programme as an alternative route (124). 
However, although the pilot scheme for a digital-based DPP demonstrated 
increased uptake (124), there is currently a lack of evidence for the effectiveness of 
digital-based diabetes interventions compared to face to face.  A recent systematic 
review, investigating the effectiveness of digital health interventions compared to 
non-technology-based interventions on weight loss and lifestyle habit changes, has 




outcomes, an important factor that determines impact of DPPs in reducing the 
incidence of diabetes (320). Additionally, the review highlighted high attrition rates 
in digital health interventions, suggesting participant engagement and motivation 
to be a major barrier.  Although digital interventions may be acceptable due to the 
empowerment of individuals to manage their own conditions, qualitative research 
suggests that factors such as digital exclusion, and concerns around privacy and 
confidentiality, could also limit engagement with the interventions (321). 
Therefore, to date evidence still suggests programme uptake to be an important 
barrier to the potential impact of NHS DPP. There is, therefore, still a need to 
explore alternative routes of increasing uptake in DPPs.   
 
7.1.2 Logic model assumptions 
 
Assumptions can be defined as a hypothesis of why and how certain activities will 
achieve the desired outcomes (319). Therefore, this section outlines a discussion of 
why and how delivering community pharmacy-based DPS could potentially increase 
uptake of DPPs amongst people with NDH. The presented assumptions, 
summarised in the logic model (See Table 7.2), have been derived from a review of 
literature (including guideline recommendations) and empirical research conducted 












Table 7.2 Logic model - assumptions 
 
Accessibility  
 Community pharmacy is an accessible primary care setting for the provision of public 
health interventions.  
 Increased representativeness of the population. 
 Majority of people with NDH already on medication and visit CP regularly.  
 
Current uptake in the NHS DPP  
 Accessibility barriers such as inconvenient session times and location feature in the NHS 
DPP.  
 Current time-lag between referral and initial assessment has also been identified as a 
barrier in the NHS DPP.  
 This research has shown that people with NDH are willing to engage in community 
pharmacy based DPP.  
 Community pharmacy has a potential role for increasing uptake in individuals motivated 
to change behaviour but limited due to accessibility and programme capacity. 
 
Guidance supporting delivery of lifestyle interventions by community pharmacy 
 The provision of community pharmacy based DPP aligns with NICE guidance.  
 The provision of CP based DPP aligns with the NHS Long term plan and the CPCF which 
advocate increased involvement of CP in provision of services for people with high risk 
conditions.  
 
Potential capacity to deliver DPS  
 Community pharmacy teams are currently involved in delivering lifestyle interventions.  
 Community pharmacy has potential infrastructure for delivering lifestyle intervention 
through the Healthy Living Pharmacy framework.  
 There is potential capacity for community pharmacy to deliver DPS due to the expanding 






Research evidence highlights accessibility as a barrier to the uptake of DPPs in 
countries such as USA and Australia (131-133, 322). This thesis presents the first 
studies to investigate barriers and facilitators of programme uptake in the NHS DPP 
in England and from the perspective of people with NDH (Chapter 3) and healthcare 
providers (Chapters 4 and 5). This research employed the COM-B as a theoretical 
model for understanding the problem with uptake in the NHS DPP and why 
community pharmacy is a potential setting for addressing this problem. The 
findings highlight opportunity and motivation as the primary COM-B components 
that influence engagement in the NHS DPP (Chapter 3).  
 
Motivation is defined in the psychology literature as ‘the psychological forces or 
energies that impel a person towards a specific goal’ (323). Many psychological 
theories identify motivation as a key behavioral determinant. In this research, the 
use of the COM-B assisted in identifying several motivational factors which align 
with most psychological theories and frameworks, thus demonstrating the 
efficiency of using the model to provide a thorough understanding of behaviours. 
For example, this research identified family history, including bad experiences with 
family members with type 2 diabetes as a facilitator for engaging with DPPs. This 
aligns with the health belief model which emphasizes that motivation could be 
based on beliefs about susceptibility to a particular disease (174). Additionally, 
perceptions of the benefits of engaging with the NHS DPP, a factor identified as 
both a barrier or facilitator in this research, aligns with the theory of reasoned 
action which suggest beliefs about outcomes of the behaviours and the value 
attached to these outcomes to be important for performing certain behaviours 
(196, 324). The findings of this research were also closely aligned with two domains 
of the TDF related to motivation (193, 325). The domains, which are ‘beliefs about 
capabilities’ and ‘motivation and goals’, have constructs such as ‘self-efficacy’ and 
‘goal priority’ respectively that were also identified as important for motivation in 
this research.  
 
The wide variety of motivational influences identified by this research suggests the 




Trans theoretical model, a well-known theory discussed in chapter 2, identifies a 
series of motivational stages through which people progress and relapse in order to 
achieve health related goals (178). The theory, which has been widely used in 
health education and promotion services (202, 203), could be used to assess 
readiness of change in people who are referred onto current DPS. Currently, with 
most people being referred to the NHS DPP through a letter sent from general 
practices, there is little opportunity for providing consultations for assessing 
readiness of change. Therefore, readiness for change could be assessed at the initial 
programme assessment. With this research identifying that the one-size-fits-all 
approach does not apply for delivering DPPs, the assessment of motivation could 
be key for the provision of focused efforts to preventing type 2 diabetes.  
 
This research has identified barriers within the opportunity component of the COM-
B such as lack of transportation, inconvenient location, inconvenient session times, 
healthcare professional influence and employer support, which were similar to 
those highlighted by other research (131, 132). Additionally, community pharmacy 
has been highlighted as a potential setting for addressing current physical 
opportunity barriers to engaging with the NHS DPP. The COM-B model proposes 
that motivation is increased by increasing opportunity (188, 192). Therefore, the 
use of community pharmacy to deliver services for those unable to access the 
current programme due to competing commitments, could indirectly increase 
motivation for engaging with DPPs. Views from nurses and GPs involved in referring 
patients to the current national programme also indicated that the involvement of 
community pharmacy in delivering DPS could potentially increase uptake in areas of 
high deprivation where community pharmacy has high accessibility (Chapter 5) 
(141).   
 
The involvement of community pharmacy in delivering DPS also has a potential for 
addressing the ‘waiting list’ of the NHS DPP (264). The findings of this research, 
suggested that the potential time lag between referral and commencement of the 
programme, attributed to challenges in arranging suitable location and session 




with NDH (Chapter 3) showed that almost a quarter of respondents were on the 
waiting list due to challenges of arranging suitable time and location. The progress 
report on the NHS DPP has highlighted that the time delay between referral and 
initial assessment is a cause of the significant variation in uptake (16% to 86%) 
across local health economies (264). The involvement of community pharmacy DPS 
could therefore be presented as an alternative for those on waiting lists.  
 
Furthermore, this research highlighted a potential monitoring role for community 
pharmacy in people who have completed the NHS DPP (Chapter 3 and 6). The new 
NHS DPP service specification highlights the need to assess progress of the 
programme against the outcome of reducing glycemic parameters at nine months 
and beyond (124).  The service specification suggests that currently NHS England 
are exploring options to work with primary healthcare providers to undertake this 
function. Community pharmacy, could therefore undertake such a function and 
thus contribute to assessing the long-term outcomes of the NHS DPP (i.e. 
maintenance of lifestyle changes and reduction in the incidence of type 2 diabetes)   
 
Current NICE guidelines support the provision of lifestyle interventions for people 
at high risk of diabetes in community pharmacy setting (32). The NHS Long Term 
Plan (LTP) and the new community pharmacy contractual framework (CPCF), clearly 
support the provision of services such as the DPS in the community pharmacy 
setting (123, 143). The NHS LTP is an NHS document which outlines priorities for 
healthcare over the next 10 years and shows how government funding should be 
utilised. The current version, released in 2019, highlights services that identify and 
treat high risk conditions as a key area for improvement. The document also 
identifies community pharmacy as a setting with potential to provide opportunities 
for the public to identify and manage high risk conditions (123). Similarly the new 
CPCF highlights a role for community pharmacy in improving current public health 
and prevention services (143). The framework, which proposes plans of how 
community pharmacy could deliver the NHS LTP, also suggests piloting prevention 
and detection services which, if found best implemented in the community 




7.1.3 Logic model inputs and outputs 
 
Inputs constitutes resources needed to be implemented in order to perform certain 
activities and outputs refers to the activities needed to be undertaken in order to 
achieve the outcomes and by whom. In this section, resources needed to enable 
uptake of community pharmacy DPS by people with NDH and resources required to 
deliver the services by community pharmacy teams are firstly discussed. Secondly 
discussed are activities that need to be performed to ensure both uptake and 
delivery of the services. As the findings of this research are suggesting a potential 
role for community pharmacy teams to deliver DPS for people with NDH in primary 
care, the target population referred to in the logic model are people with NDH, 
community pharmacy personnel, general practice personnel and commissioners.  
These findings are summarised in the inputs and outputs section of the logic model 
(See Table 7.3) and have been extracted primarily from empirical research 
presented in chapters three to six. 
 
7.1.3.1 Inputs/resources  
Time and funding, mapped to the physical opportunity domain of the COM-B, were 
identified as the main resources required for community pharmacy teams to deliver 
DPS (Chapter 4 and 5). The research also highlighted the importance of ensuring 
adequate staffing levels, to enable the availability and accessibility of community 
pharmacy DPS. A recent systematic review, exploring the views of pharmacists and 
GPs of extended community pharmacy services in the UK, has shown that the 
provision of dispensing services alongside extended services often pose time 
constraints for pharmacists (254). The review also highlighted the need for the 
provision of sufficient remuneration for the additional time and resources required 
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The CPCF outlines an important role for community pharmacy in improving public 
health and disease prevention and has highlighted the need to release pharmacist 
capacity from existing work in order to provide expanded services (143). The CPCF 
also acknowledges the need to maximise developments in skill mix in order to 
deliver both dispensing and extended services that do not create additional 
pressure on pharmacists’ time. The NHS DPP is funded by NHS England and 
commissioned locally through CCGs (124). In 2019, NHS England committed to 
doubling the funding for the programme over the next five years, in order to widen 
patient choice and reduce inequality (123). Therefore, the provision of community 
pharmacy DPS would need to be commissioned in order to ensure sufficient 
funding and resources.  
 
Training has been identified as central to the provision of DPS by community 
pharmacy personnel. The service specification for the NHS DPP highlights key areas 
of service provision including identification of eligible population, intervention 
provision (including both dietary and physical activity components of promote 
weight loss) and monitoring (124). The specification also recommends the provision 
of stop smoking interventions to individuals who smoke (124). Although community 
pharmacy currently provides all these interventions, the services are segmented, 
not focused on diabetes prevention and have different durations . In order to 
deliver DPS, community pharmacy personnel would need to be appropriately 
trained to deliver the activities and content of the interventions. Additionally, 
training needs to be regularly monitored and kept up to date.  
 
7.1.3.2 Outputs/ activities  
Raising awareness of diabetes risk factors, the availability of community pharmacy 
based DPS and the qualifications and role for community pharmacy in public health 
were identified as important activities that need to be undertaken to ensure that 
people with NDH engage with the services. This research identified simple 
interventions such as the display of posters and leaflets in both general practice and 




patients and the public. Additionally, collaboration between community pharmacy 
and general practice in the provision of DPS was identified as important for patients 
engagement with community pharmacy-based DPS. Both the endorsement and 
referral of community pharmacy-based DPS and efficient communication of 
outcomes were identified as key intervention activities that could promote 
collaboration between the two settings.     
 
The use of social support interventions including endorsement by general practice 
personnel, has been identified as an effective means of raising awareness of 
extended services in the community pharmacy (326, 327). Additionally, 
recommendations of services through public health campaigns have been identified 
as a means of raising awareness of extended services in community pharmacy (277, 
328). In England, community pharmacy participates in six campaigns set by NHS 
England by distributing leaflets and posters provided by NHS England.  Under the 
new contract, community pharmacy has agreed to align its campaigns to that of 
general practice as part of their commitment to provide more integration across 
primary care (143). Therefore, activities highlighted by this research to the raising 
of awareness align with current models of promotion.  
 
Although interventions to ensure collaboration between community pharmacy and 
general practice have been identified in this research, evidence suggests that 
current collaboration amongst the two settings is poor (254). Qualitative research 
has suggested that poor collaboration between the two settings stem from poor 
relationships (329-331) and infrequent communication (332). This research had 
identified a number of interventions that could be introduced in both settings to 
enhance communication including the use of prompts and cues as reminders to 
make referrals or to communicate clinical outcomes. Additionally, activities that 
have been identified to support the delivery of the intervention include 
interventions that would enhance communication between community pharmacy 
and both general practice and commissioners. This research suggests that as part of 
the service community pharmacy would need to engage regularly with 




that general practice could regularly communicate clinical progress data of 
individuals referred onto the NHS DPP through community pharmacy. Therefore, 
the proposed model of inputs and outputs for delivering promotes integration and 
collaboration between community pharmacy and other primary care providers.  
 
7.1.4 Logic model - outcomes  
 
Outcomes constitute the ultimate aims of the intervention and consists of short, 
medium- and long-term outcomes (319). In this section the outcomes associated 
with delivering community pharmacy-based DPS are discussed. These outcomes 
have been derived from both literature and empirical research (Chapters 3-5) and 
are summarised in Figure 7.3.  
 
To facilitate integration in primary care and to enable an efficient outcome 
evaluation, patient outcomes of providing community pharmacy-based DPS would 
need to reflect those of the NHS DPP (128). However, increased uptake and 
retention, particularly amongst regular community pharmacy users, people with 
work and social commitments and those on the waiting list would be the key 
patient outcome. Therefore, in the short-term, community pharmacy-based DPS 
would aim to increase uptake and retention of people on the programme, in the 
medium-term it would aim to achieve weight and risk reduction and in the long-
term a reduction in the incidence of type 2 diabetes and of NHS resources. The 
delivery of community pharmacy-based DPS could also increase awareness of the 
role of community pharmacy in delivering public health interventions. Evidence 
suggests that a lack awareness of the role of community pharmacy in public health 
could act as a potential barrier to engaging with community pharmacy services 
(249, 253). Therefore, with the current contract and LTP highlighting an important 
role for community pharmacy in identifying and treating high risk conditions, raising 






The provision of DPS as part of primary care could also increase the opportunity for 
providing integrated care systems, a key focus highlighted as central for the 
delivery of the LTP (123). Therefore, the increased integration between community 
pharmacy and general practice as proposed in the model could lead to increased 
engagement between the two settings through referrals and regular 
communication of outcomes. Furthermore, communication of outcomes to 
commissioners could also increase the profile and trust of community pharmacy to 
provide public health interventions thus increasing participation in primary care 
networks.  
 
The provision of community pharmacy-based DPS would require staff to be trained 
and would need to explore more efficient use of skill mix. This could lead to 
development of the community pharmacy workforce thus harnessing the third 
largest workforce group in the NHS (257). Such services could lead to the 




7.2 Strengths and Limitations 
 
This thesis constitutes one of the first studies to investigate the role of community 
pharmacy in diabetes prevention in England. The thesis proposes a model which 
outlines the theory for implementing DPS in the community pharmacy setting. The 
findings of this research, although focused on diabetes prevention, are applicable 
when considering the implementation of other public health interventions in the 
community pharmacy.  
 
7.2.1 Trustworthiness of the findings 
 
Rigorous methods were adopted for the conduct and reporting of this research to 




7.2.1.1 Participants and demographics  
This research elicited contributions from a broad range of stakeholders, purposely 
selected to ensure diverse experiences with the NHS DPP and community pharmacy 
(333). This facilitated the incorporation of different perspectives and helped to 
ensure that no particular groups’ views were privileged over others (284)(303). For 
example, most participants who attended NHS DPP were in favour of the current 
set-up of the programme and those unable to access the programme were in 
favour of community pharmacy as an alternative setting. Thus, in the conclusion 
community pharmacy has been presented as a potential alternative to the current 
programme. The inclusion of multiple stakeholders has also paved a way for the 
development of a model that considered collaboration and integration in primary 
care. The proposed model therefore fits in with current developments of primary 
care networks to ensure integrated pathways for providing patient care (123, 143). 
 
A limitation in the selection of participants for this research however was the 
exclusion of non-English speakers due to limited time and resources to enable 
translation of research materials. The exclusion of non-English speaking participants 
limited the ability for the research to explore language as a potential 
barrier/facilitator for participation in the NHS DPP. Additionally, this research was 
primarily conducted in Norfolk which largely consists of a white population with a 
relatively older age profile compared to the rest of England (261). This therefore 
limits the generalisability of this research to other parts of England (e.g. London) 
which are largely multicultural and consists of a greater proportion of younger 
working population.  
 
Additionally, although steps were taken to triangulate some of research findings in 
other areas of England (Chapter 5), limited time and resources led to the purposive 
selection of areas with the least numbers of general practices and the exclusion of 
areas where the NHS DPP was being implemented through County Councils. This 
selection criteria precluded inferential analysis to be made on areas where 
implementation of the NHS DPP was led by Councils versus those by CCGs and 




questionnaire study presented in Chapter 5 validated views of practitioners, the 
views of people with NDH were not validated. Therefore, the views of people with 
NDH expressed in this research might not be representative of other parts of the 
country. Therefore, with previous research demonstrating language, social roles, 
cultural and religious understanding of healthcare professional as potential barriers 
to uptake in DPPs (135, 145-148), and future research would need to investigate 
the impact of different contexts on the uptake of the NHS DPP.  Such factors would 
also need to be considered when implementing community pharmacy-based DPS.  
Another limitation of this research is the small sample sizes obtained in 
questionnaire studies, which precluded important inferences about engagement 
(Chapter 3) and delivery of DPS in primary care (Chapter 5) being made.   
 
7.2.1.2 Data collection  
In designing the qualitative research, the preferred data collection method was 
focus groups. This was because obtaining perspectives from a wide variety of 
stakeholders was an important factor for sufficiency describing the potential role of 
community pharmacy in diabetes prevention. Focus groups therefore offered the 
opportunity to explore multiple views and experiences of participating in the NHS 
DPP and delivering community pharmacy services. Additionally, focus groups 
afforded the opportunity for participants to exchange viewpoints and experiences 
and reflect on their own standpoint in light of what others had said. Furthermore, 
despite focus groups being the preferred data collection method participants were 
also offered interview options. This offered a more accessible option to participants 
who could not or preferred not to participate in focus group discussion. This option 
particularly increased the participation of people with NDH who had declined or 
dropped out of the NHS DPP by offering them convenience whilst allowing the 
freedom to express their views. However, a limitation of this research is that the 
interview option was only made available to people with NDH (particularly non-
engagers), GPs, nurses and commissioners. This therefore limited the opportunity 





Triangulation, achieved by using multiple methods of data collection including 
questionnaires, added to the credibility of the research findings (334). 
Questionnaires employed in this research (Chapter 3 and 5) primarily adopted the 
agree/disagree Likert Scale format. This type of format was considered appropriate 
due to the exploratory nature of this research and the need to explore multiple 
topics within the same group of participants. The scale therefore provided a 
universal method for collecting data that could easily be understood by a wide 
variety of participants. It also provided a quick, efficient and inexpensive method to 
collect data from participants with time constraints (e.g. pharmacists and GPs) and 
allowed for the data to be easily quantifiable and subjective to statistical analysis.  
However, Saris et al. have argued that the agree/disagree rating scale questions 
yield lower quality responses to comparable questions offering item specific 
response options (266). The authors primarily attribute this to acquiescence 
(reluctant acceptance without protest) which could result from personality 
dispositions where some individuals feel obliged to be polite and to avoid social 
friction, leading them to be especially agreeable (266). They also propose that, 
considering a general bias in hypothesis testing toward confirmation rather than 
disconfirmation, the agree/disagree scale inclines some respondents toward 
agreeing with assertions presented to them in this manner (266). Saris et al. 
propose the use of item specific scales (e.g.“How would you rate your health – 
excellent, very good, good, fair, or bad?) as a more direct way of collecting opinion 
from individuals. Therefore, in light of this, the present research does acknowledge 
acquiescence to be a potential limitation to the quality of responses obtained 
(Chapter 3 and 5).  
 
Finally, this research used an adapted NGT to assist the prioritising of factors 
needed to facilitate the implementation of community pharmacy based DPS. This 
method provided immediate results, whilst allowing for an opportunity for results 
to stem from a discussion of stakeholders. However, due to lack of time and 
resources, the ranking process was limited to a single group discussion rather than 
multiple rounds of discussions. Typically, NGT discussions take from 1.5-6 hours to 




complete agreement of ideas is obtained (302). This limitation had therefore led to 
a presentation of a wider number of factors that could influence participation in 
and delivery of community pharmacy-based DPS in the final logic model.  
 
7.2.1.3 Data analysis  
The use of the BCW provided a transparent structure for the conduct and analysis 
of this research which followed the steps for developing interventions outlined by 
Michie et al. (188, 192). The use of the COM-B model to explore behaviours, 
enabled the identification of a variety of influences on behaviour change that fit in 
with constructs of most theoretical models. Thus, demonstrating the coherence of 
the components of the COM-B and the efficiency in providing an integrated 
framework for understanding behaviour.  
 
Investigator triangulation was applied by involving several researchers, with a range 
of expertise, in conducting data analysis (334). This served to provide multiple 
perspectives in the interpretation of findings and helped to minimize the main 
researcher’s (TK) subjective influence on the interpretation of the findings (284).  At 
significant points during the process of data analysis, the main researcher (TK) 
regularly met with the supervisor (MT) to discuss data collection. Discussions were 
also held with the wider research team with extensive qualitative and clinical 
experience, to discuss the findings until the interpretation which we felt best 
represented the meaning of the data was found. The mapping of barriers and 
facilitators to the COM-B theoretical model, was examined by an external 
psychologist (HF) with experience of applying the COM-B in designing interventions. 
This ensured that the interpretation of the findings was supported by data received 
from participants of the study, hence enhancing dependability and confirmability of 
the research findings (335).  
 
A potential source of bias in the analysis and presentation of findings, however, was 
the community pharmacy background of the research team (336) which included 
either pharmacists (TK, JS, HA and TK) or those with previous and current 




mitigated by ensuring that data analysis primarily involved the use of raw data and 
interpretation of the research was primarily guided by the definitions of the COM-B 
domains (188, 192).  Additionally, the selection of illustrative quotes was purposive 
and aimed at presenting findings which represented the multiple stakeholders who 
were involved as participants in this research. 
 
 
7.3 Conclusion  
 
Diabetes Prevention Programmes are an effective behaviour change intervention 
for preventing and delaying progression to type 2 diabetes in individuals with non-
diabetic hyperglycemia. In England research evidence suggests the implementation 
of a national DPP to be potentially cost-effective and cost-saving. However, the 
impact of the programme could be undermined by poor uptake amongst people 
with NDH. Accessibility barriers to uptake, including lack of transportation, 
inconvenient location and session times have been identified amongst people with 
NDH who are currently not engaging with the NHS DPP. These barriers could be 
addressed by delivering programmes that mirror the current NHS DPP in alternative 
accessible settings such as community pharmacies. Additionally, with the NHS LTP 
committing to expand the programme, capacity could be maximised by utilising 
alternative settings such as community pharmacies.  
 
Interventions for implementing diabetes prevention services in the community 
pharmacy would need to target people with NDH, community pharmacy teams and 
general practice personnel. Interventions for people with NDH would need to focus 
on raising awareness of the services including the risk factors for type 2 diabetes. 
The interventions would also need to ensure a clear and integrated pathway for 
people with NDH in order to ensure engagement. Interventions targeted at 
community pharmacy teams would need to focus on providing adequate funding 
and people resources. They would also need to ensure that community pharmacy 




general practices would need to focus on enhancing communication and 
integration with community pharmacy teams.    
 
This thesis provides a logic model of the underpinning theory behind delivering 
community pharmacy-based diabetes prevention services. Further research is 
needed to test the feasibility of implementing such services in this setting in order 
to establish a clear role for community pharmacy in diabetes prevention in England.  
 
 
7.4 Research recommendations  
 
7.4.1 Feasibility study  
 
This thesis has a proposed model for delivering community pharmacy-based DPS. 
This model could be further developed by conducting a feasibility study to assess 
both the effectiveness and cost-effectiveness of implementing DPS in community 
pharmacy settings. The feasibility study would consider factors such as uptake and 
retention rates and could include a process evaluation to examine the reach of the 
intervention in terms of the characteristics of the population accessing the services.  
 
The process evaluation could also examine the feasibility of implementation and 
the fidelity of the intervention model. This would assess the ability of staff to 
deliver the intervention in accordance to DPP service specifications and the 
acceptability of the intervention from the perspective of community pharmacy staff 
and people with NDH. The suitability and acceptability of the proposed outcome 
measures to patients, commissioners and other healthcare providers would also 
need to be established.  
 
7.4.2 Development of motivation assessment tools 
 
This research has suggested motivation to be an important influence in making 
decisions to engage with DPPs.  The initial assessment session of the DPP could 




interventions. Therefore, future work could develop assessment tools underpinned 
by theoretical models such as the trans-theoretical model to assess readiness for 
change and guide referral to appropriate services. Such tools would be designed to 
assess patients individually and tailor the service to their needs.  
 
7.4.3 Development of monitoring services post NHS DPP 
 
This research has identified a potential role for community pharmacy to monitor 
long-term outcomes of the NHS DPP following completion of the nine-month 
intervention. NHS England has identified this as an area requiring further 
exploration and collaboration between local commissioners and primary care 
providers. Therefore, there is scope for community pharmacy to delivery such 
services given their accessibility. Future work could therefore explore how 
community pharmacy can work with local commissioners to monitor clinical 
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